

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 12:31:38 ; Search time 188 Seconds
(without alignments)
18.697 Million cell updates/sec

Title: US-10-053-520-143

Perfect score: 64

Sequence: 1 HWDFAWFW 8

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 291

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 1000 summaries

Database :

A_Geneseq_21:*

1: Geneseq1980s:*

2: Geneseq1990s:*

3: Geneseq2000s:*

4: Geneseq2001s:*

5: Geneseq2002s:*

6: Geneseq2003as:*

7: Geneseq2003bs:*

8: Geneseq2004s:*

9: Geneseq2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	64	100.0	8	2	Aaw19951 Heat choc
2	64	100.0	8	2	Aay16873 Peptide S
3	64	100.0	8	4	Aau72015 Melanoma
4	64	100.0	8	5	Aau80565 Heat choc
5	64	100.0	8	5	Aae13434 Javelin s
6	64	100.0	8	7	Adg72529 Heat choc
7	64	100.0	8	7	Adg72870 Heat choc
8	64	100.0	8	8	Adr69734 Novel hyb
9	64	100.0	8	8	Adu08477 Heat choc
10	64	100.0	8	8	Adu07913 High affi
11	64	100.0	9	5	Aau80739 Javelin p
12	64	100.0	9	5	Aau80740 Javelin p
13	64	100.0	12	5	Aau80735 Javelin p
14	64	100.0	12	5	Aau80736 Javelin p
15	64	100.0	16	4	Aau72257 gpl00-der
16	64	100.0	16	4	Aau72256 gpl00-der
17	64	100.0	17	4	Aau72188 Tyrosine-
18	64	100.0	17	4	Aau72227 gpl00-der
19	64	100.0	17	4	Aau72297 gpl00-der
20	64	100.0	17	4	Aau72297 gpl00-der
21	64	100.0	17	4	Aau72477 gpl00-der
22	64	100.0	17	4	Aau72266 gpl00-der
23	64	100.0	17	4	Aau72306 gpl00-der
24	64	100.0	17	4	Aau72417 gpl00-der

25	64	100.0	17	4	AAU72226
26	64	100.0	17	4	AAU72407
27	64	100.0	17	4	AAU72197
28	64	100.0	17	4	AAU72447
29	64	100.0	17	4	AAU72187
30	64	100.0	17	4	AAU72287
31	64	100.0	17	4	AAU72366
32	64	100.0	17	4	AAU72207
33	64	100.0	17	4	AAU72277
34	64	100.0	17	4	AAU72276
35	64	100.0	17	4	AAU72406
36	64	100.0	17	4	AAU72476
37	64	100.0	17	4	AAU72367
38	64	100.0	17	4	AAU72396
39	64	100.0	17	4	AAU72196
40	64	100.0	17	4	AAU72446
41	64	100.0	17	4	AAU72206
42	64	100.0	17	4	AAU72217
43	64	100.0	17	4	AAU72237
44	64	100.0	17	4	AAU72397
45	64	100.0	17	4	AAU72236
46	64	100.0	17	4	AAU72307
47	64	100.0	17	4	AAU72216
48	64	100.0	17	4	AAU72416
49	64	100.0	18	4	AAU72357
50	64	100.0	18	4	AAU72387
51	64	100.0	18	4	AAU72326
52	64	100.0	18	4	AAU72327
53	64	100.0	18	4	AAU72427
54	64	100.0	18	4	AAU72286
55	64	100.0	18	4	AAU72386
56	64	100.0	18	4	AAU72456
57	64	100.0	18	4	AAU72337
58	64	100.0	18	4	AAU72376
59	64	100.0	18	4	AAU72426
60	64	100.0	18	4	AAU72457
61	64	100.0	18	4	AAU72246
62	64	100.0	18	4	AAU72247
63	64	100.0	18	4	AAU72466
64	64	100.0	18	4	AAU72346
65	64	100.0	18	4	AAU72467
66	64	100.0	18	4	AAU72316
67	64	100.0	18	4	AAU72336
68	64	100.0	18	4	AAU72436
69	64	100.0	18	4	AAU72356
70	64	100.0	18	4	AAU72437
71	64	100.0	18	4	AAU72287
72	64	100.0	18	4	AAU72317
73	64	100.0	18	4	AAU72347
74	64	100.0	18	4	AAU72377
75	64	100.0	19	2	Aaw19956
76	64	100.0	19	2	Aaw19957
77	64	100.0	19	4	AAU72254
78	64	100.0	19	4	AAU72253
79	64	100.0	19	5	Aae13446
80	64	100.0	19	5	Aae13452
81	64	100.0	19	5	Aae13447
82	64	100.0	19	5	Aae13453
83	64	100.0	19	7	ADG72871
84	64	100.0	19	8	ADR69737
85	64	100.0	19	8	ADR69751
86	64	100.0	19	8	ADR69754
87	64	100.0	20	2	Aaw19966
88	64	100.0	20	2	Aaw19961
89	64	100.0	20	2	Aaw19967
90	64	100.0	20	2	Aaw19960
91	64	100.0	20	2	Aaw19962
92	64	100.0	20	2	Aaw19964
93	64	100.0	20	2	Aaw19965
94	64	100.0	20	2	Aaw19959
95	64	100.0	20	2	Aaw19963
96	64	100.0	20	2	Aaw19958
97	64	100.0	20	4	AAU72404

98	64	100.0	20	4	AAU72444	Aau72444	MAGE-1/3-	171	
99	64	100.0	20	4	AAU72203	Aau72203	Tyrosine-	172	
100	64	100.0	20	4	AAU72204	Aau72204	Tyrosine-	173	
101	64	100.0	20	4	AAU72274	Aau72274	gp100-der	174	
102	64	100.0	20	4	AAU72403	Aau72403	MAGE-1-de	175	
103	64	100.0	20	4	AAU72443	Aau72443	MAGE-1/3-	176	
104	64	100.0	20	4	AAU72234	Aau72234	gp100-der	177	
105	64	100.0	20	4	AAU72303	Aau72303	gp100-der	178	
106	64	100.0	20	4	AAU72193	Aau72193	Tyrosine-	179	
107	64	100.0	20	4	AAU72293	Aau72293	gp100-der	180	
108	64	100.0	20	4	AAU72294	Aau72294	gp100-der	181	
109	64	100.0	20	4	AAU72194	Aau72194	Tyrosine-	182	
110	64	100.0	20	4	AAU72263	Aau72263	gp100-der	183	
111	64	100.0	20	4	AAU72264	Aau72264	gp100-der	184	
112	64	100.0	20	4	AAU72233	Aau72233	gp100-der	185	
113	64	100.0	20	4	AAU72414	Aau72414	MAGE-1-de	186	
114	64	100.0	20	4	AAU72223	Aau72223	gp100-der	187	
115	64	100.0	20	4	AAU72413	Aau72413	MAGE-1-de	188	
116	64	100.0	20	4	AAU72473	Aau72473	MAGE-3-de	189	
117	64	100.0	20	4	AAU72191	Aau72191	Tyrosine-	190	
118	64	100.0	20	4	AAU72214	Aau72214	Tyrosine-	191	
119	64	100.0	20	4	AAU72224	Aau72224	gp100-der	192	
120	64	100.0	20	4	AAU72364	Aau72364	MART-1-de	193	
121	64	100.0	20	4	AAU72213	Aau72213	Tyrosine-	194	
122	64	100.0	20	4	AAU72393	Aau72393	MART-1-de	195	
123	64	100.0	20	4	AAU72394	Aau72394	MART-1-de	196	
124	64	100.0	20	4	AAU72304	Aau72304	gp100-der	197	
125	64	100.0	20	4	AAU72363	Aau72363	MART-1-de	198	
126	64	100.0	20	4	AAU72273	Aau72273	gp100-der	199	
127	64	100.0	20	4	AAU72274	Aau72474	MAGE-3-de	200	
128	64	100.0	20	5	AAE13455	Aae13455	Human gpl	201	
129	64	100.0	20	5	AAE13456	Aae13456	Human gpl	202	
130	64	100.0	20	8	ADR69745	Adr69745	Novel hyb	203	
131	64	100.0	20	8	ADR69746	Adr69746	Novel hyb	204	
132	64	100.0	20	8	ADR69748	Adr69748	Novel hyb	205	
133	64	100.0	20	8	ADR69749	Adr69749	Novel hyb	206	
134	64	100.0	20	8	ADU08486	Adu08486	Hybrid an	207	
135	64	100.0	21	4	AAU72453	Aau72453	MAGE-1/3-	208	
136	64	100.0	21	4	AAU72354	Aau72354	gp100-der	209	
137	64	100.0	21	4	AAU72353	Aau72353	gp100-der	210	
138	64	100.0	21	4	AAU72324	Aau72324	gp100-der	211	
139	64	100.0	21	4	AAU72333	Aau72333	gp100-der	212	
140	64	100.0	21	4	AAU72384	Aau72384	MART-1-de	213	
141	64	100.0	21	4	AAU72423	Aau72423	MAGE-1-de	214	
142	64	100.0	21	4	AAU72313	Aau72313	gp100-der	215	
143	64	100.0	21	4	AAU72344	Aau72344	gp100-der	216	
144	64	100.0	21	4	AAU72343	Aau72343	gp100-der	217	
145	64	100.0	21	4	AAU72353	Aau72353	gp100-der	218	
146	64	100.0	21	4	AAU72383	Aau72383	MART-1-de	219	
147	64	100.0	21	4	AAU72434	Aau72434	MAGE-1-de	220	
148	64	100.0	21	4	AAU72244	Aau72244	gp100-der	221	
149	64	100.0	21	4	AAU72314	Aau72314	gp100-der	222	
150	64	100.0	21	4	AAU72424	Aau72424	MAGE-1-de	223	
151	64	100.0	21	4	AAU72433	Aau72433	MAGE-1-de	224	
152	64	100.0	21	4	AAU72283	Aau72283	gp100-der	225	
153	64	100.0	21	4	AAU72373	Aau72373	MART-1-de	226	
154	64	100.0	21	4	AAU72374	Aau72374	MART-1-de	227	
155	64	100.0	21	4	AAU72243	Aau72243	gp100-der	228	
156	64	100.0	21	4	AAU72463	Aau72463	MAGE-1/3-	229	
157	64	100.0	21	4	AAU72454	Aau72454	MAGE-1/3-	230	
158	64	100.0	21	4	AAU72464	Aau72464	MAGE-1/3-	231	
159	64	100.0	21	4	AAU72284	Aau72284	gp100-der	232	
160	64	100.0	21	4	AAU72334	Aau72334	gp100-der	233	
161	64	100.0	21	8	ADR69753	Adr69753	Novel hyb	234	
162	64	100.0	24	4	AAU72262	Aau72262	gp100-der	235	
163	64	100.0	24	4	AAU72258	Aau72258	gp100-der	236	
164	64	100.0	25	4	AAU72402	Aau72402	MAGE-1-de	237	
165	64	100.0	25	4	AAU72272	Aau72272	gp100-der	238	
166	64	100.0	25	4	AAU72408	Aau72408	MAGE-1-de	239	
167	64	100.0	25	4	AAU72448	Aau72448	MAGE-1/3-	240	
168	64	100.0	25	4	AAU72452	Aau72452	MAGE-1/3-	241	
169	64	100.0	25	4	AAU72189	Aau72189	Tyrosine-	242	
170	64	100.0	25	4	AAU72368	Aau72368	MART-1-de	243	

Aau72218	Tyrosine-	25	4	AAU72218	64	100.0	25	4	AAU72218
Aau72268	gp100-der	25	4	AAU72268	64	100.0	25	4	AAU72268
Aau72282	gp100-der	25	4	AAU72282	64	100.0	25	4	AAU72282
Aau72312	gp100-der	25	4	AAU72312	64	100.0	25	4	AAU72312
Aau72228	gp100-der	25	4	AAU72228	64	100.0	25	4	AAU72228
Aau72232	gp100-der	25	4	AAU72232	64	100.0	25	4	AAU72232
Aau72302	gp100-der	25	4	AAU72302	64	100.0	25	4	AAU72302
Aau72238	gp100-der	25	4	AAU72238	64	100.0	25	4	AAU72238
Aau72202	Tyrosine-	25	4	AAU72202	64	100.0	25	4	AAU72202
Aau72308	gp100-der	25	4	AAU72308	64	100.0	25	4	AAU72308
Aau72398	MART-1-de	25	4	AAU72398	64	100.0	25	4	AAU72398
Aau72422	MAGE-1-de	25	4	AAU72422	64	100.0	25	4	AAU72422
Aau72198	Tyrosine-	25	4	AAU72198	64	100.0	25	4	AAU72198
Aau72298	gp100-der	25	4	AAU72298	64	100.0	25	4	AAU72298
Aau72478	MAGE-3-de	25	4	AAU72478	64	100.0	25	4	AAU72478
Aau72190	Tyrosine-	25	4	AAU72190	64	100.0	25	4	AAU72190
Aau72208	Tyrosine-	25	4	AAU72208	64	100.0	25	4	AAU72208
Aau72212	Tyrosine-	25	4	AAU72212	64	100.0	25	4	AAU72212
Aau72242	gp100-der	25	4	AAU72242	64	100.0	25	4	AAU72242
Aau72372	MART-1-de	25	4	AAU72372	64	100.0	25	4	AAU72372
Aau72418	MAGE-1-de	25	4	AAU72418	64	100.0	25	4	AAU72418
Aau72278	gp100-der	25	4	AAU72278	64	100.0	25	4	AAU72278
Aau72412	MAGE-1-de	25	4	AAU72412	64	100.0	25	4	AAU72412
Aau72222	gp100-der	25	4	AAU72222	64	100.0	25	4	AAU72222
Aau72288	gp100-der	25	4	AAU72288	64	100.0	25	4	AAU72288
Aau72432	MAGE-1-de	26	4	AAU72432	64	100.0	26	4	AAU72432
Aau72328	gp100-der	26	4	AAU72328	64	100.0	26	4	AAU72328
Aau72332	gp100-der	26	4	AAU72332	64	100.0	26	4	AAU72332
Aau72348	gp100-der	26	4	AAU72348	64	100.0	26	4	AAU72348
Aau72322	gp100-der	26	4	AAU72322	64	100.0	26	4	AAU72322
Aau72378	MART-1-de	26	4	AAU72378	64	100.0	26	4	AAU72378
Aau72382	MART-1-de	26	4	AAU72382	64	100.0	26	4	AAU72382
Aau72388	MART-1-de	26	4	AAU72388	64	100.0	26	4	AAU72388
Aau72468	MAGE-1/3-	26	4	AAU72468	64	100.0	26	4	AAU72468
Aau72358	gp100-der	26	4	AAU72358	64	100.0	26	4	AAU72358
Aau72472	MAGE-3-de	26	4	AAU72472	64	100.0	26	4	AAU72472
Aau72292	gp100-der	26	4	AAU72292	64	100.0	26	4	AAU72292
Aau72458	MAGE-1/3-	26	4	AAU72458	64	100.0	26	4	AAU72458
Aau72252	gp100-der	26	4	AAU72252	64	100.0	26	4	AAU72252
Aau72338	gp100-der	26	4	AAU72338	64	100.0	26	4	AAU72338
Aau72248	gp100-der	26	4	AAU72248	64	100.0	26	4	AAU72248
Aau72428	MAGE-1-de	26	4	AAU72428	64	100.0	26	4	AAU72428
Aau72342	gp100-der	26	4	AAU72342	64	100.0	26	4	AAU72342
Aau72362	MART-1-de	26	4	AAU72362	64	100.0	26	4	AAU72362
Aau72392	MART-1-de	26	4	AAU72392	64	100.0	26	4	AAU72392
Aau72438	MAGE-1-de	26	4	AAU72438	64	100.0	26	4	AAU72438
Aau72318	gp100-der	26	4	AAU72318	64	100.0	26	4	AAU72318
Aau72352	gp100-der	26	4	AAU72352	64	100.0	26	4	AAU72352
Aau72462	MAGE-1/3-	26	4	AAU72462	64	100.0	26	4	AAU72462
Aau72442	MAGE-1/3-	27	5	AAE13449	64	100.0	27	5	AAE13449
Aae13449	Chicken M	27	5	AAE13449	64	100.0	27	5	AAE13449
Aae13450	Chicken M	27	5	AAE13450	64	100.0	27	5	AAE13450
Aau72255	gp100-der	30	4	AAU72255	64	100.0	30	4	AAU72255
Aau72260	gp100-der	30	4	AAU72260	64	100.0	30	4	AAU72260
Aae13448	Chicken M	30	5	AAE13448	64	100.0	30	5	AAE13448
Aae13454	Herpes si	30	5	AAE13454	64	100.0	30	5	AAE13454
Aau72295	gp100-der	31	4	AAU72295	64	100.0	31	4	AAU72295
Aau72192	Tyrosine-	31	4	AAU72192	64	100.0	31	4	AAU72192
Aau72230	gp100-der	31	4	AAU72230	64	100.0	31	4	AAU72230
Aau72480	MAGE-3-de	31	4	AAU72480	64	100.0	31	4	AAU72480
Aau72205	Tyrosine-	31	4	AAU72205	64	100.0	31	4	AAU72205
Aau72215	Tyrosine-	31	4	AAU72215	64	100.0	31	4	AAU72215
Aau72240	gp100-der	31	4	AAU72240	64	100.0	31	4	AAU72240
Aau72370	MART-1-de	31	4	AAU72370	64	100.0	31	4	AAU72370
Aau72400	MART-1-de	31	4	AAU72400	64	100.0	31	4	AAU72400
Aau72405	MAGE-1-de	31	4	AAU72405	64	100.0	31	4	AAU72405
Aau72405	MAGE-1-de	31	4	AAU72405	64	100.0	31	4	AAU72405
Aau72220	Tyrosine-	31	4	AAU72220	64	100.0	31	4	AAU72220
Aau72420	MAGE-1-de	31	4	AAU72420	64	100.0	31	4	AAU72420
Aau72200	Tyrosine-	31	4	AAU72200	64	100.0	31	4	AAU72200
Aau72265	gp100-der	31	4	AAU72265	64	100.0	31	4	AAU72265
Aau72395	MART-1-de	31	4	AAU72395	64	100.0	31	4	AAU72395
Aau72415	MAGE-1-de	31	4	AAU72415	64	100.0	31	4	AAU72415

244 64 100.0 31 4 AAU72410
 245 64 100.0 31 4 AAU72305
 246 64 100.0 31 4 AAU72300
 247 64 100.0 31 4 AAU72310
 248 64 100.0 31 4 AAU72450
 249 64 100.0 31 4 AAU72195
 250 64 100.0 31 4 AAU72365
 251 64 100.0 31 4 AAU72315
 252 64 100.0 31 4 AAU72225
 253 64 100.0 31 4 AAU72275
 254 64 100.0 31 4 AAU72280
 255 64 100.0 31 4 AAU72475
 256 64 100.0 31 4 AAU72210
 257 64 100.0 31 4 AAU72235
 258 64 100.0 31 4 AAU72270
 259 64 100.0 31 5 AAU72457
 260 64 100.0 32 4 AAU72245
 261 64 100.0 32 4 AAU72355
 262 64 100.0 32 4 AAU72285
 263 64 100.0 32 4 AAU72315
 264 64 100.0 32 4 AAU72345
 265 64 100.0 32 4 AAU72325
 266 64 100.0 32 4 AAU72330
 267 64 100.0 32 4 AAU72375
 268 64 100.0 32 4 AAU72390
 269 64 100.0 32 4 AAU72290
 270 64 100.0 32 4 AAU72440
 271 64 100.0 32 4 AAU72460
 272 64 100.0 32 4 AAU72470
 273 64 100.0 32 4 AAU72250
 274 64 100.0 32 4 AAU72425
 275 64 100.0 32 4 AAU72435
 276 64 100.0 32 4 AAU72380
 277 64 100.0 32 4 AAU72335
 278 64 100.0 32 4 AAU72455
 279 64 100.0 32 4 AAU72320
 280 64 100.0 32 4 AAU72430
 281 64 100.0 32 4 AAU72350
 282 64 100.0 32 4 AAU72360
 283 64 100.0 32 4 AAU72465
 284 64 100.0 32 4 AAU72385
 285 64 100.0 38 5 AAU72451
 286 64 100.0 100 5 AAU72460
 287 64 100.0 100 5 AAU72458
 288 64 100.0 103 5 AAU72461
 289 64 100.0 103 5 AAU72459
 290 64 100.0 108 5 AAU72462
 291 64 100.0 111 5 AAU72463

ALIGNMENTS

RESULT 1
 ID AAW19951 standard; peptide; 8 AA.
 XX
 AC AAW19951;
 XX
 DT 10-NOV-1997 (first entry)
 XX
 DE Heat shock protein Bip binding domain.
 XX
 KW Vaccine; immunotherapy; heat shock protein; Bip; cancer;
 KW infectious disease.
 XX
 OS Mus musculus.
 XX
 PN WO9706821-A1.
 XX
 PD 27-FEB-1997.
 XX
 PF 16-AUG-1996; 96WO-US013363.

XX
 PR 18-AUG-1995; 95US-0002479P.
 PR 18-AUG-1995; 95US-0002490P.
 XX
 PA (SLOK) SLOAN KETTERING INST CANCER RES.
 XX
 PI Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
 WIPI; 1997-165035/15.
 XX
 DR Compens. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.
 XX
 PS Claim 9; Page 45; 58pp; English.
 XX
 CC The mouse Bip heat shock protein (HSP) binding domain (AAW19951) can be
 CC used as a component of a hybrid target antigen that also comprises an
 CC immunogenic domain. The hybrid antigen (see also AAW19955-67) is combined
 CC in vitro with a HSP to form a complex that, when administered to a
 CC subject, induces an immune response. Target antigen-HSP complexes can be
 CC used to treat infectious diseases, or to treat cancers by eliciting an
 CC immune response to a tumour antigen. Alternatively, a nucleic acid
 CC encoding the HSP and the target antigen is administered such that the HSP
 CC and target antigen bind in situ
 XX
 SQ Sequence 8 AA;
 Query Match 100.0%; Score 64; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 2
 ID AAY16873 standard; peptide; 8 AA.
 XX
 AC AAY16873;
 XX
 DT 20-JUL-1999 (first entry)
 XX
 DE Peptide Seq ID No: 143 of WO9922761.
 XX
 KW Conjugate peptide; heat shock protein; hsp; phage display library; virus;
 KW surface protein; tethering peptide; chaperone process; cytokine; cancer;
 KW neoplastic disease; infectious disease; bacterium; immune system; fungus;
 KW acquired immune deficiency; autoimmune disease.
 XX
 OS Synthetic.
 XX
 PN WO9922761-A1.
 XX
 PD 14-MAY-1999.
 XX
 PF 22-OCT-1998; 98WO-US022335.
 XX
 PR 31-OCT-1997; 97US-00961707.
 XX
 PA (SLOK) SLOAN KETTERING INST CANCER RES.
 XX
 PI Rothman JE, Mayhew M, Hoe MH, Houghton A, Hartl U, Ouerfelli O;
 PI Moroi Y;
 XX
 DR WIPI; 1999-313177/26.
 XX
 PT Identifying peptides which bind heat shock proteins.
 XX
 PS Example; Page 19; 155pp; English.
 XX

CC The invention relates to conjugate peptides engineered to noncovalently
 CC bind to heat shock proteins (hsp). A method of identifying a hsp binding
 CC peptide comprises (a) contacting a phage display library having
 CC bacteriophage expressing, in a surface protein, inserted peptides with a
 CC hsp target, and bound to a benzquinone anamycin antibiotic (BAA), in a
 CC physiologic binding buffer; (b) isolating a phage binding to the hsp
 CC target; and (c) identifying the inserted peptide expressed. The peptides
 CC which bind to a hsp can be used as tethering peptides for a hsp which may
 CC serve as an accessory in a chaperone process and/or may comprise a
 CC cytokine. They can also be coupled to antigens to induce an immune
 CC response. Such compositions can be used for treating neoplastic disease,
 CC e.g. cancers, infectious diseases, e.g. diseases caused by a bacterium,
 CC virus, protozoan, mycoplasma, fungus, yeast, parasite or prion, or a
 CC disease of the immune system, e.g. acquired immune deficiencies or
 CC autoimmune diseases

XX SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 2; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 3

AAU72015

ID AAU72015 standard; peptide; 8 AA.
 XX
 AC AAU72015;
 XX
 DT 11-SEP-2003 (revised)
 DT 26-FEB-2002 (first entry)
 XX
 DE Melanoma antigen, javelin peptide #1.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Enterobacteria phage M13.
 OS WO200178655-A2.
 PN
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Claim 5; Page 14; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention. (Updated on 11-SEP-2003 to standardise
 CC OS field)

XX SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 4

AAU80565

ID AAU80565 standard; peptide; 8 AA.
 XX
 AC AAU80565;
 XX
 DT 26-MAR-2002 (first entry)
 XX
 DE Heat shock binding peptide #1 useful as javelin peptide.
 XX
 KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection;
 KW heat shock binding peptide.
 XX
 OS Homo sapiens.
 XX WO200178772-A1.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012568.
 PF
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 PA
 XX Hoe M, Landsberger F;
 XX WPI; 2002-049177/06.
 DR

XX New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.

PS Disclosure; Page 9; 75pp; English.

XX The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80565-AAU80570 represent heat shock binding
 CC peptides which may be used as javeline

XX SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 5; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 5
 AAEL3434
 ID AAEL3434 standard; peptide; 8 AA.

XX AC AAEL3434;
 DT 12-FEB-2002 (first entry)
 XX Javelin sequence #1.

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy.

XX Unidentified.

XX WO200179259-A1.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012567.

XX 17-APR-2000; 2000US-0197462P.

XX (ROTH/) ROTHMAN J E.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Rothman JE, Mayhew M, Hoe M;

XX WPI; 2002-017594/02.

XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.

XX Disclosure; Page 10; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is a javelin peptide

XX Sequence 8 AA;

Query Match 100.0%; Score 64; DB 5; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 6
 ADG72529
 ID ADG72529 standard; peptide; 8 AA.

XX AC ADG72529;

XX 11-MAR-2004 (first entry)
 DT Heat shock protein (hap) conjugate peptide #71.

XX Heat shock protein (hap) conjugate peptide #71.

XX Heat shock protein; hep; conjugate peptide; benzoquinone anasmycin;
 KW infectious disease; human papillomavirus; herpes virus; retrovirus;
 KW hepatitis virus; influenza virus; rhinovirus;
 KW respiratory syncytial virus; cytomegalovirus; adenovirus;
 KW malignant disease; neoplastic disease; sarcoma; lymphoma; leukaemia;
 KW melanoma; carcinoma; breast; prostate; ovary; cervix; uterus; colon;
 KW lung; glioblastoma; astrocytoma; immunological disease; AIDS;
 KW autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus;
 KW diabetes mellitus; thyroiditis; multiple sclerosis.

XX Synthetic.

XX US2003194409-A1.

XX 16-OCT-2003.

XX 17-JAN-2002; 2002US-00053498.

XX 17-JAN-2002; 2002US-00053498.

XX (ROTH/) ROTHMAN J E.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M H.

XX (HOUG/) HOUGHTON A.

XX (HART/) HARTL U.

XX (OUER/) OUERPELLI O.

XX (MORO/) MOROI Y.

XX Rothman JE, Mayhew M, Hoe MH, Houghton A, Hartl U, Ouerfelli O;
 PI Moroi Y;

XX WPI; 2003-899769/82.

XX Identification of a peptide binding to a heat shock protein involves
 PT contacting a phase display library of several bacteriophages expressing
 PT in a surface protein of inserted peptides with a target followed by
 PT isolation and identification.

XX Disclosure; Page 7; 62pp; English.

XX The invention relates to a method for identification of a peptide binding
 CC to a heat shock protein (hsp) involving contacting a phase display
 CC library of several bacteriophage which express, in a surface protein,
 CC several inserted peptides with an hsp target or hsp target bound to a
 CC benzoquinone anasmycin antibiotic in a physiological binding buffer or
 CC binding buffer, isolating the phage, and identifying the inserted peptide
 CC expressed in the surface protein of the phage. The method is useful for
 CC identifying a peptide, which binds to a heat shock protein, which is used
 CC in a conjugate peptide for inducing an immune response, for the treatment
 CC of infectious diseases (e.g. diseases caused by a bacterium, virus,
 CC protozoan, mycoplasma, fungus, yeast, parasite or prion such as human
 CC papillomavirus, a herpes virus such as herpes simplex virus, a retrovirus
 CC such as human immunodeficiency virus 1 or 2, a hepatitis virus, an
 CC influenza virus, a rhinovirus, respiratory syncytial virus, a
 CC cytomegalovirus, an adenovirus, Mycoplasma pneumoniae, a bacterium of the
 CC genus Salmonella, Staphylococcus, Streptococcus, Enterococcus,
 CC Clostridium, Escherichia, Klebsiella, Vibrio or Mycobacterium, a
 CC protozoan such as an amoeba, malarial parasite or Trypanosoma cruzi), or
 CC malignant diseases, for treating or preventing neoplastic diseases (e.g.
 CC sarcoma, lymphoma, leukaemia, melanoma, carcinoma of the breast,
 CC carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix,
 CC uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma
 CC or astrocytoma) or immunological diseases (e.g. AIDS) and for treating
 CC autoimmune diseases such as rheumatoid arthritis, systemic lupus
 CC erythematosus, diabetes mellitus, thyroiditis and multiple sclerosis.
 CC This sequence represents an hsp conjugate peptide of the invention.

XX Sequence 8 AA;

SQ

Query Match 100.0%; Score 64; DB 7; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 |||||

RESULT 7
 ADG72870
 ID ADG72870 standard; peptide; 8 AA.
 XX
 AC ADG72870;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Heat shock protein (hsp) related peptide #3.
 XX
 KW Heat shock protein; hsp; conjugate peptide; benzoquinone ansamycin;
 KW infectious disease; human papillomavirus; herpes virus; retrovirus;
 KW hepatitis virus; influenza virus; rhinovirus;
 KW respiratory syncytial virus; cytomegalovirus; adenovirus;
 KW malignant disease; neoplastic disease; sarcoma; lymphoma; leukaemia;
 KW melanoma; carcinoma; breast; prostate; ovary; cervix; uterus; colon;
 KW lung; glioblastoma; astrocytoma; immunological disease; AIDS;
 KW autoimmune disease; rheumatoid arthritis; systemic lupus erythematosus;
 KW diabetes mellitus; thyroiditis; multiple sclerosis.
 XX
 OS Synthetic.
 XX
 PN US2003194409-A1.
 XX
 PD 16-OCT-2003.
 XX
 PF 17-JAN-2002; 2002US-00053498.
 XX
 PR 17-JAN-2002; 2002US-00053498.
 XX
 PA (ROTH// ROTHMAN J E.
 PA (MAYH// MAYHEW M.
 PA (HOEM// HOE M H.
 PA (HOUG// HOUGHTON A.
 PA (HART// HARTL U.
 PA (OUER// OUFERFELLI O.
 PA (MORO// MOROI Y.
 XX
 PI Rothman JS, Mayhew M, Hoe MH, Houghton A, Hartl U, Ouerfelli O;
 PI Moroi Y;
 XX
 DR WPI; 2003-899769/82.
 XX
 PT Identification of a peptide binding to a heat shock protein involves
 PT contacting a phage display library of several bacteriophages expressing
 PT in a surface protein of inserted peptides with a target followed by
 PT isolation and identification.
 XX
 PS Example; Page 18; 62pp; English.
 XX
 CC The invention relates to a method for identification of a peptide binding
 CC to a heat shock protein (hsp) involving contacting a phage display
 CC library of several bacteriophage which express, in a surface protein,
 CC several inserted peptides with an hsp target or hsp target bound to a
 CC benzoquinone ansamycin antibiotic in a physiological binding buffer or
 CC binding buffer, isolating the phage, and identifying the inserted peptide
 CC expressed in the surface protein of the phage. The method is useful for
 CC identifying a peptide, which binds to a heat shock protein, which is used
 CC in a conjugate peptide for inducing an immune response, for the treatment
 CC of infectious diseases (e.g. diseases caused by a bacterium, virus,
 CC protozoan, mycoplasma, fungus, yeast, parasite or prion such as human
 CC papillomavirus, a herpes virus such as herpes simplex virus, a retrovirus
 CC such as human immunodeficiency virus 1 or 2, a hepatitis virus, an

CC influenza virus, a rhinovirus, respiratory syncytial virus, a
 CC cytomegalovirus, an adenovirus, Mycoplasma pneumoniae, a bacterium of the
 CC genus Salmonella, Staphylococcus, Streptococcus, Enterococcus, a
 CC Clostridium, Escherichia, Klebsiella, Vibrio or Mycobacterium, a
 CC protozoan such as an amoeba, malarial parasite or Trypanosoma cruzi), or
 CC malignant diseases, for treating or preventing neoplastic diseases (e.g.
 CC sarcoma, lymphoma, leukaemia, melanoma, carcinoma of the breast,
 CC carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix,
 CC uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma
 CC or astrocytoma) or immunological diseases (e.g. AIDS) and for treating
 CC autoimmune diseases such as rheumatoid arthritis, systemic lupus
 CC erythematosus, diabetes mellitus, thyroiditis and multiple sclerosis.
 CC This sequence represents an hsp related peptide of the invention.
 XX
 SQ Sequence 8 AA;
 Query Match 100.0%; Score 64; DB 7; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 |||||

RESULT 8
 ADR69734
 ID ADR69734 standard; peptide; 8 AA.
 XX
 AC ADR69734;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Novel hybrid antigen-related peptide #1314.
 XX
 KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX
 OS Unidentified.
 XX
 PN WO2004071457-A2.
 XX
 PD 26-AUG-2004.
 XX
 PF 13-FEB-2004; 2004WO-US004340.
 XX
 PR 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 PI Fletchner J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 PI Barber B;
 XX
 DR WPI; 2004-625768/60.
 XX
 PT New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX
 PS Example 1; Page 30; 56pp; English.
 XX
 CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating

CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 8; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 (|||||)
 Db 1 HWDFAWPW 8

RESULT 9

ID ADU08477 standard; peptide; 8 AA.

XX AC ADU08477;

XX DT 13-JAN-2005 (first entry)

XX DE Heat shock protein binding domain #226.

XX KW Hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; hsp; immune response;
 KW infectious disease; cancer; cytostatic; antimicrobial; immunostimulant.

XX OS Unidentified.

XX PN WO2004091493-A2.

XX PD 28-OCT-2004.

XX PF 09-APR-2004; 2004WO-US010983.

XX PR 11-APR-2003; 2003US-0462469P.

XX PR 18-APR-2003; 2003US-0463746P.

XX PR 16-SEP-2003; 2003US-0503417P.

XX PR 12-FEB-2004; 2004US-00776521.

XX PR 13-FEB-2004; 2004WO-US004340.

XX PR 08-APR-2004; 2004US-00820067.

XX PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX PI Flechtner JB, Prince-Cohane K, Mehta S, Slusaregicz P, Andjelic S;
 PI Barber BH;

XX WPI; 2004-775516/76.

XX PT Hybrid antigen useful for treating an infectious disease or cancer.
 PT comprises an antigenic domain from the infectious agent or cancer joined
 PT to a heat shock protein binding domain through an improved linker
 PT peptide.

XX PS Example 1; Page 58; 99pp; English.

XX CC The invention relates to hybrid antigens comprising at least one
 CC antigenic domain of an infectious agent or tumour antigen, at least one
 CC binding domain that non-covalently binds to a heat shock protein (hsp),
 CC and at least one peptide linker between them. Also disclosed are: (a) a
 CC composition for inducing an immune response to an infectious agent or
 CC tumour antigen comprising at least one of the hybrid antigens or a
 CC complex of at least one heat shock protein and at least one of the hybrid
 CC antigens, (b) a method for inducing an immune response to an infectious
 CC agent or tumour antigen by administering a hybrid antigen and a heat
 CC shock protein, where the hybrid antigen and the heat shock protein are
 CC non-covalently bound, and (c) treating an infectious disease or cancer by
 CC administering a hybrid antigen and a heat shock protein. The heat shock
 CC protein is preferably hsp70. The composition is administered via oral or
 CC parenteral route. The hybrid antigen is useful in preparing a composition
 CC for treating or preventing cancer or infectious disease. The new peptide
 CC linkers give the antigens improved activity. Note: Many of the SEQ ID Nos

CC are replicated more than once in the specification but the sequences of
 CC these replicated SEQ ID Nos are not the same. This sequence represents a
 CC heat shock protein binding sequence.

SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 8; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 (|||||)
 Db 1 HWDFAWPW 8

RESULT 10

ID ADU07913 standard; peptide; 8 AA.

XX AC ADU07913;

XX DT 13-JAN-2005 (first entry)

XX DE High affinity heat shock protein binding sequence #1.

XX KW Hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; hsp; immune response;
 KW infectious disease; cancer; cytostatic; antimicrobial; immunostimulant.

XX OS Unidentified.

XX PN WO2004091493-A2.

XX PD 28-OCT-2004.

XX PF 09-APR-2004; 2004WO-US010983.

XX PR 11-APR-2003; 2003US-0462469P.

XX PR 18-APR-2003; 2003US-0463746P.

XX PR 16-SEP-2003; 2003US-0503417P.

XX PR 12-FEB-2004; 2004US-00776521.

XX PR 13-FEB-2004; 2004WO-US004340.

XX PR 08-APR-2004; 2004US-00820067.

XX PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX PI Flechtner JB, Prince-Cohane K, Mehta S, Slusaregicz P, Andjelic S;
 PI Barber BH;

XX WPI; 2004-775516/76.

XX PT Hybrid antigen useful for treating an infectious disease or cancer,
 PT comprises an antigenic domain from the infectious agent or cancer joined
 PT to a heat shock protein binding domain through an improved linker
 PT peptide.

XX PS Disclosure; SEQ ID NO 1; 99pp; English.

XX CC The invention relates to hybrid antigens comprising at least one
 CC antigenic domain of an infectious agent or tumour antigen, at least one
 CC binding domain that non-covalently binds to a heat shock protein (hsp),
 CC and at least one peptide linker between them. Also disclosed are: (a) a
 CC composition for inducing an immune response to an infectious agent or
 CC tumour antigen comprising at least one of the hybrid antigens or a
 CC complex of at least one heat shock protein and at least one of the hybrid
 CC antigens, (b) a method for inducing an immune response to an infectious
 CC agent or tumour antigen by administering a hybrid antigen and a heat
 CC shock protein, where the hybrid antigen and the heat shock protein are
 CC non-covalently bound, and (c) treating an infectious disease or cancer by
 CC administering a hybrid antigen and a heat shock protein. The heat shock
 CC protein is preferably hsp70. The composition is administered via oral or
 CC parenteral route. The hybrid antigen is useful in preparing a composition
 CC for treating or preventing cancer or infectious disease. The new peptide

CC linkers give the antigens improved activity. Note: Many of the SEQ ID Nos
 CC are replicated more than once in the specification but the sequences of
 CC these replicated SEQ ID Nos are not the same. This sequence represents a
 CC heat shock protein binding sequence.

XX
 SQ Sequence 8 AA;

Query Match 100.0%; Score 64; DB 8; Length 8;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 11

AAU80739
 ID AAU80739 standard; peptide; 9 AA.

XX
 AC AAU80739;

XX
 DT 26-MAR-2002 (first entry)

XX
 DE Javelin peptide #5 comprising javelin and linker regions.

XX
 KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection.

XX
 OS Synthetic.

XX
 PN WO200178772-A1.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012568.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX
 PI Hoe M, Landsberger F;

XX
 DR WPI; 2002-049177/06.

XX
 PT New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.

XX
 PS Disclosure; Page 14; 75pp; English.

XX
 CC The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles

XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 64; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 2 HWDFAWPW 9

RESULT 12

AAU80740
 ID AAU80740 standard; peptide; 9 AA.

XX
 AC AAU80740;

XX
 DT 26-MAR-2002 (first entry)

XX
 DE Javelin peptide #6 comprising javelin and linker regions.

XX
 KW Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection.

XX
 OS Synthetic.

XX
 PN WO200178772-A1.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012568.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX
 PI Hoe M, Landsberger F;

XX
 DR WPI; 2002-049177/06.

XX
 PT New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.

XX
 PS Disclosure; Page 14; 75pp; English.

XX
 CC The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles

XX
 SQ Sequence 9 AA;

Query Match 100.0%; Score 64; DB 5; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 13

AAU80735
 ID AAU80735 standard; peptide; 12 AA.

XX

AC AAU80735;
 XX 26-MAR-2002 (first entry)
 XX Javelin peptide #1 comprising javelin and linker regions.
 DE
 XX Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;
 KW tick-borne encephalitis; ebola virus infection.
 XX
 OS Synthetic.
 XX
 XX WO200178772-A1.
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012568.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 XX Hoe M, Landsberger F;
 XX
 XX WPI; 2002-049177/06.
 XX
 XX New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.
 XX
 XX Disclosure; Page 14; 75pp; English.
 XX
 XX The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles
 XX
 XX Sequence 12 AA;
 PS
 XX Query Match 100.0%; Score 64; DB 5; Length 12;
 XX Best Local Similarity 100.0%; Pred. No. 0.0051;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 5 HWDFAWPW 12
 RESULT 14
 AAU80736
 ID AAU80736 standard; peptide; 12 AA.
 XX
 XX AC AAU80736;
 XX
 XX 26-MAR-2002 (first entry)
 XX
 XX Javelin peptide #2 comprising javelin and linker regions.
 DE
 XX Immunogenic complex; non-pathogenic multi-component viral particle;
 KW javelin; heat shock protein; humoral immunity; cellular immunity;
 KW anti-viral immune response; viral infection; hepatitis; influenza; mumps;
 KW HIV infection; human immunodeficiency virus; polio;

KW tick-borne encephalitis; ebola virus infection.
 XX
 XX Synthetic.
 XX
 XX WO200178772-A1.
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012568.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 XX Hoe M, Landsberger F;
 XX
 XX WPI; 2002-049177/06.
 XX
 XX New heat shock protein-based viral vaccines, useful for enhancing anti-
 PT viral immune response in an organism, particularly as a vaccine for
 PT preventing or ameliorating viral infections, e.g. hepatitis, influenza or
 PT HIV infection.
 XX
 XX Disclosure; Page 14; 75pp; English.
 XX
 XX The present invention relates to the use of an immunogenic complex,
 CC comprising a non-pathogenic multi-component viral particle covalently
 CC linked to a javelin molecule (preferably a peptide) that selectively
 CC binds to a heat shock protein. The immunogenic complex is useful for
 CC inducing both humoral and cellular immunity, especially for enhancing the
 CC anti-viral immune response, in a human or non-human subject. The
 CC immunogenic complex is particularly useful as a vaccine for preventing or
 CC ameliorating viral infections, e.g. hepatitis, influenza, mumps, HIV
 CC (human immunodeficiency virus) infection, polio, tick-borne encephalitis
 CC or ebola virus infection. AAU80735-AAU80742 represent javelin peptides,
 CC comprising javelin and linker regions, which may be covalently conjugated
 CC to multi-component viral particles
 XX
 XX Sequence 12 AA;
 PS
 XX Query Match 100.0%; Score 64; DB 5; Length 12;
 XX Best Local Similarity 100.0%; Pred. No. 0.0051;
 XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 15
 AAU72257
 ID AAU72257 standard; peptide; 16 AA.
 XX
 XX AC AAU72257;
 XX
 XX 26-FEB-2002 (first entry)
 XX
 XX gp100-derived melanoma antigen, javelin peptide #36.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX


```

PR 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 25; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 16 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.0068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 HWDFAWPW 8
DB |||||
1 HWDFAWPW 8
XX
RESULT 17
AAU72188
ID AAU72188 standard; peptide; 17 AA.
XX
AC AAU72188;
XX
DT 26-FEB-2002 (first entry)
XX
DE Tyrosine-derived melanoma antigen, javelin peptide #2.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 21; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 16 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.0068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 HWDFAWPW 8
DB |||||
9 HWDFAWPW 16
XX
RESULT 16
AAU72256
ID AAU72256 standard; peptide; 16 AA.
XX
AC AAU72256;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #35.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

```

CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 18

AAU72227
 ID AAU72227 standard; peptide; 17 AA.

XX
 AC AAU72227;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #6.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 24; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 19

AAU72296
 ID AAU72296 standard; peptide; 17 AA.

XX
 AC AAU72296;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #75.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 26; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX

XX Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8


```

XX Homo sapiens.
OS Synthetic.
XX WO200178655-A2.
XX 25-OCT-2001.
XX 17-APR-2001; 2001WO-US012449.
XX 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX Disclosure; Page 25; 150pp; English.
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX Sequence 17 AA;
XX Query Match 100.0%; Score 64; DB 4; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 0.0072;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 HWDFAWFW 8
XX |||||||
XX Db 1 HWDFAWFW 8
XX
XX RESULT 23
XX AAU72306
XX ID AAU72306 standard; peptide; 17 AA.
XX AC AAU72306;
XX 26-FEB-2002 (first entry)
XX DE gpl00-derived melanoma antigen, javelin peptide #85.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX WO200178655-A2.
XX 25-OCT-2001.
XX 17-APR-2001; 2001WO-US012449.

```

```

XX 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX Disclosure; Page 26; 150pp; English.
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX Sequence 17 AA;
XX Query Match 100.0%; Score 64; DB 4; Length 17;
XX Best Local Similarity 100.0%; Pred. No. 0.0072;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX QY 1 HWDFAWFW 8
XX |||||||
XX Db 1 HWDFAWFW 8
XX
XX RESULT 24
XX AAU72417
XX ID AAU72417 standard; peptide; 17 AA.
XX AC AAU72417;
XX 26-FEB-2002 (first entry)
XX DE MAGE-1-derived melanoma antigen, javelin peptide #16.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX WO200178655-A2.
XX 25-OCT-2001.
XX 17-APR-2001; 2001WO-US012449.
XX 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX

```


CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 27

AAU72197
 ID AAU72197 standard; peptide; 17 AA.

XX AAU72197;

AC 26-FEB-2002 (first entry)

DE Tyrosine-derived melanoma antigen, javelin peptide #11.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

OS WO200178655-A2.

PN 25-OCT-2001.

PD 17-APR-2001; 2001WO-US012449.

PF 17-APR-2000; 2000US-0197462P.

PR (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 23; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 28

AAU72447
 ID AAU72447 standard; peptide; 17 AA.

XX AAU72447;

AC 26-FEB-2002 (first entry)

DE MAGE-1/3-derived melanoma antigen, javelin peptide #6.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

OS WO200178655-A2.

PN 25-OCT-2001.

PD 17-APR-2001; 2001WO-US012449.

PF 17-APR-2000; 2000US-0197462P.

PR (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 10 HWDFAWPW 17

RESULT 29

AAU72187
 ID AAU72187 standard; peptide; 17 AA.

XX

AC AAU72187;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #1.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 21; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8
 |||||
 RESULT 30
 AAU72267
 ID AAU72267 standard; peptide; 17 AA.
 XX
 AC AAU72267;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #46.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 10 HWDFAWPW 17
 |||||
 RESULT 31
 AAU72366
 ID AAU72366 standard; peptide; 17 AA.
 XX
 AC AAU72366;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #5.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX


```

PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT
XX Disclosure; Page 29; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 17 AA;
Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 10 HWDFAWPW 17
|||||||

RESULT 32
AAU72207
ID AAU72207 standard; peptide; 17 AA.
XX
AC AAU72207;
XX
DT 26-FEB-2002 (first entry)
XX
DE Tyrosine-derived melanoma antigen, javelin peptide #21.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT
XX Disclosure; Page 25; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 17 AA;
Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 10 HWDFAWPW 17
|||||||

RESULT 33
AAU72276
ID AAU72276 standard; peptide; 17 AA.
XX
AC AAU72276;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #55.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT
XX Disclosure; Page 25; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 17 AA;
Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 10 HWDFAWPW 17
|||||||

```

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 34
 AAU72277
 ID AAU72277 standard; peptide; 17 AA.
 XX
 AC AAU72277;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #56.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 10 HWDFAWPW 17
 |||||

RESULT 35
 AAU72406
 ID AAU72406 standard; peptide; 17 AA.
 XX
 AC AAU72406;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1-derived melanoma antigen, javelin peptide #5.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 31; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 36
 AAU72476
 ID AAU72476 standard; peptide; 17 AA.
 XX
 AC AAU72476;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 OS (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 34; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 37
 AAU72367
 ID AAU72367 standard; peptide; 17 AA.

XX AAU72367;
 AC
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 OS (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 10 HWDFAWPW 17

RESULT 38
 AAU72396
 ID AAU72396 standard; peptide; 17 AA.
 XX
 AC AAU72396;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE
 XX
 DE
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 30; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, NYES01, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX Sequence 17 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 39
 AAU72196
 ID AAU72196 standard; peptide; 17 AA.
 AC AAU72196;
 XX 26-FEB-2002 (first entry)
 DT
 XX Tyrosine-derived melanoma antigen, javelin peptide #10.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 OS WO200178655-A2.
 XX 25-OCT-2001.
 PD

XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 23; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, NYES01, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX Sequence 17 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 RESULT 40
 AAU72446
 ID AAU72446 standard; peptide; 17 AA.
 XX AAU72446;
 AC AAU72446;
 XX 26-FEB-2002 (first entry)
 DT
 XX MAGE-1/3-derived melanoma antigen, javelin peptide #5.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 OS WO200178655-A2.
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 PT Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 41
 AAU72206
 ID AAU72206 standard; peptide; 17 AA.
 XX
 AC AAU72206;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #20.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 CC Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 42
 AAU72217
 ID AAU72217 standard; peptide; 17 AA.
 XX
 AC AAU72217;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #31.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 CC Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 PS Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
DB 10 HWDFAWPW 17

RESULT 43
AAU72237
ID AAU72237 standard; peptide; 17 AA.

XX AC AAU72237;

XX DT 26-FEB-2002 (first entry)

XX DE gpl00-derived melanoma antigen, javelin peptide #16.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 24; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention

XX SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
|||
DB 10 HWDFAWPW 17

RESULT 44

AAU72397
ID AAU72397 standard; peptide; 17 AA.

XX AC AAU72397;

XX DT 26-FEB-2002 (first entry)

XX DE MART-1-derived melanoma antigen, javelin peptide #36.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 30; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention

XX SQ Sequence 17 AA;

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.0072;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||
DB 10 HWDFAWPW 17

RESULT 45
AAU72236

ID AAU72236 standard; peptide; 17 AA.
 AC AAU72236;
 DT 26-FEB-2002 (first entry)
 DE
 DE gp100-derived melanoma antigen, javelin peptide #15.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 PD
 PD 17-APR-2001; 2001WO-US012449.
 PF
 PF 17-APR-2000; 2000US-0197462P.
 PR
 PR (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 DR
 PA Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 24; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||
 RESULT 46
 AAU72307
 ID AAU72307 standard; peptide; 17 AA.
 XX
 AC AAU72307;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 DE gp100-derived melanoma antigen, javelin peptide #86.
 DE Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 PD
 PD 17-APR-2001; 2001WO-US012449.
 PF
 PF 17-APR-2000; 2000US-0197462P.
 PR
 PR (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 DR
 PA Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 26; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 17 AA;
 Query Match 100.0%; Score 64; DB 4; Length 17;
 Best Local Similarity 100.0%; Pred. No. 0.0072;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 10 HWDFAWPW 17
 |||||
 RESULT 47
 AAU72216
 ID AAU72216 standard; peptide; 17 AA.
 XX
 AC AAU72216;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 DE Tyrosine-derived melanoma antigen, javelin peptide #30.
 DE Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX

[illegible]

XX Disclosure; Page 28; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8

Db 11 HWDFAWPM 18

RESULT 50

AAU72387

ID AAU72387 standard; peptide; 18 AA.

XX AAU72387;

XX 26-FEB-2002 (first entry)

XX MART-1-derived melanoma antigen, javelin peptide #26.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

XX Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 29; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8

Db 11 HWDFAWPM 18

RESULT 51

AAU72326

ID AAU72326 standard; peptide; 18 AA.

XX AAU72326;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #105.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

XX Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 27; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8

Db 11 HWDFAWPM 18

RESULT 51

AAU72326

ID AAU72326 standard; peptide; 18 AA.

XX AAU72326;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #105.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

XX Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 27; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 52
AAU72327
ID AAU72327 standard; peptide; 18 AA.
XX
AC AAU72327;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE gp100-derived melanoma antigen, javelin peptide #106.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 27; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 11 HWDFAWPW 18

RESULT 53
AAU72286
ID AAU72286 standard; peptide; 18 AA.
XX
AC AAU72286;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE gp100-derived melanoma antigen, javelin peptide #65.
XX

AAU72427
ID AAU72427 standard; peptide; 18 AA.
XX
AC AAU72427;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE MAGE-1-derived melanoma antigen, javelin peptide #26.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 31; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 11 HWDFAWPW 18

RESULT 54
AAU72286
ID AAU72286 standard; peptide; 18 AA.
XX
AC AAU72286;
XX
XX 26-FEB-2002 (first entry)
DT
XX
DE gp100-derived melanoma antigen, javelin peptide #65.
XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 26; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 1 HWDFAWPW 8
 RESULT 55
 AAU72385
 ID AAU72386 standard; peptide; 18 AA.
 XX
 AC AAU72386;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #25.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.

XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 29; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 1 HWDFAWPW 8
 RESULT 56
 AAU72456
 ID AAU72456 standard; peptide; 18 AA.
 XX
 AC AAU72456;
 XX
 XX 26-FEB-2002 (first entry)
 DT
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #15.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 XX (HOEW/) HOE M.
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWFW 8
 DB |||||||
 1 HWDFAWFW 8
 RESULT 57
 AAU72337
 ID AAU72337 standard; peptide; 18 AA.
 XX
 AC AAU72337;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #116.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;
 Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWFW 8
 DB |||||||
 11 HWDFAWFW 18
 RESULT 58
 AAU72376
 ID AAU72376 standard; peptide; 18 AA.
 XX
 AC AAU72376;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #15.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 59

AAU72426
ID AAU72426 standard; peptide; 18 AA.

XX
AC AAU72426;

XX
DT 26-FEB-2002 (first entry)

XX
DE MAGE-1-derived melanoma antigen, javelin peptide #25.

XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX
OS Homo sapiens.
OS Synthetic.

XX
PN WO200178655-A2.

XX
PD 25-OCT-2001.

XX
PF 17-APR-2001; 2001WO-US012449.

XX
PR 17-APR-2000; 2000US-0197462P.

XX
PA (HOUG/) HOUGHTON A.

XX
PA (LIVI/) LIVINGSTON P.

XX
PA (ALAW/) AL-AWQATI Q.

XX
PA (MAYH/) MAYHEW M.

XX
PA (HOEM/) HOE M.

XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX
DR WPI; 2001-663092/76.

XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX
PS Disclosure; Page 31; 150pp; English.

XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 60

AAU72457
ID AAU72457 standard; peptide; 18 AA.

XX
AC AAU72457;

XX
DT 26-FEB-2002 (first entry)

XX
DE MAGE-1/3-derived melanoma antigen, javelin peptide #16.

XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX
OS Homo sapiens.
OS Synthetic.

XX
PN WO200178655-A2.

XX
PD 25-OCT-2001.

XX
PF 17-APR-2001; 2001WO-US012449.

XX
PR 17-APR-2000; 2000US-0197462P.

XX
PA (HOUG/) HOUGHTON A.

XX
PA (LIVI/) LIVINGSTON P.

XX
PA (ALAW/) AL-AWQATI Q.

XX
PA (MAYH/) MAYHEW M.

XX
PA (HOEM/) HOE M.

XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX
DR WPI; 2001-663092/76.

XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX
PS Disclosure; Page 33; 150pp; English.

XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX
SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 11 HWDFAWPW 18

```

RESULT 61
AAU72246
ID AAU72246 standard; peptide; 18 AA.
XX AC AAU72246;
XX DT 26-FEB-2002 (first entry)
XX DE gp100-derived melanoma antigen, javelin peptide #25.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX XX (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 24; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 18 AA;
Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 11 HWDFAWPW 18
RESULT 62
AAU72247
ID AAU72247 standard; peptide; 18 AA.
XX AC AAU72247;
XX DT 26-FEB-2002 (first entry)
XX DE gp100-derived melanoma antigen, javelin peptide #26.

```

```

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX XX (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 24; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 18 AA;
Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 11 HWDFAWPW 18
RESULT 63
AAU72466
ID AAU72466 standard; peptide; 18 AA.
XX AC AAU72466;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1/3-derived melanoma antigen, javelin peptide #25.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.

```


PN WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 33; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 18 AA;
 SQ Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 64
 AAU72346
 ID AAU72346 standard; peptide; 18 AA.
 XX
 AC AAU72346;
 XX 26-FEB-2002 (first entry)
 DT
 XX gpl00-derived melanoma antigen, javelin peptide #125.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 28; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 18 AA;
 SQ Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 65
 AAU72467
 ID AAU72467 standard; peptide; 18 AA.
 XX
 AC AAU72467;
 XX 26-FEB-2002 (first entry)
 DT
 XX MAGE-1/3-derived melanoma antigen, javelin peptide #26.
 DE
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 11 HWDFAWPW 18

RESULT 66
 AAU72316
 ID AAU72316 standard; peptide; 18 AA.
 XX
 AC AAU72316;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #95.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX

OS Homo sapiens.
 OS Synthetic.

PN WO200178655-A2.

PD 25-OCT-2001.

PF 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 27; 150pp; English.

PS The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 67
 AAU72336
 ID AAU72336 standard; peptide; 18 AA.

XX AC AAU72336;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #115.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX

OS Homo sapiens.

OS Synthetic.

PN WO200178655-A2.

PD 25-OCT-2001.

PF 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 27; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 68
AAU72436
ID AAU72436 standard; peptide; 18 AA.
XX
AC AAU72436;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-1-derived melanoma antigen, javelin peptide #35.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 32; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 18 AA;

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 70
AAU72437
ID AAU72437 standard; peptide; 18 AA.
XX
AC AAU72437;
XX
DT 26-FEB-2002 (first entry)
XX

```

```

RESULT 69
AAU72356
ID AAU72356 standard; peptide; 18 AA.
XX
AC AAU72356;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #135.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 28; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 18 AA;

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.0076;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 70
AAU72437
ID AAU72437 standard; peptide; 18 AA.
XX
AC AAU72437;
XX
DT 26-FEB-2002 (first entry)
XX

```

DE MAGE-1-derived melanoma antigen, javelin peptide #36.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX

XX WO200178655-A2.

XX

XX 25-OCT-2001.

XX

XX 17-APR-2001; 2001WO-US012449.

XX

XX 17-APR-2000; 2000US-0197462P.

XX

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

XX Disclosure; Page 32; 150pp; English.

XX

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db |||||

11 HWDFAWPW 18

RESULT 71

AAU72287

ID AAU72287 standard; peptide; 18 AA.

XX

XX AAU72287;

XX

XX 26-FEB-2002 (first entry)

XX

XX gp100-derived melanoma antigen, javelin peptide #66.

XX

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX

XX 25-OCT-2001.

XX

XX 17-APR-2001; 2001WO-US012449.

XX

XX 17-APR-2000; 2000US-0197462P.

XX

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX

XX Disclosure; Page 26; 150pp; English.

XX

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;

Best Local Similarity 100.0%; Pred. No. 0.0076;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db |||||

11 HWDFAWPW 18

RESULT 72

AAU72317

ID AAU72317 standard; peptide; 18 AA.

XX

XX AAU72317;

XX

XX 26-FEB-2002 (first entry)

XX

XX gp100-derived melanoma antigen, javelin peptide #96.

XX

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX

OS Homo sapiens.

OS Synthetic.

XX

XX WO200178655-A2.

XX

XX 25-OCT-2001.

XX

XX 17-APR-2001; 2001WO-US012449.

XX

XX 17-APR-2000; 2000US-0197462P.

XX

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 18 AA;

Query Match 100.0%; Score 64; DB 4; Length 18;
 Best Local Similarity 100.0%; Pred. No. 0.0076;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 11 HWDFAWPW 18

RESULT 75
 AAW19956
 ID AAW19956 standard; peptide; 19 AA.
 AC AAW19956;
 XX

DT 10-NOV-1997 (first entry)

DE OVA-BiP-binding domain hybrid peptide.

KW Vaccine; immunotherapy; heat shock protein; BiP; OVA; cancer;
 KW infectious disease.
 XX

OS Synthetic.

XX Key Location/Qualifiers
 FT Peptide 1..8
 FT /label= OVA
 FT Peptide 9..11
 FT /label= Linker
 FT Peptide 12..19
 FT /label= BiP
 XX

PN WO9706821-A1.

XX 27-FEB-1997.

XX 16-AUG-1996; 96WO-US013363.

XX 18-AUG-1995; 95US-0002479P.

PR 18-AUG-1995; 95US-0002490P.

XX (SLOK) SLOAN KETTERING INST CANCER RES.

PA Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
 PI WPI; 1997-165035/15.
 XX

XX Compn. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.
 XX

PS Example 1; Page 18; 58pp; English.

XX Hybrid peptides OVA-BiP (AAW19956) and BiP-OVA (AAW19957) comprise
 CC chicken OVA-peptide (see AAW19955) joined via a peptide linker to heat
 CC shock protein (HSP) BiP binding domain (see also AAW19951). The hybrid
 CC peptide can be combined in vitro with a HSP, such as hep70, to form a
 CC complex that, when administered to a subject, induces an immune response
 XX

XX Sequence 19 AA;

Query Match 100.0%; Score 64; DB 2; Length 19;

Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 12 HWDFAWPW 19

RESULT 76
 AAW19957
 ID AAW19957 standard; peptide; 19 AA.
 XX
 AC AAW19957;
 XX

DT 10-NOV-1997 (first entry)

DE BiP-binding domain-OVA hybrid peptide.

KW Vaccine; immunotherapy; heat shock protein; BiP; OVA; cancer;
 KW infectious disease.
 XX

OS Synthetic.

XX Key Location/Qualifiers
 FT Peptide 1..8
 FT /label= BiP
 FT Peptide 9..11
 FT /label= Linker
 FT Peptide 12..19
 FT /label= Ova
 XX

PN WO9706821-A1.

XX 27-FEB-1997.

XX 16-AUG-1996; 96WO-US013363.

PR 18-AUG-1995; 95US-0002479P.

PR 18-AUG-1995; 95US-0002490P.

XX (SLOK) SLOAN KETTERING INST CANCER RES.

XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
 XX WPI; 1997-165035/15.

XX Compn. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.
 XX

PS Example 1; Page 18; 58pp; English.

XX Hybrid peptides OVA-BiP (AAW19956) and BiP-OVA (AAW19957) comprise
 CC chicken OVA-peptide (see AAW19955) joined via a peptide linker to heat
 CC shock protein (HSP) BiP binding domain (see also AAW19951). The hybrid
 CC peptide can be combined in vitro with a HSP, such as hep70, to form a
 CC complex that, when administered to a subject, induces an immune response
 XX

XX Sequence 19 AA;

Query Match 100.0%; Score 64; DB 2; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 77
 AAU72254
 ID AAU72254 standard; peptide; 19 AA.
 XX

AAU72254;
 AC 26-FEB-2002 (first entry)
 DT
 XX
 DE gp100-derived melanoma antigen, javelin peptide #33.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 PT
 PT Disclosure; Page 25; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 19 AA;
 Query Match 100.0%; Score 64; DB 4; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 |||||
 Db 12 HWDFAWPW 19
 RESULT 78
 AAU72253
 ID AAU72253 standard; peptide; 19 AA.
 XX
 AC AAU72253;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #32.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 PT
 PT Disclosure; Page 25; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 19 AA;
 Query Match 100.0%; Score 64; DB 4; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8
 RESULT 79
 AAEL13446
 ID AAEL13446 standard; peptide; 19 AA.
 XX
 AC AAEL13446;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 DE Chicken MHC class I peptide antigen #1.
 XX
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; chicken.
 XX
 OS Gallus gallus.
 XX
 PH Key Location/Qualifiers
 FT Region 1..8
 FT /note= "MHC class I epitope"
 FT Region 9..11
 FT /note= "Linker"
 FT Region 12..19

PT isolation and identification.

XX Example; Page 18; 62pp; English.

XX
CC The invention relates to a method for identification of a peptide binding
CC to a heat shock protein (hsp) involving contacting a phage display
CC library of several bacteriophage which express, in a surface protein,
CC several inserted peptides with an hsp target or hsp target bound to a
CC benzquinone anisamycin antibiotic in a physiological binding buffer or
CC binding buffer, isolating the phage, and identifying the inserted peptide
CC expressed in the surface protein of the phage. The method is useful for
CC identifying a peptide, which binds to a heat shock protein, which is used
CC in a conjugate peptide for inducing an immune response, for the treatment
CC of infectious diseases (e.g. diseases caused by a bacterium, virus,
CC protozoan, mycoplasma, fungus, yeast, parasite or prion such as human
CC papillomavirus, a herpes virus such as herpes simplex virus, a retrovirus
CC such as human immunodeficiency virus 1 or 2, a hepatitis virus, an
CC influenza virus, a rhinovirus, respiratory syncytial virus, a
CC cytomegalovirus, an adenovirus, Mycoplasma pneumoniae, a bacterium of the
CC genus Salmonella, Staphylococcus, Streptococcus, Enterococcus,
CC Clostridium, Escherichia, Klebsiella, Vibrio or Mycobacterium, a
CC protozoan such as an amoeba, malarial parasite or Trypanosoma cruzi), or
CC malignant diseases, for treating or preventing neoplastic diseases (e.g.
CC sarcoma, lymphoma, leukaemia, melanoma, carcinoma of the breast,
CC carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix,
CC uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma
CC or astrocytoma) or immunological diseases (e.g. AIDS) and for treating
CC autoimmune diseases such as rheumatoid arthritis, systemic lupus
CC erythematosus, diabetes mellitus, thyroiditis and multiple sclerosis.
CC This sequence represents an hsp related peptide of the invention.

XX Sequence 19 AA;

Query Match 100.0%; Score 64; DB 7; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0081;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 12 HWDFAWPW 19
|||||

RESULT 84

ADR69737
ID ADR69737 standard; peptide; 19 AA.

XX ADR69737;

XX 18-NOV-2004 (first entry)

XX Novel hybrid antigen-related peptide #1317.

XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
KW gene therapy; infectious disease; cancer.

XX Unidentified.

XX WO2004071457-A2.

XX 26-AUG-2004.

XX 13-FEB-2004; 2004WO-US004340.

XX 13-FEB-2003; 2003US-0447142P.

XX 11-APR-2003; 2003US-0462469P.

XX 18-APR-2003; 2003US-0463746P.

XX 16-SEP-2003; 2003US-0503417P.

XX 12-FEB-2004; 2004US-00776521.

XX (MOJA-) MOJAVE THERAPEUTICS INC.

XX Fletchner J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;

PI Barber B;

XX WPI; 2004-625768/60.

XX
PT New hybrid antigens comprising an antigenic domain and improved heat
PT shock protein-binding domains, useful for preventing or treating
PT infectious diseases or cancer.

XX Example 1; Page 30; 56pp; English.

XX This invention relates to a novel hybrid antigen which comprises at least
CC one antigenic domain of an infectious agent or tumour antigen and a
CC binding domain that non-covalently binds to a heat shock protein. The
CC invention may be useful for the production of compounds with an
CC antimicrobial or cytostatic activity. In addition, the invention may
CC prove useful for the production of a vaccine or for gene therapy. The
CC composition and methods disclosed are useful for preventing or treating
CC infectious diseases or cancer. The present sequence is that of a peptide
CC which was used in the exemplification of the invention.

XX Sequence 19 AA;

Query Match 100.0%; Score 64; DB 8; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0081;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 12 HWDFAWPW 19
|||||

RESULT 85

ADR69751

ID ADR69751 standard; peptide; 19 AA.

XX ADR69751;

XX 18-NOV-2004 (first entry)

XX Novel hybrid antigen-related peptide #1331.

XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
KW gene therapy; infectious disease; cancer.

XX Unidentified.

XX Synthetic.

XX WO2004071457-A2.

XX 26-AUG-2004.

XX 13-FEB-2004; 2004WO-US004340.

XX 13-FEB-2003; 2003US-0447142P.

XX 11-APR-2003; 2003US-0462469P.

XX 18-APR-2003; 2003US-0463746P.

XX 16-SEP-2003; 2003US-0503417P.

XX 12-FEB-2004; 2004US-00776521.

XX (MOJA-) MOJAVE THERAPEUTICS INC.

XX Fletchner J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;

XX Barber B;
XX WPI; 2004-625768/60.

XX New hybrid antigens comprising an antigenic domain and improved heat
XX shock protein-binding domains, useful for preventing or treating
XX infectious diseases or cancer.

XX Example 1; Page 38; 56pp; English.

CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

XX SQ Sequence 19 AA;

Query Match 100.0%; Score 64; DB 8; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 12 HWDFAWPW 19
 |||||

RESULT 86

ADR69754
 ID ADR69754 standard; peptide; 19 AA.

XX AC ADR69754;

XX DT 18-NOV-2004 (first entry)

XX DE Novel hybrid antigen-related peptide #1334.

XX KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.

XX OS Unidentified.

XX OS Synthetic.

XX PN WO2004071457-A2.

XX PD 26-AUG-2004.

XX PF 13-FEB-2004; 2004WO-US004340.

XX PR 13-FEB-2003; 2003US-0447142P.

XX PR 11-APR-2003; 2003US-0462469P.

XX PR 18-APR-2003; 2003US-0463746P.

XX PR 16-SEP-2003; 2003US-0503417P.

XX PR 12-FEB-2004; 2004US-00776521.

XX PA (MOJA-) MOJAVE THERAPEUTICS INC.

XX PI Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 PI Barber B;

XX WPI; 2004-625768/60.

XX DR New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.

XX PS Example 1; Page 38; 56pp; English.

XX CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

SQ Sequence 19 AA;

Query Match 100.0%; Score 64; DB 8; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0081;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 87

AAW19966

ID AAW19966 standard; peptide; 20 AA.

XX AC AAW19966;

XX DT 10-NOV-1997 (first entry)

XX DE HPV hybrid protein E7.2 (Type 6b)-BiP for use in vaccine.

XX KW Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
 KW HPV.

XX OS Synthetic.

XX PH Key Location/Qualifiers

FT Peptide 1..9

FT Peptide /label= E7

FT Peptide 10..12

FT Peptide /label= Linker

FT Peptide 13..20

FT Peptide /label= BiP

XX PN WO9706821-A1.

XX PD 27-FEB-1997.

XX PF 16-AUG-1996; 96WO-US013363.

XX PR 18-AUG-1995; 95US-0002479P.

XX PR 18-AUG-1995; 95US-0002490P.

XX PA (SLOK) SLOAN KETTERING INST CANCER RES.

XX PI Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
 WPI; 1997-165035/15.

XX DR WPI; 1997-165035/15.

XX PT Compan. for inducing immune response contg. antigen and heat shock
 PT protein -also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX PS Example 10; Page 24; 58pp; English.

XX CC Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein BiP binding domain (see also AAW19951). The
 CC peptide given in AAW19966 comprises a fusion of HCV E7.2 (Type 6b)
 CC peptide and BiP binding domain. The hybrid peptide is combined in vitro
 CC with a HSP to form a complex that, when administered to a subject,
 CC induces an immune response against HCV

XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 13 HWDFAWPW 20
 |||||

RESULT 88	
AAW19961	
ID	AAW19961 standard; peptide; 20 AA.
XX	
AC	AAW19961;
XX	
DT	10-NOV-1997 (first entry)
XX	
DE	HPV hybrid protein Bip-E7 (Type 16) for use in vaccine.
XX	
KW	Vaccine; immunotherapy; heat shock protein; Bip; human papilloma virus;
KW	HPV.
XX	
OS	Synthetic.
XX	
FH	Key
FT	Peptide
FT	1. .8
FT	/label= Bip
FT	9. .11
FT	/label= Linker
FT	12. .20
FT	/label= E7
XX	
PN	WO9706821-A1.
XX	
PD	27-FEB-1997.
XX	
PF	16-AUG-1996; 96WO-US013363.
XX	
PR	18-AUG-1995; 95US-0002479P.
PR	18-AUG-1995; 95US-0002490P.
XX	
PA	(SLOK) LOAN KETTERING INST CANCER RES.
XX	
PI	Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
XX	
DR	WPI; 1997-165035/15.
XX	
PT	Compan. for inducing immune response contg. antigen and heat shock
PT	protein - also new hybrid peptide and related nucleic acid, for treatment
PT	of infectious diseases and tumours.
XX	
PS	Example 10; Page 23; 58pp; English.
XX	
CC	Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
CC	virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
CC	to a heat shock protein Bip binding domain (see also AAW19951). The
CC	peptide given in AAW19961 comprises a fusion of Bip binding domain and
CC	HCV E7 (type 16) peptide. The hybrid peptide is combined in vitro with a
CC	HSP to form a complex that, when administered to a subject, induces an
CC	immune response against HCV
XX	
SQ	Sequence 20 AA;
Query Match	100.0%; Score 64; DB 2; Length 20;
Best Local Similarity	100.0%; Pred. No. 0.0085;
Matches	8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1 HWDFAWPW 8
Db	1 HWDFAWPW 8
RESULT 89	
AAW19967	
ID	AAW19967 standard; peptide; 20 AA.
XX	
AC	AAW19967;
XX	
DT	10-NOV-1997 (first entry)
XX	
DE	HPV hybrid protein Bip-E7.2 (Type 6b) for use in vaccine.

PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX Example 10; Page 24; 58pp; English.

XX Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein Bip binding domain (see also AAW19951). The
 CC peptide given in AAW19964 comprises a fusion of HCV E7.1 (Type 6b)
 CC peptide and Bip binding domain. The hybrid peptide is combined in vitro
 CC with a HSP to form a complex that, when administered to a subject,
 CC induces an immune response against HCV

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 13 HWDFAWPW 20

RESULT 93

AAW19965
 ID AAW19965 standard; peptide; 20 AA.

XX AAW19965;

XX 10-NOV-1997 (first entry)

XX HPV hybrid protein BiP-E7.1 (Type 6b) for use in vaccine.

XX Vaccine; immunotherapy; heat shock protein; Bip; human papilloma virus;
 KW HPV.

XX Synthetic.

Key	Location/Qualifiers
FT Peptide	1..8
FT Peptide	/label= Bip
FT Peptide	9..11
FT Peptide	/label= Linker
FT Peptide	12..20
FT Peptide	/label= E7

XX WO9706821-A1.

XX 27-FEB-1997.

XX 16-AUG-1996; 96WO-US013363.

XX 18-AUG-1995; 95US-0002479P.

XX 18-AUG-1995; 95US-0002490P.

XX (SLOK) SLOAN KETTERING INST CANCER RES.

XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;

XX WPI; 1997-165035/15.

XX Compon. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX Example 10; Page 24; 58pp; English.

XX Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein Bip binding domain (see also AAW19951). The
 CC peptide given in AAW19965 comprises a fusion of Bip binding domain and
 CC HCV E7.1 (type 6b) peptide. The hybrid peptide is combined in vitro with

CC a HSP to form a complex that, when administered to a subject, induces an
 CC immune response against HCV

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 94

AAW19959
 ID AAW19959 standard; peptide; 20 AA.

XX AAW19959;

XX 10-NOV-1997 (first entry)

XX HPV hybrid protein BiP-E7 (Type 11) for use in vaccine.

XX Vaccine; immunotherapy; heat shock protein; Bip; human papilloma virus;
 KW HPV.

XX Synthetic.

Key	Location/Qualifiers
FT Peptide	1..8
FT Peptide	/label= Bip
FT Peptide	9..11
FT Peptide	/label= Linker
FT Peptide	12..20
FT Peptide	/label= E7

XX WO9706821-A1.

XX 27-FEB-1997.

XX 16-AUG-1996; 96WO-US013363.

XX 18-AUG-1995; 95US-0002479P.

XX 18-AUG-1995; 95US-0002490P.

XX (SLOK) SLOAN KETTERING INST CANCER RES.

XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;

XX WPI; 1997-165035/15.

XX Compon. for inducing immune response contg. antigen and heat shock
 PT protein - also new hybrid peptide and related nucleic acid, for treatment
 PT of infectious diseases and tumours.

XX Example 10; Page 23; 58pp; English.

XX Hybrid peptides (AAW19958-67) for use in vaccines against human papilloma
 CC virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
 CC to a heat shock protein Bip binding domain (see also AAW19951). The
 CC peptide given in AAW19959 comprises a fusion of Bip binding domain and
 CC HCV E7 (type 11) peptide. The hybrid peptide is combined in vitro with a
 CC HSP to form a complex that, when administered to a subject, induces an
 CC immune response against HCV

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 2; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8

```

Db      |||||
      1 HWDFAWPW 8

RESULT 95
AAW19963
ID AAW19963 standard; peptide; 20 AA.
XX
AC AAW19963;
XX
DT 10-NOV-1997 (first entry)
XX
DE HPV hybrid protein BiP-E7 (Type 18) for use in vaccine.
XX
KW Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
KW HPV.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Peptide 1..8
FT Peptide /label= BiP
FT Peptide 9..11
FT Peptide /label= Linker
FT Peptide 12..20
FT Peptide /label= E7
XX
PN WO9706821-A1.
XX
XX 27-FEB-1997.
XX
XX 16-AUG-1996; 96WO-US013363.
XX
XX 18-AUG-1995; 95US-0002479P.
XX
XX 18-AUG-1995; 95US-0002490P.
XX
XX (SLOK ) SLOAN KETTERING INST CANCER RES.
XX
XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
XX WPI; 1997-165035/15.
XX
XX Compsn. for inducing immune response contg. antigen and heat shock
XX protein - also new hybrid peptide and related nucleic acid, for treatment
XX of infectious diseases and tumours.
XX
XX Example 10; Page 23; 58pp; English.
XX
XX Hybrid peptides (AAW1958-67) for use in vaccines against human papilloma
XX virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
XX to a heat shock protein BiP binding domain (see also AAW19951). The
XX peptide given in AAW1963 comprises a fusion of BiP binding domain and
XX HCV E7 (type 18) peptide. The hybrid peptide is combined in vitro with a
XX HSP to form a complex that, when administered to a subject, induces an
XX immune response against HCV
XX
XX Sequence 20 AA;
XX
XX Query Match 100.0%; Score 64; DB 2; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.0085;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 HWDFAWPW 8
XX |||||
XX Db 1 HWDFAWPW 8

RESULT 96
AAW19958
ID AAW19958 standard; peptide; 20 AA.
XX
AC AAW19958;
XX

```

```

DT 10-NOV-1997 (first entry)
XX
XX HPV hybrid protein E7 (Type 11)-BiP for use in vaccine.
XX
XX Vaccine; immunotherapy; heat shock protein; BiP; human papilloma virus;
XX HPV.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Peptide 1..9
XX Peptide /label= E7
XX Peptide 10..12
XX Peptide /label= Linker
XX Peptide 13..20
XX Peptide /label= BiP
XX
XX WO9706821-A1.
XX
XX 27-FEB-1997.
XX
XX 16-AUG-1996; 96WO-US013363.
XX
XX 18-AUG-1995; 95US-0002479P.
XX
XX 18-AUG-1995; 95US-0002490P.
XX
XX (SLOK ) SLOAN KETTERING INST CANCER RES.
XX
XX Rothman JE, Hartl FU, Hoe MH, Houghton A, Takeuchi Y, Mayhew M;
XX WPI; 1997-165035/15.
XX
XX Compsn. for inducing immune response contg. antigen and heat shock
XX protein - also new hybrid peptide and related nucleic acid, for treatment
XX of infectious diseases and tumours.
XX
XX Example 10; Page 23; 58pp; English.
XX
XX Hybrid peptides (AAW1958-67) for use in vaccines against human papilloma
XX virus (HPV) comprise an HPV antigenic peptide joined via a peptide linker
XX to a heat shock protein BiP binding domain (see also AAW19951). The
XX peptide given in AAW1958 comprises a fusion of HCV E7 (type 11) peptide
XX and BiP binding domain. The hybrid peptide is combined in vitro with a
XX HSP to form a complex that, when administered to a subject, induces an
XX immune response against HCV
XX
XX Sequence 20 AA;
XX
XX Query Match 100.0%; Score 64; DB 2; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 0.0085;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 HWDFAWPW 8
XX |||||
XX Db 13 HWDFAWPW 20

RESULT 97
AAU72404
ID AAU72404 standard; peptide; 20 AA.
XX
XX AAU72404;
XX
XX 26-FEB-2002 (first entry)
XX
XX MAGE-1-derived melanoma antigen, javelin peptide #3.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX

```

OS Synthetic.
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 31; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. NO. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 13 HWDFAWPW 20
 RESULT 98
 AAU72444
 ID AAU72444 standard; peptide; 20 AA.
 XX
 AC AAU72444;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #3.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR

XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 PT
 XX Disclosure; Page 33; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 13 HWDFAWPW 20
 RESULT 99
 AAU72203
 ID AAU72203 standard; peptide; 20 AA.
 XX
 AC AAU72203;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #17.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX


```

XX SQ Sequence 20 AA;
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 13 HWDFAPWP 20
|||||

RESULT 102
AAU72403
ID AAU72403 standard; peptide; 20 AA.
XX AC AAU72403;
XX DT 26-FEB-2002 (first entry)
XX DE
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 31; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 20 AA;
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 13 HWDFAPWP 20
|||||

RESULT 104
AAU72234
ID AAU72234 standard; peptide; 20 AA.
XX AC AAU72234;
XX XX

```

DT 26-FEB-2002 (first entry)
 XX
 DE
 XX gpl00-derived melanoma antigen, javelin peptide #13.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 24; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAFPW 8
 Db |||||
 13 HWDFAFPW 20
 RESULT 105
 AAU72303
 ID AAU72303 standard; peptide; 20 AA.
 XX
 AC AAU72303;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gpl00-derived melanoma antigen, javelin peptide #82.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX

OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 26; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAFPW 8
 Db |||||
 1 HWDFAFPW 8
 RESULT 106
 AAU72193
 ID AAU72193 standard; peptide; 20 AA.
 XX
 AC AAU72193;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #7.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX

```

PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 23; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
XX
RESULT 107
AAU72293
ID AAU72293 standard; peptide; 20 AA.
XX
AC AAU72293;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #72.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 23; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
XX
RESULT 108
AAU72294
ID AAU72294 standard; peptide; 20 AA.
XX
AC AAU72294;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #73.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 26; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,

```

comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 109

AAU72194
ID AAU72194 standard; peptide; 20 AA.

XX AC AAU72194;

XX DT 26-FEB-2002 (first entry)

XX DE Tyrosine-derived melanoma antigen, javelin peptide #8.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 23; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention
XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 110

AAU72263
ID AAU72263 standard; peptide; 20 AA.

XX AC AAU72263;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #42.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 25; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

```

Db      1 HWDFAWPW 8
|||||
RESULT 111
AAU72264
ID AAU72264 standard; peptide; 20 AA.
XX
XX AAU72264;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #43.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX
XX 25-OCT-2001.
XX PD
XX PF 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX PR
XX (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 25; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE801, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 20 AA;
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
|||||
Db 1 HWDFAWPW 8

RESULT 113
AAU72414
ID AAU72414 standard; peptide; 20 AA.
XX
XX AAU72414;
XX
XX 26-FEB-2002 (first entry)
XX
XX MAGE-1-derived melanoma antigen, javelin peptide #13.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE801; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX

```

```

XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX XX
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 31; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 114
AAU72223
ID AAU72223 standard; peptide; 20 AA.
XX AC AAU72223;
XX DT 26-FEB-2002 (first entry)
XX DE gpl00-derived melanoma antigen, javelin peptide #2.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.

```

```

XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX XX
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 24; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 115
AAU72413
ID AAU72413 standard; peptide; 20 AA.
XX AC AAU72413;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1-derived melanoma antigen, javelin peptide #12.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX

```

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.

Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 31; 150pp; English.

The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE5 antigens, BAGE antigens, NYE801, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

Sequence 20 AA;

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy 1 HWDFAWPW 8
|||
Db 1 HWDFAWPW 8

RESULT 116

AAU72473
ID AAU72473 standard; peptide; 20 AA.

AAU72473:

XX	DT	26-FEB-2002	(first entry)

XX DE MAGE-3-derived melanoma antigen, javelin peptide #2,

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; KW
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE901; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW favein molecule; melanoma antigen recognised by T cells-1; human.

XX	
OS	Homo sapiens.
OS	Synthetic.

XX PN WO200178655-A2.

XX
PD
25-OCT-2001.

XX
PF 17-APR-2001: 2001WO-US012449.

PR 17-APR-2000: 2000US-0197462P.

XX	PA	(HOUG//)	HOUGHTON A.
	PA	(LIVI//)	LIVINGSTON P.
	PA	(ALAW//)	AL-AWQATI Q.
	PA	(MAYH//)	MAYHEW M.
	PA	(HOEM//)	HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

WPI; 2001-663092/76.

AA Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
PT

PS Disclosure; Page 34; 150pp; English.

CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NY8501, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

Sequence 20 AA;

Query Match	100.0%;	Score 64;	DB 4;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 0.0085;		
Matches 8;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
pb 1 HWDFAWPW 8

RESULT 117

AAU72191
ID AAU72191 standard; peptide; 20 AA.

AC AAU72191;

DT 26-FEB-2002 (first entry)

DE Tyrosine-derived melanoma antigen, javelin peptide #5.

Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGs; NYES01; GM2; tyrosinase related protein 1; tyrosinase related protein 2; vaccine; tyrosinase related protein 1; tyrosinase related protein 2; human. tavelin molecule; melanoma antigen recognised by T cells-; human.

OS	Homo sapiens.
OS	Synthetic.

XX PN WO200178655-A2.

25-OCT-2001.

XX PF 17-APR-2001: 2001WO-US012449.

XX
PR 17-APR-2000: 2000US-0197462P.

XX	PA	(HOUG/)	HOUGHTON A.
	PA	(LIVI/)	LIVINGSTON P.
	PA	(ALAW/)	AL-AWQATI Q.
	PA	(MAYH/)	MAYHEW M.
	PA	(HOEM/)	HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

WPI: 2001-663092/76.

xx Anti cancer vaccine for the treatment of melanoma comprises a heat shock
pt protein and a melanoma antigen i.e. tyrosinase.
pt

XX
PS Disclosure: Page 21: 150pp; English:

The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response.

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 118

AAU72214
 ID AAU72214 standard; peptide; 20 AA.

XX AC AAU72214;

XX DT 26-FEB-2002 (first entry)

XX DE Tyrosine-derived melanoma antigen, javelin peptide #28.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 23; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 119

AAU72224

ID AAU72224 standard; peptide; 20 AA.

XX AC AAU72224;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #3.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 24; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 120

AAU72364

ID AAU72364 standard; peptide; 20 AA.

XX

AC AAU72364;
 XX
 XX 26-FEB-2002 (first entry)
 XX
 XX MART-1-derived melanoma antigen, javelin peptide #3.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 |||||
 DB 13 HWDFAPWP 20
 RESULT 121
 AAU72213
 ID AAU72213 standard; peptide; 20 AA.
 XX
 AC AAU72213;
 XX
 XX 26-FEB-2002 (first entry)
 XX
 XX Tyrosine-derived melanoma antigen, javelin peptide #27.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 |||||
 DB 1 HWDFAPWP 8
 RESULT 122
 AAU72393
 ID AAU72393 standard; peptide; 20 AA.
 XX
 AC AAU72393;
 XX
 XX 26-FEB-2002 (first entry)
 XX
 XX MART-1-derived melanoma antigen, javelin peptide #32.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX

PF 17-APR-2001; 2001WO-US012449.
 PR 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 30; 150pp; English.
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 20 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 123
 AAU72394
 ID AAU72394 standard; peptide; 20 AA.
 AC AAU72394;
 XX 26-FEB-2002 (first entry)
 DT
 DE MART-1-derived melanoma antigen, javelin peptide #33.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 OS
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 30; 150pp; English.
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX Sequence 20 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 13 HWDFAWPW 20
 RESULT 124
 AAU72304
 ID AAU72304 standard; peptide; 20 AA.
 AC AAU72304;
 XX 26-FEB-2002 (first entry)
 DT
 DE gp100-derived melanoma antigen, javelin peptide #83.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 OS
 XX WO200178655-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 17-APR-2001; 2001WO-US012449.
 PF
 XX 17-APR-2000; 2000US-0197462P.
 PR
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 26; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 13 HWDFAWPW 20
 |||||

RESULT 125
 AAU72363
 ID AAU72363 standard; peptide; 20 AA.
 XX
 AC AAU72363;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #2.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 126
 AAU72273
 ID AAU72273 standard; peptide; 20 AA.
 XX
 AC AAU72273;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #52.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 20 AA;

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 127
 AAU72474
 ID AAU72474 standard; peptide; 20 AA.
 XX
 AC AAU72474;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-3-derived melanoma antigen, javelin peptide #3.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGS; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 FF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 WPI; 2001-663092/76.

Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 protein and a melanoma antigen i.e. tyrosinase.

Disclosure; Page 34; 150pp; English.

The invention relates to a method of induction of an immune response,
 comprising administration of an immunotherapeutic composition, comprising
 a heat shock protein, and a melanoma antigen, where the melanoma antigen
 is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 related protein 2, gp 100, MAGE antigens, BAGS antigens, NYES01, MART
 antigens, GM2, antigenic portions and combinations of these. The melanoma
 antigen is covalently bound to a javelin molecule, where the melanoma
 antigen bound to the javelin molecule is non-covalently bound to the heat
 shock protein. The composition is useful for inducing an immune response
 for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 antigen peptides of the invention

Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 13 HWDFAWPW 20

RESULT 128
 AAU13455
 ID AAU13455 standard; peptide; 20 AA.

XX AAE13455;
 AC
 XX 12-FEB-2002 (first entry)
 DT
 XX Human gp100 MHC class I mutant peptide antigen #1.
 DE
 XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 XX Region 1..8
 FT /note= "Javelin sequence"
 FT Region 9..11
 FT /note= "Linker"
 FT Region 12..20
 FT /note= "MHC class I epitope"
 XX
 PN WO200179259-A1.
 XX
 XX 25-OCT-2001.
 XX
 PD 17-APR-2001; 2001WO-US012567.
 XX
 PF 17-APR-2000; 2000US-0197462P.
 XX
 PR (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

Rothman JE, Mayhew M, Hoe M;
 WPI; 2002-017594/02.

A new antigenic complex comprising epitopes non-covalently joined to a
 heat shock protein by a molecular tether designated a javelin are useful
 to treat or prevent infectious disease or malignancy.

Disclosure; Page 14; 47pp; English.

The present invention relates to an antigenic complex, comprising a
 number of epitopes non-covalently joined to a heat shock protein (HSP) by
 a tethering molecule referred to as javelin which has affinity for the
 HSP under physiological conditions, where the epitopes are covalently
 joined to the tethering molecule and one epitope is major
 histocompatibility complex class I (MHC) and the other MHC class II. The
 antigenic complex is used to induce immune responses directed towards the
 treatment or prevention of infectious diseases and malignancies. The
 present sequence is human gp100 MHC class I mutant peptide antigen

Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 5; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 129
 AAU13456
 ID AAU13456 standard; peptide; 20 AA.
 XX
 AC AAE13456;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 DE Human gp100 MHC class I mutant peptide antigen #2.

```

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
KW major histocompatibility complex; MHC; therapy; immune response;
KW malignancy; human.
XX
XX Homo sapiens.
XX
FH Key Location/Qualifiers
FT Region 1..8
FT /note= "MHC class I epitope"
FT Region 10..12
FT /note= "Linker"
FT Region 13..20
FT /note= "Javelin sequence"
XX
XX WO200179259-A1.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012567.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (ROTH/) ROTHMAN J E.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Rothman JE, Mayhew M, Hoe M;
XX WPI; 2002-017594/02.
XX
XX A new antigenic complex comprising epitopes non-covalently joined to a
FT heat shock protein by a molecular tether designated a javelin are useful
FT to treat or prevent infectious disease or malignancy.
XX
XX Disclosure; Page 14; 47pp; English.
XX
XX The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is human gp100 MHC class I mutant peptide antigen
XX
XX Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db |||||
13 HWDFAPWP 20

RESULT 130
ADR69745
ID ADR69745 standard; peptide; 20 AA.
XX
XX ADR69745;
XX
XX 18-NOV-2004 (first entry)
XX
XX Novel hybrid antigen-related peptide #1325.
XX
XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
KW gene therapy; infectious disease; cancer.
XX
XX Unidentified.
OS

```

```

OS Synthetic.
XX WO2004071457-A2.
XX
XX 26-AUG-2004.
XX
XX 13-FEB-2004; 2004WO-US004340.
XX
XX 13-FEB-2003; 2003US-0447142P.
PR 11-APR-2003; 2003US-0462469P.
PR 18-APR-2003; 2003US-0463746P.
PR 16-SEP-2003; 2003US-0503417P.
PR 12-FEB-2004; 2004US-00776521.
XX
XX (MOJA-) MOJAVE THERAPEUTICS INC.
XX
XX Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
PI Barber B;
XX
XX WPI; 2004-625768/60.
XX
XX New hybrid antigens comprising an antigenic domain and improved heat-
FT shock protein-binding domains, useful for preventing or treating
FT infectious diseases or cancer.
XX
XX Example 1; Page 38; 56pp; English.
XX
XX This invention relates to a novel hybrid antigen which comprises at least
CC one antigenic domain of an infectious agent or tumour antigen and a
CC binding domain that non-covalently binds to a heat shock protein. The
CC invention may be useful for the production of compounds with an
CC antimicrobial or cytostatic activity. In addition, the invention may
CC prove useful for the production of a vaccine or for gene therapy. The
CC composition and methods disclosed are useful for preventing or treating
CC infectious diseases or cancer. The present sequence is that of a peptide
CC which was used in the exemplification of the invention.
XX
XX Sequence 20 AA;
XX
Query Match 100.0%; Score 64; DB 8; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db |||||
13 HWDFAPWP 20

RESULT 131
ADR69746
ID ADR69746 standard; peptide; 20 AA.
XX
XX ADR69746;
XX
XX 18-NOV-2004 (first entry)
XX
XX Novel hybrid antigen-related peptide #1326.
XX
XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
KW gene therapy; infectious disease; cancer.
XX
XX Unidentified.
OS
XX Synthetic.
XX
XX WO2004071457-A2.
XX
XX 26-AUG-2004.
XX
XX 13-FEB-2004; 2004WO-US004340.
XX
XX 13-FEB-2003; 2003US-0447142P.
PR 11-APR-2003; 2003US-0462469P.
PR

```

PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 FI Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 FI Barber B;
 XX
 DR WPI; 2004-625768/60.
 XX
 PT New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX
 PS Example 1; Page 38; 56pp; English.
 XX
 CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 13 HWDFAWPW 20
 RESULT 132
 ADR69748
 ID ADR69748 standard; peptide; 20 AA.
 XX
 AC ADR69748;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Novel hybrid antigen-related peptide #1328.
 XX
 KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX
 OS Unidentified.
 OS Synthetic.
 XX
 PN WO2004071457-A2.
 XX
 PD 26-AUG-2004.
 XX
 PF 13-FEB-2004; 2004WO-US004340.
 XX
 PR 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 FI Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 FI Barber B;
 XX
 DR WPI; 2004-625768/60.

XX
 PT New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX
 PS Example 1; Page 38; 56pp; English.
 XX
 CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.
 XX
 SQ Sequence 20 AA;
 Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 13 HWDFAWPW 20
 RESULT 133
 ADR69749
 ID ADR69749 standard; peptide; 20 AA.
 XX
 AC ADR69749;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Novel hybrid antigen-related peptide #1329.
 XX
 KW hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.
 XX
 OS Unidentified.
 OS Synthetic.
 XX
 PN WO2004071457-A2.
 XX
 PD 26-AUG-2004.
 XX
 PF 13-FEB-2004; 2004WO-US004340.
 XX
 PR 13-FEB-2003; 2003US-0447142P.
 PR 11-APR-2003; 2003US-0462469P.
 PR 18-APR-2003; 2003US-0463746P.
 PR 16-SEP-2003; 2003US-0503417P.
 PR 12-FEB-2004; 2004US-00776521.
 XX
 PA (MOJA-) MOJAVE THERAPEUTICS INC.
 XX
 FI Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 FI Barber B;
 XX
 DR WPI; 2004-625768/60.
 XX
 PT New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.
 XX
 PS Example 1; Page 38; 56pp; English.
 XX
 CC This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The

CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 134

ADU08486
 ID ADU08486 standard; peptide; 20 AA.

XX AC

XX ADU08486;

DT 13-JAN-2005 (first entry)

XX Hybrid antigen #1.

XX Hybrid antigen; antigenic domain; infectious agent; tumour antigen;

KW binding domain; heat shock protein; hsp; immune response;

KW infectious disease; cancer; cytostatic; antimicrobial; immunostimulant.

XX Synthetic.

OS Unidentified.

XX WO2004091493-A2.

XX 28-OCT-2004.

XX 09-APR-2004; 2004WO-US010983.

XX 11-APR-2003; 2003US-0462469P.

PR 18-APR-2003; 2003US-0463746P.

PR 16-SEP-2003; 2003US-0503417P.

PR 12-FEB-2004; 2004US-00776521.

PR 13-FEB-2004; 2004WO-US004340.

PR 08-APR-2004; 2004US-00820067.

XX (MOJA-) MOJAVE THERAPEUTICS INC.

XX Flechtner JB, Prince-Cohane K, Mehta S, Slusaregicz P, Andjelic S;

PI Barber BH;

XX WPI; 2004-775516/76.

DR Hybrid antigen useful for treating an infectious disease or cancer,

PT comprises an antigenic domain from the infectious agent or cancer, joined

PT to a heat shock protein binding domain through an improved linker

PT peptide.

XX Example 2; Page 59; 99pp; English.

PS The invention relates to hybrid antigens comprising at least one

XX antigenic domain of an infectious agent or tumour antigen, at least one

CC binding domain that non-covalently binds to a heat shock protein (hsp),

CC and at least one peptide linker between them. Also disclosed are: (a) a

CC composition for inducing an immune response to an infectious agent or

CC tumour antigen comprising at least one of the hybrid antigens or a

CC complex of at least one heat shock protein and at least one of the hybrid

CC antigens, (b) a method for inducing an immune response to an infectious

CC agent or tumour antigen by administering a hybrid antigen and a heat

CC shock protein, where the hybrid antigen and the heat shock protein are

CC non-covalently bound, and (c) treating an infectious disease or cancer by

CC administering a hybrid antigen and a heat shock protein. The heat shock
 CC protein is preferably hsp70. The composition is administered via oral or
 CC parenteral route. The hybrid antigen is useful in preparing a composition
 CC for treating or preventing cancer or infectious disease. The new peptide
 CC linkers give the antigens improved activity. Note: Many of the SEQ ID Nos
 CC are replicated more than once in the specification but the sequences of
 CC these replicated SEQ ID Nos are not the same. This sequence represents a
 CC hybrid antigen.

XX Sequence 20 AA;

Query Match 100.0%; Score 64; DB 8; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.0085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 135

AAU72453

ID AAU72453 standard; peptide; 21 AA.

XX AC

XX AAU72453;

XX 26-FEB-2002 (first entry)

XX MAGE-1/3-derived melanoma antigen, javelin peptide #12.

XX Melanoma antigen; MART-1, MAGE-1; gp100; cytostatic; immune response;

KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE01; GM2;

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEW/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,

CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX

SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 136

AAU72354

ID AAU72354 standard; peptide; 21 AA.

XX AC AAU72354;

XX DT 26-FEB-2002 (first entry)

XX DE

XX DE gpl100-derived melanoma antigen, javelin peptide #133.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUH/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 28; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 14 HWDFAWPW 21

SQ Sequence 21 AA;

Query Match

Best Local Similarity 100.0%; Score 64; DB 4; Length 21;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 14 HWDFAWPW 21

RESULT 137

AAU72323

ID AAU72323 standard; peptide; 21 AA.

XX AC AAU72323;

XX DT 26-FEB-2002 (first entry)

XX DE

XX DE gpl100-derived melanoma antigen, javelin peptide #102.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUH/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 27; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 138

AAU72324

ID AAU72324 standard; peptide; 21 AA.

XX AC AAU72324;

XX DT 26-FEB-2002 (first entry)

```

XX DE gpl00-derived melanoma antigen, javelin peptide #103.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUH/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 27; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 21 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 21;
XX Best Local Similarity 100.0%; Pred. NO. 0.0089;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 HWDFAPWP 8
XX |||||
XX Db 14 HWDFAPWP 21
XX
XX RESULT 139
XX AAU72333
XX ID AAU72333 standard; peptide; 21 AA.
XX
XX AC AAU72333;
XX
XX 26-FEB-2002 (first entry)
XX
XX gpl00-derived melanoma antigen, javelin peptide #112.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.

```

```

OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUH/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 27; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 21 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 21;
XX Best Local Similarity 100.0%; Pred. NO. 0.0089;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 HWDFAPWP 8
XX |||||
XX Db 1 HWDFAPWP 8
XX
XX RESULT 140
XX AAU72384
XX ID AAU72384 standard; peptide; 21 AA.
XX
XX AC AAU72384;
XX
XX 26-FEB-2002 (first entry)
XX
XX MART-1-derived melanoma antigen, javelin peptide #23.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.

```

XX (HOUGH/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 14 HWDFAWPW 21
 RESULT 141
 AAU72423
 ID AAU72423 standard; peptide; 21 AA.
 XX
 AC AAU72423;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1-derived melanoma antigen, javelin peptide #22.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUGH/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 14 HWDFAWPW 21
 RESULT 142
 AAU72313
 ID AAU72313 standard; peptide; 21 AA.
 XX
 AC AAU72313;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #92.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUGH/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising

DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 31; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYESO1, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 142
 AAU72313
 ID AAU72313 standard; peptide; 21 AA.
 XX
 AC AAU72313;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #92.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYESO1; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUGH/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising

CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||||
 DB 1 HWDFAWPW 8

RESULT 143
 AAU72344
 ID AAU72344 standard; peptide; 21 AA.

AC AAU72344;

XX 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #123.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 28; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||||
 DB 14 HWDFAWPW 21

RESULT 144
 AAU72343
 ID AAU72343 standard; peptide; 21 AA.

XX AAU72343;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #122.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 28; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||||

Db 1 HWDFAWPW 8

RESULT 145
AAU72353
ID AAU72353 standard; peptide; 21 AA.
XX
AC AAU72353;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #132.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 28; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 21 AA;
Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 146
AAU72383
ID AAU72383 standard; peptide; 21 AA.
XX
AC AAU72383;
XX

DT 26-FEB-2002 (first entry)
XX
DE MART-1-derived melanoma antigen, javelin peptide #22.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 29; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 21 AA;
Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 147
AAU72434
ID AAU72434 standard; peptide; 21 AA.
XX
AC AAU72434;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-1-derived melanoma antigen, javelin peptide #33.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX

CC	comprising administration of an immunotherapeutic composition, comprising
CC	a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC	is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC	related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC	antigens, GM2, antigenic portions and combinations of these. The melanoma
CC	antigen is covalently bound to a javelin molecule, where the melanoma
CC	antigen bound to the javelin molecule is non-covalently bound to the heat
CC	shock protein. The composition is useful for inducing an immune response
CC	for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC	antigen peptides of the invention
XX	
SQ	Sequence 21 AA;
	Query Match 100.0%; Score 64; DB 4; Length 21;
	Best Local Similarity 100.0%; Pred. No. 0.0089;
	Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy	1 HWDFAWFW 8
Dd	14 HWDFAWFW 21
RESULT 151	
AAU72433	
ID	AAU72433 standard; peptide; 21 AA.
XX	: :
AC	AAU72433;
XX	:
DT	26-FEB-2002 (first entry)
XX	:
DE	MAGE-1-derived melanoma antigen, javelin peptide #32.
XX	:
KW	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	WO20017855-A2.
XX	
PD	25-OCT-2001.
Pf	
Pf	17-APR-2001; 2001WO-US012449.
XX	
PR	17-APR-2000; 2000US-0197462P.
XX	
PA	(HOUG// HOUGHTON A.
PA	(LIVI// LIVINGSTON P.
PA	(ALAW// AL-AWQATI Q.
PA	(MAYH// MAYHEW M.
PA	(HOEM// HOE M.
XX	
PI	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
PI	WPI; 2001-663092/76.
DR	
XX	
PT	Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT	protein and a melanoma antigen i.e. tyrosinase.
XX	
PS	Disclosure; Page 32; 150pp; English.
XX	
CC	The invention relates to a method of induction of an immune response,
CC	comprising administration of an immunotherapeutic composition, comprising
CC	a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC	is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC	related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC	antigens, GM2, antigenic portions and combinations of these. The melanoma
CC	antigen is covalently bound to a javelin molecule, where the melanoma
CC	antigen bound to the javelin molecule is non-covalently bound to the heat
CC	shock protein. The composition is useful for inducing an immune response
CC	for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention
XX Sequence 21 AA;
SQ

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
DB 1 HWDFAPWP 8

RESULT 152

AAU72283
ID AAU72283 standard; peptide; 21 AA.

XX AC AAU72283;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #62.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

PN 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 26; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8

DB 1 HWDFAPWP 8

RESULT 153

AAU72373

ID AAU72373 standard; peptide; 21 AA.

XX AC AAU72373;

DT 26-FEB-2002 (first entry)

DE MART-1-derived melanoma antigen, javelin peptide #12.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

PN 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 29; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.0089;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
DB 1 HWDFAPWP 8

RESULT 154

AAU72374

ID AAU72374 standard; peptide; 21 AA.

XX AC AAU72374;

XX DT 26-FEB-2002 (first entry)
 XX DE MART-1-derived melanoma antigen, javelin peptide #13.
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (HOUG/) HOUGHTON A.
 XX PA (LIVI/) LIVINGSTON P.
 XX PA (ALAW/) AL-AWQATI Q.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX DR WPI; 2001-663092/76.
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX PS Disclosure; Page 29; 150pp; English.
 XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAPWP 8
 |||||
 Db 14 HWDFAPWP 21
 RESULT 155
 AAU72243
 ID AAU72243 standard; peptide; 21 AA.
 XX AC AAU72243;
 XX DT 26-FEB-2002 (first entry)
 XX DE gpl00-derived melanoma antigen, javelin peptide #22.
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.

XX OS Homo sapiens.
 OS Synthetic.
 XX PN WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (HOUG/) HOUGHTON A.
 XX PA (LIVI/) LIVINGSTON P.
 XX PA (ALAW/) AL-AWQATI Q.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX DR WPI; 2001-663092/76.
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX PS Disclosure; Page 24; 150pp; English.
 XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAPWP 8
 |||||
 Db 1 HWDFAPWP 8
 RESULT 156
 AAU72463
 ID AAU72463 standard; peptide; 21 AA.
 XX AC AAU72463;
 XX DT 26-FEB-2002 (first entry)
 XX DE MAGE-1/3-derived melanoma antigen, javelin peptide #22.
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX OS Homo sapiens.
 OS Synthetic.
 XX PN WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.
 XX PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||||
 1 HWDFAWPW 8
 RESULT 157
 AAU72454
 ID AAU72454 standard; peptide; 21 AA.
 AC AAU72454;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #13.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||||
 1 HWDFAWPW 8

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 21 AA;
 Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||||
 14 HWDFAWPW 21
 RESULT 158
 AAU72464
 ID AAU72464 standard; peptide; 21 AA.
 AC AAU72464;
 XX
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #23.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEW/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX

CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 14 HWDFAWPW 21

RESULT 159

AAU72284
 ID AAU72284 standard; peptide; 21 AA.

XX AC AAU72284;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #63.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 26; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 14 HWDFAWPW 21

RESULT 160

AAU72334

ID AAU72334 standard; peptide; 21 AA.

XX AC AAU72334;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #113.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 27; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 21 AA;

Query Match 100.0%; Score 64; DB 4; Length 21;
 Best Local Similarity 100.0%; Pred. No. 0.0089;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
 |||||
 Db 14 HWDFAPWP 21

RESULT 161

ADR69753

ID ADR69753 standard; peptide; 21 AA.

XX ADR69753;

XX 18-NOV-2004 (first entry)

XX Novel hybrid antigen-related peptide #1333.

XX hybrid antigen; antigenic domain; infectious agent; tumour antigen;
 KW binding domain; heat shock protein; antimicrobial; cytostatic; vaccine;
 KW gene therapy; infectious disease; cancer.

XX Unidentified.

XX Synthetic.

XX WO2004071457-A2.

XX 26-AUG-2004.

XX 13-FEB-2004; 2004WO-US004340.

XX 13-FEB-2003; 2003US-0447142P.

XX 11-APR-2003; 2003US-0462469P.

XX 18-APR-2003; 2003US-0463746P.

XX 16-SEP-2003; 2003US-0503417P.

XX 12-FEB-2004; 2004US-00776521.

XX (MOJA-) MOJAVE THERAPEUTICS INC.

XX Fletcher J, Prince-Cohane K, Mehta S, Slusarewicz P, Andjelic S;
 PI Barber B;

XX WPI; 2004-625768/60.

XX New hybrid antigens comprising an antigenic domain and improved heat
 PT shock protein-binding domains, useful for preventing or treating
 PT infectious diseases or cancer.

XX Example 1; Page 38; 56pp; English.

XX This invention relates to a novel hybrid antigen which comprises at least
 CC one antigenic domain of an infectious agent or tumour antigen and a
 CC binding domain that non-covalently binds to a heat shock protein. The
 CC invention may be useful for the production of compounds with an
 CC antimicrobial or cytostatic activity. In addition, the invention may
 CC prove useful for the production of a vaccine or for gene therapy. The
 CC composition and methods disclosed are useful for preventing or treating
 CC infectious diseases or cancer. The present sequence is that of a peptide
 CC which was used in the exemplification of the invention.

XX Sequence 21 AA;

Query Match 100.0%; Score 64; DB 8; Length 21;

Best Local Similarity 100.0%; Pred. No. 0.0089;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

 |||||
 Db 14 HWDFAPWP 21

RESULT 162

AAU72262

ID AAU72262 standard; peptide; 24 AA.

XX AAU72262;

XX 26-FEB-2002 (first entry)
 DT gp100-derived melanoma antigen, javelin peptide #41.
 DE
 XX

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

XX Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 24 AA;

Query Match 100.0%; Score 64; DB 4; Length 24;

Best Local Similarity 100.0%; Pred. No. 0.01;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

 |||||
 Db 1 HWDFAPWP 8

RESULT 163

AAU72258

ID AAU72258 standard; peptide; 24 AA.

XX AAU72258;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #37.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

```

XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 25; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 24 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
|||||

RESULT 164
AAU72402
ID AAU72402 standard; peptide; 25 AA.
XX AC AAU72402;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1-derived melanoma antigen, javelin peptide #1.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.

```

```

XX 17-APR-2000; 2000US-0197462P.
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 31; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 25 AA;
XX
Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.01;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
|||||

RESULT 165
AAU72272
ID AAU72272 standard; peptide; 25 AA.
XX AC AAU72272;
XX DT 26-FEB-2002 (first entry)
XX DE gp100-derived melanoma antigen, javelin peptide #51.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.

```

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 166

AAU72408

ID AAU72408 standard; peptide; 25 AA.

XX AAU72408;

XX 26-FEB-2002 (first entry)

XX MAGE-1-derived melanoma antigen, javelin peptide #7.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

OS Homo sapiens.

OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

PP 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 31; 150pp; English.

CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011; Indels 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 167

AAU72448

ID AAU72448 standard; peptide; 25 AA.

XX AAU72448;

XX 26-FEB-2002 (first entry)

XX MAGE-1/3-derived melanoma antigen, javelin peptide #7.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

OS Homo sapiens.

OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

PP 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 168

AAU72452 AAU72452 standard; peptide; 25 AA.

XX AC AAU72452;

DT 26-FEB-2002 (first entry)

DE MAG-1/3-derived melanoma antigen, javelin peptide #11.

XX Melanoma antigen; MART-1; MAG-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAG-1, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 169

AAU72189 AAU72189 standard; peptide; 25 AA.

XX AC AAU72189;

XX 26-FEB-2002 (first entry)

XX Tyrosine-derived melanoma antigen, javelin peptide #3.

XX Melanoma antigen; MART-1; MAG-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 21; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAG-1, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

XX Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 170

AAU72368 AAU72368 standard; peptide; 25 AA.

XX

AC AAU72368;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #7.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 PI WPI; 2001-663092/76.
 XX
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8
 RESULT 171
 AAU72218
 ID AAU72218 standard; peptide; 25 AA.
 XX
 AC AAU72218;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #32.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 PI WPI; 2001-663092/76.
 XX
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8
 RESULT 172
 AAU72268
 ID AAU72268 standard; peptide; 25 AA.
 XX
 AC AAU72268;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #47.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX 25-OCT-2001.
 XX

PF 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUH/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8
 |||||
 RESULT 173
 AAU72282
 ID AAU72282 standard; peptide; 25 AA.
 XX
 AC AAU72282;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #61.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUH/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 26; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8
 |||||
 RESULT 174
 AAU72312
 ID AAU72312 standard; peptide; 25 AA.
 XX
 AC AAU72312;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #91.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUH/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.


```

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 177
AAU72302
ID AAU72302 standard; peptide; 25 AA.
XX
XX
AC AAU72302;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #81.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUH/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 26; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.011;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 178
AAU72302
ID AAU72302 standard; peptide; 25 AA.
XX
XX
AC AAU72302;
XX
XX 26-FEB-2002 (first entry)
XX
XX Tyrosine-derived melanoma antigen, javelin peptide #16.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

```

```

XX AAU72238;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #17.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUH/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 24; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.011;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 179
AAU72202
ID AAU72202 standard; peptide; 25 AA.
XX
XX AAU72202;
XX
XX 26-FEB-2002 (first entry)
XX
XX Tyrosine-derived melanoma antigen, javelin peptide #16.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

```

KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 17-APR-2001; 2001WO-US012449.
 XX
 XX 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 23; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 |||||
 RESULT 180
 AAU72308
 ID AAU72308 standard; peptide; 25 AA.
 XX
 AC AAU72308;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gpl00-derived melanoma antigen, javelin peptide #87.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 XX 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 26; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;
 Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 |||||
 RESULT 181
 AAU72398
 ID AAU72398 standard; peptide; 25 AA.
 XX
 AC AAU72398;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #37.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W0200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.

CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
 |||||
 Db 1 HWDFAPWP 8

RESULT 184

AAU72298
 ID AAU72298 standard; peptide; 25 AA.

XX
 AC AAU72298;

XX
 DT 26-FEB-2002 (first entry)

XX
 DE gpl00-derived melanoma antigen, javelin peptide #77.

XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX

OS Homo sapiens.
 OS Synthetic.

XX
 PN WO200178655-A2.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012449.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX
 DR WPI; 2001-663092/76.

XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX
 PS Disclosure; Page 26; 150pp; English.

XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX
 SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAPWP 8
 |||||
 Db 1 HWDFAPWP 8

RESULT 185

AAU72478
 ID AAU72478 standard; peptide; 25 AA.

XX
 AC AAU72478;

XX
 DT 26-FEB-2002 (first entry)

XX
 DE MAGE-3-derived melanoma antigen, javelin peptide #7.

XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX

OS Homo sapiens.

OS Synthetic.

XX
 PN WO200178655-A2.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012449.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX
 DR WPI; 2001-663092/76.

XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX
 PS Disclosure; Page 34; 150pp; English.

XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX
 SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
 |||||

Db 1 HWDFAPWP 8

RESULT 186

AAU72190

AAU72190	standard; peptide; 25 AA.
AAU72190;	
26-FEB-2002	(first entry)
Tyrosine-derived melanoma antigen, javelin peptide #4.	
Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;	
tyrosinase related protein 1; tyrosinase related protein 2; vaccine;	
javelin molecule; melanoma antigen recognised by T cells-1; human.	
Homo sapiens.	
Synthetic.	
W020017855-A2.	
25-OCT-2001.	
17-APR-2001; 2001WO-US012449.	
17-APR-2000; 2000US-0197462P.	
(HOUG/) HOUGHTON A.	
(LIVI/) LIVINGSTON P.	
(ALAW/) AL-AWQATI Q.	
(MAYH/) MAYHEW M.	
(HOEW/) HOE M.	
Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;	
WPI; 2001-663092/76.	
Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.	
Disclosure; Page 21; 150pp; English.	
The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention	
Sequence 25 AA;	
Query Match	100.0%; Score 64; DB 4; Length 25;
Best Local Similarity	100.0%; Pred. No. 0.011;
Matches	8; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1 HWDFAWPW 8
DB	1 HWDFAWPW 8
RESULT 187	
AAU72208	
ID	AAU72208 standard; peptide; 25 AA.
XX	
AC	
AAU72208;	
26-FEB-2002	(first entry)
Tyrosine-derived melanoma antigen, javelin peptide #22.	
Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;	

KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;	
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;	
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.	
XX		
OS	Homo sapiens.	
OS	Synthetic.	
XX		
PN	W0200178655-A2.	
XX		
PD	25-OCT-2001.	
XX		
PF	17-APR-2001; 2001WO-US012449.	
XX		
PR	17-APR-2000; 2000US-0197462P.	
XX		
XX	(HOUG/) HOUGHTON A.	
PA	(LIVI/) LIVINGSTON P.	
PA	(ALAW/) AL-AWOATI Q.	
PA	(MAYH/) MAYHEW M.	
PA	(HOEM/) HOE M.	
XX		
PI	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;	
XX		
DR	WPI; 2001-663092/76.	
XX		
PT	Anti cancer vaccine for the treatment of melanoma comprises a heat shock	
PT	protein and a melanoma antigen i.e. tyrosinase.	
XX		
PS	Disclosure; Page 23; 150pp; English.	
XX		
CC	The invention relates to a method of induction of an immune response,	
CC	comprising administration of an immunotherapeutic composition, comprising	
CC	a heat shock protein, and a melanoma antigen, where the melanoma antigen	
CC	is selected from tyrosinase, tyrosinase related protein 1, tyrosinase	
CC	related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART	
CC	antigens, GM2, antigenic portions and combinations of these. The melanoma	
CC	antigen is covalently bound to a javelin molecule, where the melanoma	
CC	antigen bound to the javelin molecule is non-covalently bound to the heat	
CC	shock protein. The composition is useful for inducing an immune response	
CC	for the treatment of melanoma. AAU71980-AAU72481 represent melanoma	
CC	antigen peptides of the invention	
XX		
SQ	Sequence 25 AA;	
Query Match		
Best Local Similarity	100.0%;	Score 64; DB 4; Length 25;
Matches	8; Conservative	0; Mismatches 0; Indels 0; Gaps 0;
Qy		
1	HWDFAWPW	8
Db		
1	HWDFAWPW	8
RESULT 188		
AAU72212		
ID	AAU72212	standard; peptide; 25 AA.
XX		
AC	AAU72212;	
XX		
DT	26-FEB-2002	(first entry)
XX		
DE	Tyrosine-derived melanoma antigen, javelin peptide #26.	
XX		
KW	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;	
KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;	
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;	
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.	
XX		
OS	Homo sapiens.	
OS	Synthetic.	
XX		
PN	W0200178655-A2.	
XX		

```

PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
(HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
PS Disclosure; Page 23; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 25 AA;
Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db |||||
1 HWDFAWPW 8

RESULT 189
AAU72242
ID AAU72242 standard; peptide; 25 AA.
XX
AC AAU72242;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #21.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
(HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
SQ Sequence 25 AA;
Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db |||||
1 HWDFAWPW 8

RESULT 190
AAU72372
ID AAU72372 standard; peptide; 25 AA.
XX
AC AAU72372;
XX
DT 26-FEB-2002 (first entry)
XX
DE MART-1-derived melanoma antigen, javelin peptide #11.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
(HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.

```


XX PS Disclosure; Page 29; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 191

AAU72418

ID AAU72418 standard; peptide; 25 AA.

AC AAU72418;

DT 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #17.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 31; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 192

AAU72278

ID AAU72278 standard; peptide; 25 AA.

AC AAU72278;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #57.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

Best Local Similarity 100.0%; Pred. No. 0.011;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8

Db 1 HWDFAPWP 8

RESULT 192

AAU72278

ID AAU72278 standard; peptide; 25 AA.

AC AAU72278;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #57.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 25; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

XX SQ Sequence 25 AA;

Query Match 100.0%; Score 64; DB 4; Length 25;

```

Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 193
AAU72412
ID AAU72412 standard; peptide; 25 AA.
AC AAU72412;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #11.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 31; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.011;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 194
AAU72288
ID AAU72288 standard; peptide; 26 AA.
AC AAU72288;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #67.
XX

```

```

AAU72222
ID AAU72222 standard; peptide; 25 AA.
XX
XX AAU72222;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #1.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 24; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 25 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 0.011;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 195
AAU72288
ID AAU72288 standard; peptide; 26 AA.
AC AAU72288;
XX
XX 26-FEB-2002 (first entry)
XX
XX gp100-derived melanoma antigen, javelin peptide #67.
XX

```

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 26; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 196
 AAU72432
 ID AAU72432 standard; peptide; 26 AA.
 XX AC AAU72432;
 XX DT 26-FEB-2002 (first entry)
 XX DE MAGE-1-derived melanoma antigen, javelin peptide #31.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.

XX 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 32; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 197
 AAU72328
 ID AAU72328 standard; peptide; 26 AA.
 XX AC AAU72328;
 XX DT 26-FEB-2002 (first entry)
 XX DE gp100-derived melanoma antigen, javelin peptide #107.
 XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 DB |||||||
 1 HWDFAPWP 8
 RESULT 198
 AAU72332
 ID AAU72332 standard; peptide; 26 AA.
 XX
 AC AAU72332;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #11.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAPWP 8
 DB |||||||
 1 HWDFAPWP 8
 RESULT 199
 AAU72348
 ID AAU72348 standard; peptide; 26 AA.
 XX
 AC AAU72348;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #127.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 28; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 200

AAU72322
 ID AAU72322 standard; peptide; 26 AA.

XX
 AC AAU72322;

XX
 DT 26-FEB-2002 (first entry)

XX
 DE gp100-derived melanoma antigen, javelin peptide #101.

XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX
 OS Homo sapiens.
 OS Synthetic.

XX
 PN WO200178655-A2.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012449.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (HOUG/) HOUGHTON A.

XX
 PA (LIVI/) LIVINGSTON P.

XX
 PA (ALAW/) AL-AWQATI Q.

XX
 PA (MAYH/) MAYHEW M.

XX
 PA (HOEM/) HOE M.

XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX
 DR WPI; 2001-663092/76.

XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX
 PS Disclosure; Page 27; 150pp; English.

XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 201

AAU72378
 ID AAU72378 standard; peptide; 26 AA.

XX
 AC AAU72378;

XX
 DT 26-FEB-2002 (first entry)

XX
 DE MART-1-derived melanoma antigen, javelin peptide #17.

XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX
 OS Homo sapiens.

XX
 OS Synthetic.

XX
 PN WO200178655-A2.

XX
 PD 25-OCT-2001.

XX
 PF 17-APR-2001; 2001WO-US012449.

XX
 PR 17-APR-2000; 2000US-0197462P.

XX
 PA (HOUG/) HOUGHTON A.

XX
 PA (LIVI/) LIVINGSTON P.

XX
 PA (ALAW/) AL-AWQATI Q.

XX
 PA (MAYH/) MAYHEW M.

XX
 PA (HOEM/) HOE M.

XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX
 DR WPI; 2001-663092/76.

XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX
 PS Disclosure; Page 29; 150pp; English.

XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 202
AAU72382
ID AAU72382 standard; peptide; 26 AA.
XX
AC AAU72382;
XX
DT 26-FEB-2002 (first entry)
XX
XX
DE MART-1-derived melanoma antigen, javelin peptide #21.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 29; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
XX
XX
RESULT 203
AAU72388
ID AAU72388 standard; peptide; 26 AA.
XX
AC AAU72388;
XX
DT 26-FEB-2002 (first entry)
XX
XX
DE MART-1-derived melanoma antigen, javelin peptide #27.

XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 29; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
XX
XX
RESULT 204
AAU72468
ID AAU72468 standard; peptide; 26 AA.
XX
AC AAU72468;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-1/3-derived melanoma antigen, javelin peptide #27.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX

PN WO200178655-A2.
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 33; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 26 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 205
 AAU72358
 ID AAU72358 standard; peptide; 26 AA.
 XX
 AC AAU72358;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gpi00-derived melanoma antigen, javelin peptide #137.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 33; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 26 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 205
 AAU72358
 ID AAU72358 standard; peptide; 26 AA.
 XX
 AC AAU72358;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gpi00-derived melanoma antigen, javelin peptide #137.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 28; 150pp; English.
 PS
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 26 AA;
 SQ
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB |||||
 1 HWDFAWPW 8
 RESULT 206
 AAU72472
 ID AAU72472 standard; peptide; 26 AA.
 XX
 AC AAU72472;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-3-derived melanoma antigen, javelin peptide #1.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 34; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 207

AAU72292
 ID AAU72292 standard; peptide; 26 AA.

XX AAU72292;

XX 26-FEB-2002 (first entry)

XX gp100-derived melanoma antigen, javelin peptide #71.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 26; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8

RESULT 208

AAU72458
 ID AAU72458 standard; peptide; 26 AA.

XX AAU72458;

XX 26-FEB-2002 (first entry)

XX MAGE-1/3-derived melanoma antigen, javelin peptide #17.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.

OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure; Page 33; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 209
 AAU72252
 ID AAU72252 standard; peptide; 26 AA.
 XX
 AC AAU72252;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #31.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 210
 AAU72338
 ID AAU72338 standard; peptide; 26 AA.
 XX
 AC AAU72338;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #117.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 211
 AAU72248
 ID AAU72248 standard; peptide; 26 AA.
 XX
 AC AAU72248;
 XX
 DT 26-FEB-2002 (first entry)
 XX

DE gp100-derived melanoma antigen, javelin peptide #27.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 24; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDPAFPW 8
 Db |||||
 1 HWDPAFPW 8
 RESULT 212
 AAU72428
 ID AAU72428 standard; peptide; 26 AA.
 XX
 AC AAU72428;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1-derived melanoma antigen, javelin peptide #27.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 24; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDPAFPW 8
 Db |||||
 1 HWDPAFPW 8
 RESULT 213
 AAU72342
 ID AAU72342 standard; peptide; 26 AA.
 XX
 AC AAU72342;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #121.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 31; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDPAFPW 8
 Db |||||
 1 HWDPAFPW 8

XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 31; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDPAFPW 8
 Db |||||
 1 HWDPAFPW 8
 RESULT 213
 AAU72342
 ID AAU72342 standard; peptide; 26 AA.
 XX
 AC AAU72342;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #121.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 31; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 XX comprising administration of an immunotherapeutic composition, comprising
 XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
 XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 XX antigens, GM2, antigenic portions and combinations of these. The melanoma
 XX antigen is covalently bound to a javelin molecule, where the melanoma
 XX antigen bound to the javelin molecule is non-covalently bound to the heat
 XX shock protein. The composition is useful for inducing an immune response
 XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 XX antigen peptides of the invention
 XX
 SQ Sequence 26 AA;
 Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDPAFPW 8
 Db |||||
 1 HWDPAFPW 8

CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 216

AAU72438
 ID AAU72438 standard; peptide; 26 AA.

AC AAU72438;

DT 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #37.

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

PF 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 32; 150pp; English.

CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

RESULT 217

AAU72318

ID AAU72318 standard; peptide; 26 AA.

AC AAU72318;

DT 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #97.

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.

PN WO200178655-A2.

XX 25-OCT-2001.

PF 17-APR-2001; 2001WO-US012449.

PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

PA (LIVI/) LIVINGSTON P.

PA (ALAW/) AL-AWQATI Q.

PA (MAYH/) MAYHEW M.

PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 27; 150pp; English.

CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

SQ Sequence 26 AA;

Query Match 100.0%; Score 64; DB 4; Length 26;
 Best Local Similarity 100.0%; Pred. No. 0.011;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8

```

RESULT 218
AAU72352
ID AAU72352 standard; peptide; 26 AA.
XX
AC AAU72352;
XX
DT 26-FEB-2002 (first entry)
XX
DE gp100-derived melanoma antigen, javelin peptide #131.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
FS Disclosure; Page 28; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPW 8
Db 1 HWDFAPW 8

RESULT 219
AAU72462
ID AAU72462 standard; peptide; 26 AA.
XX
AC AAU72462;
XX
DT 26-FEB-2002 (first entry)
XX

```

```

XX
DE MAGE-1/3-derived melanoma antigen, javelin peptide #21.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200178655-A2.
XX
PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT protein and a melanoma antigen i.e. tyrosinase.
XX
FS Disclosure; Page 33; 150pp; English.
XX
CC The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 26 AA;
Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.011;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPW 8
Db 1 HWDFAPW 8

RESULT 220
AAU72442
ID AAU72442 standard; peptide; 27 AA.
XX
AC AAU72442;
XX
DT 26-FEB-2002 (first entry)
XX
DE MAGE-1/3-derived melanoma antigen, javelin peptide #1.
XX
KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
OS Homo sapiens.

```

OS Synthetic.
 XX WO200178655-A2.
 PN PD 25-OCT-2001.
 XX PD 17-APR-2001; 2001WO-US012449.
 XX PF 17-APR-2000; 2000US-0197462P.
 XX PR (HOUGH/) HOUGHTON A.
 XX PA (LIVI/) LIVINGSTON P.
 XX PA (ALAW/) AL-AWQATI Q.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 33; 150pp; English.
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 27 AA;
 Query Match 100.0%; Score 64; DB 4; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.012;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 1 HWDFAWPW 8
 RESULT 221
 AAEL3449
 ID AAEL3449 standard; peptide; 27 AA.
 XX AAEL3449;
 AC
 XX 12-FEB-2002 (first entry)
 DT Chicken MHC class II peptide antigen #1.
 DE Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 XX major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.
 OS Gallus gallus.
 XX Key Location/Qualifiers
 FH Region 1..8
 FT /notes= "Javelin sequence"
 FT Region 9..11
 FT /notes= "Linker"
 FT Region 12..27
 FT /notes= "MHC class II epitope"
 XX WO200179259-A1.

XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012567.
 XX 17-APR-2000; 2000US-0197462P.
 XX (ROTH/) ROTHMAN J E.
 XX PA (MAYH/) MAYHEW M.
 XX PA (HOEM/) HOE M.
 XX Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX Disclosure; Page 13; 47pp; English.
 XX The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken MHC class II peptide antigen
 XX SQ Sequence 27 AA;
 Query Match 100.0%; Score 64; DB 5; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.012;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db |||||
 1 HWDFAWPW 8
 RESULT 222
 AAEL3450
 ID AAEL3450 standard; peptide; 27 AA.
 XX AAEL3450;
 AC
 XX 12-FEB-2002 (first entry)
 DT Chicken MHC class II peptide antigen #2.
 DE Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 XX major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.
 OS Gallus gallus.
 XX Key Location/Qualifiers
 FH Region 1..16
 FT /notes= "MHC class II epitope"
 FT Region 17..19
 FT /notes= "Linker"
 FT Region 20..27
 FT /notes= "Javelin sequence"
 XX WO200179259-A1.
 XX 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012567.
 XX 17-APR-2000; 2000US-0197462P.

XX (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 DR
 XX A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX
 PS Disclosure; Page 13; 47pp; English.
 XX
 CC The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken MHC class II peptide antigen
 XX
 SQ Sequence 27 AA;
 Query Match 100.0%; Score 64; DB 5; Length 27;
 Best Local Similarity 100.0%; Pred. No. 0.012;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 20 HWDFAWPW 27
 |||||
 RESULT 223
 AAU72255
 ID AAU72255 standard; peptide; 30 AA.
 XX
 AC AAU72255;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #34.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 30 AA;
 Query Match 100.0%; Score 64; DB 4; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||
 RESULT 224
 AAU72260
 ID AAU72260 standard; peptide; 30 AA.
 XX
 AC AAU72260;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #39.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 25; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 30 AA;

Query Match 100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 225
AAE13448
ID AAE13448 standard; peptide; 30 AA.
XX
AC AAE13448;
XX

12-FEB-2002 (first entry)

Chicken MHC class I peptide antigen #3.

Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
major histocompatibility complex; MHC; therapy; immune response;
malignancy; chicken.

Gallus gallus.

Key Location/Qualifiers
Region 1..8 /note= "Javelin sequence"
Region 9..11 /note= "Linker"
Region 12..19 /note= "MHC class I epitope"
Region 20..22 /note= "Linker"
Region 23..30 /note= "Javelin sequence"

WO200179259-A1.

25-OCT-2001.

17-APR-2001; 2001WO-US012567.

17-APR-2000; 2000US-0197462P.

(ROTH/) ROTHMAN J E.
(MAYH/) MAYHEW M.
(HOEM/) HOE M.

Rothman JE, Mayhew M, Hoe M;

WPI; 2002-017594/02.

A new antigenic complex comprising epitopes non-covalently joined to a
heat shock protein by a molecular tether designated a javelin are useful
to treat or prevent infectious disease or malignancy.

Disclosure; Page 13; 47pp; English.

The present invention relates to an antigenic complex, comprising a
number of epitopes non-covalently joined to a heat shock protein (HSP) by
a tethering molecule referred to as javelin which has affinity for the
HSP under physiological conditions, where the epitopes are covalently
joined to the tethering molecule and one epitope is major

CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is chicken MHC class I peptide antigen
XX
SQ Sequence 30 AA;

Query Match 100.0%; Score 64; DB 5; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 226
AAE13454
ID AAE13454 standard; peptide; 30 AA.
XX
AC AAE13454;
XX

12-FEB-2002 (first entry)

Herpes simplex virus MHC class I peptide antigen #6.

Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
major histocompatibility complex; MHC; therapy; immune response;
malignancy.

Herpes simplex virus.

Key Location/Qualifiers
Region 1..8 /note= "Javelin sequence"
Region 9..11 /note= "Linker"
Region 12..19 /note= "MHC class I epitope"
Region 20..22 /note= "Linker"
Region 23..30 /note= "Javelin sequence"

WO200179259-A1.

25-OCT-2001.

17-APR-2001; 2001WO-US012567.

17-APR-2000; 2000US-0197462P.

(ROTH/) ROTHMAN J E.
(MAYH/) MAYHEW M.
(HOEM/) HOE M.

Rothman JE, Mayhew M, Hoe M;

WPI; 2002-017594/02.

A new antigenic complex comprising epitopes non-covalently joined to a
heat shock protein by a molecular tether designated a javelin are useful
to treat or prevent infectious disease or malignancy.

Disclosure; Page 14; 47pp; English.

The present invention relates to an antigenic complex, comprising a
number of epitopes non-covalently joined to a heat shock protein (HSP) by
a tethering molecule referred to as javelin which has affinity for the
HSP under physiological conditions, where the epitopes are covalently
joined to the tethering molecule and one epitope is major
histocompatibility complex class I (MHC) and the other MHC class II. The
antigenic complex is used to induce immune responses directed towards the

CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is Herpes simplex virus MHC class I peptide antigen
 XX
 SQ Sequence 30 AA;

Query Match 100.0%; Score 64; DB 5; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 227
 AAU72295
 ID AAU72295 standard; peptide; 31 AA.
 AC AAU72295;
 XX 26-FEB-2002 (first entry)
 DT
 DE Tyrosine-derived melanoma antigen, javelin peptide #74.
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 26; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen is bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 229
 AAU72230
 ID AAU72230 standard; peptide; 31 AA.
 XX

AC AAU72230;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gpl00-derived melanoma antigen, javelin peptide #9.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 24; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8
 |||||
 RESULT 230
 AAU72480
 ID AAU72480 standard; peptide; 31 AA.
 XX
 AC AAU72480;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-3-derived melanoma antigen, javelin peptide #9.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 34; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 |||||
 DB 1 HWDFAWPW 8
 |||||
 RESULT 231
 AAU72205
 ID AAU72205 standard; peptide; 31 AA.
 XX
 AC AAU72205;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Tyrosine-derived melanoma antigen, javelin peptide #19.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX

XX The invention relates to a method of induction of an immune response;
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||||
 Db 1 HWDFAWPW 8

RESULT 234

AAU72370

ID AAU72370 standard; peptide; 31 AA.

AC AAU72370;

DT 26-FEB-2002 (first entry)

DE MART-1-derived melanoma antigen, javelin peptide #9.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.
 OS WO200178655-A2.
 PN 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 29; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||||
 Db 1 HWDFAWPW 8

RESULT 235

AAU72400

ID AAU72400 standard; peptide; 31 AA.

AC AAU72400;

DT 26-FEB-2002 (first entry)

DE MART-1-derived melanoma antigen, javelin peptide #39.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
 OS Synthetic.
 OS WO200178655-A2.
 PN 25-OCT-2001.
 XX 17-APR-2001; 2001WO-US012449.
 XX 17-APR-2000; 2000US-0197462P.
 XX (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 30; 150pp; English.

XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

OY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 236
AAU72405
ID AAU72405 standard; peptide; 31 AA.
XX
XX AAU72405;
XX
XX 26-FEB-2002 (first entry)
XX
XX MAGE-1-derived melanoma antigen, javelin peptide #4.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 31; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 237
AAU72445
ID AAU72445 standard; peptide; 31 AA.
XX
XX AAU72445;
XX
XX 26-FEB-2002 (first entry)
XX
XX Tyrosine-derived melanoma antigen, javelin peptide #34.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 31; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

XX AAU72445;
XX
XX 26-FEB-2002 (first entry)
XX
XX MAGE-1/3-derived melanoma antigen, javelin peptide #4.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 33; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 238
AAU72220
ID AAU72220 standard; peptide; 31 AA.
XX
XX AAU72220;
XX
XX 26-FEB-2002 (first entry)
XX
XX Tyrosine-derived melanoma antigen, javelin peptide #34.
XX
XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO200178655-A2.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012449.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (HOUG/) HOUGHTON A.
XX (LIVI/) LIVINGSTON P.
XX (ALAW/) AL-AWQATI Q.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX WPI; 2001-663092/76.
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 33; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```


PA (HOEM/) HOE M.
 XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 23; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 31 AA;
 CC
 CC Query Match 100.0%; Score 64; DB 4; Length 31;
 CC Best Local Similarity 100.0%; Pred. No. 0.013;
 CC Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC Qy 1 HWDPAWPW 8
 CC | | | | | | | |
 CC Db 1 HWDPAWPW 8
 CC
 CC RESULT 241
 CC AAU72265
 CC ID AAU72265 standard; peptide; 31 AA.
 CC
 CC AC AAU72265;
 CC
 CC DT 26-FEB-2002 (first entry)
 CC
 CC DE gp100-derived melanoma antigen, javelin peptide #44.
 CC
 CC KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 CC immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 CC tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 CC javelin molecule; melanoma antigen recognised by T cells-1; human.
 CC
 CC OS Homo sapiens.
 CC OS Synthetic.
 CC
 CC PN WO200178655-A2.
 CC
 CC XX 25-OCT-2001.
 CC
 CC XX 17-APR-2001; 2001WO-US012449.
 CC
 CC XX 17-APR-2000; 2000US-0197462P.
 CC
 CC PA (HOUG/) HOUGHTON A.
 CC PA (LIVI/) LIVINGSTON P.
 CC PA (ALAW/) AL-AWQATI Q.
 CC PA (MAYH/) MAYHEW M.
 CC PA (HOEM/) HOE M.
 CC
 CC XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 CC WPI; 2001-663092/76.
 CC
 CC PA Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 30; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

PS Disclosure; Page 25; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 XX Sequence 31 AA;
 CC
 CC Query Match 100.0%; Score 64; DB 4; Length 31;
 CC Best Local Similarity 100.0%; Pred. No. 0.013;
 CC Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC Qy 1 HWDPAWPW 8
 CC | | | | | | | |
 CC Db 1 HWDPAWPW 8
 CC
 CC RESULT 242
 CC AAU72395
 CC ID AAU72395 standard; peptide; 31 AA.
 CC
 CC AC AAU72395;
 CC
 CC DT 26-FEB-2002 (first entry)
 CC
 CC DE MART-1-derived melanoma antigen, javelin peptide #34.
 CC
 CC KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 CC immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 CC tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 CC javelin molecule; melanoma antigen recognised by T cells-1; human.
 CC
 CC OS Homo sapiens.
 CC OS Synthetic.
 CC
 CC PN WO200178655-A2.
 CC
 CC XX 25-OCT-2001.
 CC
 CC XX 17-APR-2001; 2001WO-US012449.
 CC
 CC XX 17-APR-2000; 2000US-0197462P.
 CC
 CC PA (HOUG/) HOUGHTON A.
 CC PA (LIVI/) LIVINGSTON P.
 CC PA (ALAW/) AL-AWQATI Q.
 CC PA (MAYH/) MAYHEW M.
 CC PA (HOEM/) HOE M.
 CC
 CC XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 CC WPI; 2001-663092/76.
 CC
 CC PA Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX Disclosure; Page 30; 150pp; English.
 XX
 XX The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC
CC antigen peptides of the invention
XX
XX Sequence 31 AA:

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
|||||

Dp 1 HWDFAWPW 8

RESULT 243
AAU72415
ID AAU72415 standard; peptide; 31 AA.

AC AAU72415;

DT 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #14.

Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGs; NYEg01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine.
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine.
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine.

OS Homo sapiens.
OS Synthetic.

AA WO200178655-A2.

25-OCT-2001.

17-APR-2001: 2001WO-US012449.

AA
PR 17-APR-2000: 2000US-0197462P.

PA (HOUH/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

WPI: 2001-663092/76.

Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure: page 31: 150pp: English.

The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE901, MART antigen, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

Sequence 31 AA;

Query Match	100.0%;	Score 64;	DB 4;	Length 31;
Best Local Similarity	100.0%;	Pred. No. 0.013;		

	Matches	8;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1	HWDFAWPW	8							
Dd	1	HWDFAWFW	8							

RESULT 244
AAU72410
ID AAU72410 standard; peptide; 31 AA.

AC AAU72410;

DT 26-FEB-2002 (first entry)

DE MAGE-1-derived melanoma antigen, javelin peptide #9.

Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGS; NYE801; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vacnine;
KW tyrosinase related protein 1; tyrosinase related protein 2; vacnine;
KW tyrosinase related protein 1; tyrosinase related protein 2; vacnine;
KW tyrosinase related protein 1; tyrosinase related protein 2; vacnine;

OS Homo sapiens.
OS Synthetic.

XX
PN
WO200178655-A2.

25-OCT-2001.

PF 17-APR-2001; 2001WO-US012449.

17-APR-2000; 2000US-0197462P.

PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

XX
PI
Houghton A. Livingston P. Al-Awqati O. Mayhew M. Hoe M;

WPI: 2001-663092/76.

Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

PS Disclosure: Page 31: 150pp; English.

The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

Sequence 31 AA;

Query Match	100.0%;	Score 64;	DB 4;	Length 31;
Best Local Similarity	100.0%;	Pred. No. 0.013;		
Matches 8;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 245
AAU72305

AAU72305 standard; peptide; 31 AA.	AAU72305;	26-FEB-2002 (first entry)	gpl100-derived melanoma antigen, javelin peptide #84.	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response; immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2; tyrosinase related protein 1; tyrosinase related protein 2; vaccine; javelin molecule; melanoma antigen recognised by T cells-1; human.
Homo sapiens.	Synthetic.	WO200178555-A2.	25-OCT-2001.	17-APR-2001; 2001WO-US012449.
17-APR-2000; 2000US-0197462P.	(HOUG// HOUGHTON A.	(LIVI// LIVINGSTON P.	(ALAW// AL-AWQATI Q.	(MAYH// MAYHEW M.
(HOEM// HOE M.	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;	WPI; 2001-663092/76.	Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.	Disclosure; Page 26; 150pp; English.
The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention	Sequence 31 AA;	Query Match 100.0%; Score 64; DB 4; Length 31;	Best Local Similarity 100.0%; Pred. No. 0.013;	Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	1 HWDFAPWP 8	11111111	1 HWDFAPWP 8	
Db				
RESULT 246	AAU72300	AAU72300 standard; peptide; 31 AA.	AAU72300;	26-FEB-2002 (first entry)
DE	gpl100-derived melanoma antigen, javelin peptide #79.	Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;		

KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	WO200178655-A2.
XX	
PD	25-OCT-2001.
XX	
PF	17-APR-2001; 2001WO-US012449.
XX	
PR	17-APR-2000; 2000US-0197462P.
XX	
PA	(HOUG/) HOUGHTON A.
PA	(LIVI/) LIVINGSTON P.
PA	(ALAW/) AL-AWQATI Q.
PA	(MAYH/) MAYHEW M.
PA	(HOEM/) HOE M.
XX	
PI	Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX	
DR	WPI; 2001-663092/76.
XX	
PT	Anti cancer vaccine for the treatment of melanoma comprises a heat shock
PT	protein and a melanoma antigen i.e. tyrosinase.
XX	
PS	Disclosure; Page 26; 150pp; English.
XX	
CC	The invention relates to a method of induction of an immune response,
CC	comprising administration of an immunotherapeutic composition, comprising
CC	a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC	is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC	related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC	antigens, GM2, antigenic portions and combinations of these. The melanoma
CC	antigen is covalently bound to a javelin molecule, where the melanoma
CC	antigen bound to the javelin molecule is non-covalently bound to the heat
CC	shock protein. The composition is useful for inducing an immune response
CC	for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC	antigen peptides of the invention
XX	
SQ	Sequence 31 AA;
	Query Match 100.0%; Score 64; DB 4; Length 31;
	Beet Local Similarity 100.0%; Pred. No. 0.013;
	Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy	1 HWDPAWPW B
Db	1 HWDPAWPW B
RESULT 247	
AAU72310	
ID	AAU72310 standard; peptide; 31 AA.
XX	
AC	AAU72310;
XX	
DT	26-FEB-2002 (first entry)
XX	
DE	gpi00-derived melanoma antigen, javelin peptide #89.
XX	
KW	Melanoma antigen: MART-1; MAGE-1; gp100; cytostatic; immune response;
KW	immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW	tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW	javelin molecule; melanoma antigen recognised by T cells-1; human.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	WO200178655-A2.
XX	

```

PD 25-OCT-2001.
XX
PF 17-APR-2001; 2001WO-US012449.
XX
PR 17-APR-2000; 2000US-0197462P.
XX
PA (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
DR WPI; 2001-663092/76.
XX
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 26; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE901, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 HWDFAWPW 8
XX |||||
XX Db 1 HWDFAWPW 8
XX
XX
XX RESULT 248
XX AAU72450
XX ID AAU72450 standard; peptide; 31 AA.
XX
XX AC AAU72450;
XX
XX DT 26-FEB-2002 (first entry)
XX
XX DE MAGE-1/3-derived melanoma antigen, javelin peptide #9.
XX
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE901; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX PN WO200178655-A2.
XX
XX PD 25-OCT-2001.
XX
XX PF 17-APR-2001; 2001WO-US012449.
XX
XX PR 17-APR-2000; 2000US-0197462P.
XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX DR WPI; 2001-663092/76.
XX
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX Disclosure; Page 26; 150pp; English.
XX
XX The invention relates to a method of induction of an immune response,
XX comprising administration of an immunotherapeutic composition, comprising
XX a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYE901, MART
XX antigens, GM2, antigenic portions and combinations of these. The melanoma
XX antigen is covalently bound to a javelin molecule, where the melanoma
XX antigen bound to the javelin molecule is non-covalently bound to the heat
XX shock protein. The composition is useful for inducing an immune response
XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX antigen peptides of the invention
XX
XX Sequence 31 AA;
XX
XX Query Match 100.0%; Score 64; DB 4; Length 31;
XX Best Local Similarity 100.0%; Pred. No. 0.013;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1 HWDFAWPW 8
XX |||||
XX Db 1 HWDFAWPW 8
XX
XX
XX RESULT 249
XX AAU72195
XX ID AAU72195 standard; peptide; 31 AA.
XX
XX AC AAU72195;
XX
XX DT 26-FEB-2002 (first entry)
XX
XX DE Tyrosine-derived melanoma antigen, javelin peptide #9.
XX
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYE901; GM2;
XX tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX javelin molecule; melanoma antigen recognised by T cells-1; human.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX PN WO200178655-A2.
XX
XX PD 25-OCT-2001.
XX
XX PF 17-APR-2001; 2001WO-US012449.
XX
XX PR 17-APR-2000; 2000US-0197462P.
XX
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX
XX DR WPI; 2001-663092/76.
XX
XX
XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.
XX
XX
XX

```

XX Disclosure; Page 23; 150pp; English.

XX The invention relates to a method of induction of an immune response,

XX comprising administration of an immunotherapeutic composition, comprising

XX a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX antigens, GM2, antigenic portions and combinations of these. The melanoma

XX antigen is covalently bound to a javelin molecule, where the melanoma

XX antigen bound to the javelin molecule is non-covalently bound to the heat

XX shock protein. The composition is useful for inducing an immune response

XX for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX antigen peptides of the invention

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

|||||

RESULT 250

AAU72365

ID AAU72365 standard; peptide; 31 AA.

XX AC AAU72365;

XX DT 26-FEB-2002 (first entry)

XX DE MART-1-derived melanoma antigen, javelin peptide #4.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 29; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

|||||

RESULT 251

AAU72225

ID AAU72225 standard; peptide; 31 AA.

XX AC AAU72225;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #4.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 24; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat

CC shock protein. The composition is useful for inducing an immune response

CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

CC antigen peptides of the invention

XX SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

Best Local Similarity 100.0%; Pred. No. 0.013;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

|||||

RESULT 251

AAU72225

ID AAU72225 standard; peptide; 31 AA.

XX AC AAU72225;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #4.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 24; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 4; Length 31;

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX
 XX PD 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX PS Disclosure; Page 34; 150pp; English.
 XX
 XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 255
 AAU72210
 ID AAU72210 standard; peptide; 31 AA.
 AC AAU72210;
 XX
 XX DT 26-FEB-2002 (first entry)
 XX
 XX DE Tyrosine-derived melanoma antigen, javelin peptide #24.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX PN

XX 25-OCT-2001.
 XX PF 17-APR-2001; 2001WO-US012449.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.
 XX (ALAW/) AL-AWQATI Q.
 XX (MAYH/) MAYHEW M.
 XX (HOEM/) HOE M.
 XX
 XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 XX protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX PS Disclosure; Page 23; 150pp; English.
 XX
 XX CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX SQ Sequence 31 AA;
 Query Match 100.0%; Score 64; DB 4; Length 31;
 Best Local Similarity 100.0%; Pred. No. 0.013;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 256
 AAU72235
 ID AAU72235 standard; peptide; 31 AA.
 AC AAU72235;
 XX
 XX DT 26-FEB-2002 (first entry)
 XX
 XX DE gp100-derived melanoma antigen, javelin peptide #14.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO200178655-A2.
 XX PN 25-OCT-2001.
 XX PD 17-APR-2001; 2001WO-US012449.
 XX PF 17-APR-2000; 2000US-0197462P.
 XX PR 17-APR-2000; 2000US-0197462P.
 XX
 XX (HOUG/) HOUGHTON A.
 XX (LIVI/) LIVINGSTON P.

PT to treat or prevent infectious disease or malignancy.

PS Disclosure; Page 14; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is human gp100 MHC class I mutant peptide antigen

SQ Sequence 31 AA;

Query Match 100.0%; Score 64; DB 5; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.013;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 259

AAU72245
ID AAU72245 standard; peptide; 32 AA.

AC AAU72245;

XX 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #24.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 24; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma

CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 260

AAU72355

ID AAU72355 standard; peptide; 32 AA.

XX AAU72355;

XX 26-FEB-2002 (first entry)

DE gp100-derived melanoma antigen, javelin peptide #134.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX Homo sapiens.
OS Synthetic.

XX WO200178655-A2.

XX 25-OCT-2001.

XX 17-APR-2001; 2001WO-US012449.

XX 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX (LIVI/) LIVINGSTON P.

XX (ALAW/) AL-AWQATI Q.

XX (MAYH/) MAYHEW M.

XX (HOEM/) HOE M.

XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX protein and a melanoma antigen i.e. tyrosinase.

XX Disclosure; Page 28; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention

SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 261
 AAU72285
 ID AAU72285 standard; peptide; 32 AA.
 XX
 AC AAU72285;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #64.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 26; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 262
 AAU72315
 ID AAU72315 standard; peptide; 32 AA.
 XX
 AC AAU72315;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #124.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 26; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ID AAU72315 standard; peptide; 32 AA.
 XX
 AC AAU72315;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #94.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 |||||

RESULT 263
 AAU72345
 ID AAU72345 standard; peptide; 32 AA.
 XX
 AC AAU72345;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #124.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 XX
 DR
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;

Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 268

AAU72290

ID AAU72290 standard; peptide; 32 AA.

XX AC AAU72290;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #69.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX FN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;

Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 269

AAU72440

ID AAU72440 standard; peptide; 32 AA.

XX AC AAU72440;

XX DT 26-FEB-2002 (first entry)

XX DE MAGE-1-derived melanoma antigen, javelin peptide #39.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;

XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;

XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;

XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX FN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX PA (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 32; 150pp; English.

XX CC The invention relates to a method of induction of an immune response,

XX CC comprising administration of an immunotherapeutic composition, comprising

XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen

XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART

XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma

XX CC antigen is covalently bound to a javelin molecule, where the melanoma

XX CC antigen bound to the javelin molecule is non-covalently bound to the heat

XX CC shock protein. The composition is useful for inducing an immune response

XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma

XX CC antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;

Best Local Similarity 100.0%; Pred. No. 0.014;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 270

AAU72460
 ID AAU72460 standard; peptide; 32 AA.
 AC AAU72460;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #19.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 XX
 RESULT 271
 AAU72470
 ID AAU72470 standard; peptide; 32 AA.
 XX
 AC AAU72470;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #29.
 XX

KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAWPW 8
 DB 1 HWDFAWPW 8
 XX
 RESULT 272
 AAU72250
 ID AAU72250 standard; peptide; 32 AA.
 XX
 AC AAU72250;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #29.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.

```

XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 24; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWPW 8
Db 1 HWDFAPWPW 8

RESULT 273
AAU72425
ID AAU72425 standard; peptide; 32 AA.
XX AC AAU72425;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1-derived melanoma antigen, javelin peptide #24.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 24; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWPW 8
Db 1 HWDFAPWPW 8

RESULT 274
AAU72435
ID AAU72435 standard; peptide; 32 AA.
XX AC AAU72435;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1-derived melanoma antigen, javelin peptide #34.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

```

```

PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.
XX PS Disclosure; Page 31; 150pp; English.
XX CC The invention relates to a method of induction of an immune response,
XX CC comprising administration of an immunotherapeutic composition, comprising
XX CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
XX CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
XX CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
XX CC antigens, GM2, antigenic portions and combinations of these. The melanoma
XX CC antigen is covalently bound to a javelin molecule, where the melanoma
XX CC antigen bound to the javelin molecule is non-covalently bound to the heat
XX CC shock protein. The composition is useful for inducing an immune response
XX CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
XX CC antigen peptides of the invention
XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWPW 8
Db 1 HWDFAPWPW 8

RESULT 274
AAU72435
ID AAU72435 standard; peptide; 32 AA.
XX AC AAU72435;
XX DT 26-FEB-2002 (first entry)
XX DE MAGE-1-derived melanoma antigen, javelin peptide #34.
XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
XX KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
XX KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
XX KW javelin molecule; melanoma antigen recognised by T cells-1; human.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200178655-A2.
XX XX
XX PD 25-OCT-2001.
XX PF 17-APR-2001; 2001WO-US012449.
XX PR 17-APR-2000; 2000US-0197462P.
XX PA (HOUG/) HOUGHTON A.
XX PA (LIVI/) LIVINGSTON P.
XX PA (ALAW/) AL-AWQATI Q.
XX PA (MAYH/) MAYHEW M.
XX PA (HOEM/) HOE M.
XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
XX DR WPI; 2001-663092/76.
XX PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock

```

PT protein and a melanoma antigen i.e. tyrosinase.
 XX Disclosure; Page 32; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 DB 1 HWDFAPWP 8
 |||||

RESULT 275
 AAU72380
 ID AAU72380 standard; peptide; 32 AA.
 XX
 AC AAU72380;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MART-1-derived melanoma antigen, javelin peptide #19.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 29; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;

CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 DB 1 HWDFAPWP 8
 |||||

RESULT 276
 AAU72335
 ID AAU72335 standard; peptide; 32 AA.
 XX
 AC AAU72335;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #114.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX
 DR WPI; 2001-663092/76.
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 PS Disclosure; Page 27; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 277

AAU72340
 ID AAU72340 standard; peptide; 32 AA.

XX AC AAU72340;
 XX DT 26-FEB-2002 (first entry)
 XX DE gp100-derived melanoma antigen, javelin peptide #119.
 XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
 XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX FI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 27; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 278

AAU72455

ID AAU72455 standard; peptide; 32 AA.

XX AC AAU72455;

XX DT 26-FEB-2002 (first entry)

XX DE MAGE-1/3-derived melanoma antigen, javelin peptide #14.

XX KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.

XX PA (LIVI/) LIVINGSTON P.

XX PA (ALAW/) AL-AWQATI Q.

XX PA (MAYH/) MAYHEW M.

XX PA (HOEM/) HOE M.

XX FI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX DR WPI; 2001-663092/76.

XX Anti cancer vaccine for the treatment of melanoma comprises a heat shock protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 33; 150pp; English.

XX CC The invention relates to a method of induction of an immune response, comprising administration of an immunotherapeutic composition, comprising a heat shock protein, and a melanoma antigen, where the melanoma antigen is selected from tyrosinase, tyrosinase related protein 1, tyrosinase related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART antigens, GM2, antigenic portions and combinations of these. The melanoma antigen is covalently bound to a javelin molecule, where the melanoma antigen bound to the javelin molecule is non-covalently bound to the heat shock protein. The composition is useful for inducing an immune response for the treatment of melanoma. AAU71980-AAU72481 represent melanoma antigen peptides of the invention

XX SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 279

AAU72320

ID AAU72320 standard; peptide; 32 AA.

XX AC AAU72320;

XX DT 26-FEB-2002 (first entry)

XX DE gp100-derived melanoma antigen, javelin peptide #99.

PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 XX
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 28; 150pp; English.
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 282
 AAU72360
 ID AAU72360 standard; peptide; 32 AA.
 XX
 AC AAU72360;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #139.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 28; 150pp; English.
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 282
 AAU72360
 ID AAU72360 standard; peptide; 32 AA.
 XX
 AC AAU72360;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE gp100-derived melanoma antigen, javelin peptide #139.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX

PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 28; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
 CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYES01, MART
 CC antigens, GM2, antigenic portions and combinations of these. The melanoma
 CC antigen is covalently bound to a javelin molecule, where the melanoma
 CC antigen bound to the javelin molecule is non-covalently bound to the heat
 CC shock protein. The composition is useful for inducing an immune response
 CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
 CC antigen peptides of the invention
 XX
 SQ Sequence 32 AA;
 Query Match 100.0%; Score 64; DB 4; Length 32;
 Best Local Similarity 100.0%; Pred. No. 0.014;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8
 RESULT 283
 AAU72465
 ID AAU72465 standard; peptide; 32 AA.
 XX
 AC AAU72465;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE MAGE-1/3-derived melanoma antigen, javelin peptide #24.
 XX
 KW Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
 KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYES01; GM2;
 KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
 KW javelin molecule; melanoma antigen recognised by T cells-1; human.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200178655-A2.
 XX
 XX 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012449.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (HOUG/) HOUGHTON A.
 PA (LIVI/) LIVINGSTON P.
 PA (ALAW/) AL-AWQATI Q.
 PA (MAYH/) MAYHEW M.
 PA (HOEM/) HOE M.
 XX
 PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;
 XX WPI; 2001-663092/76.
 DR
 XX
 PT Anti cancer vaccine for the treatment of melanoma comprises a heat shock
 PT protein and a melanoma antigen i.e. tyrosinase.
 XX
 XX
 PS Disclosure; Page 33; 150pp; English.
 XX
 CC The invention relates to a method of induction of an immune response,
 CC comprising administration of an immunotherapeutic composition, comprising
 CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
 CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase

CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 284
AAU72385
ID AAU72385 standard; peptide; 32 AA.

XX AC AAU72385;

DT 26-FEB-2002 (first entry)

DE MART-1-derived melanoma antigen, javelin peptide #24.

XX Melanoma antigen; MART-1; MAGE-1; gp100; cytostatic; immune response;
KW immunotherapeutic; heat shock protein; tyrosinase; BAGE; NYEs01; GM2;
KW tyrosinase related protein 1; tyrosinase related protein 2; vaccine;
KW javelin molecule; melanoma antigen recognised by T cells-1; human.

XX OS Homo sapiens.
OS Synthetic.

XX PN WO200178655-A2.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012449.

XX PR 17-APR-2000; 2000US-0197462P.

XX (HOUG/) HOUGHTON A.
PA (LIVI/) LIVINGSTON P.
PA (ALAW/) AL-AWQATI Q.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

XX PI Houghton A, Livingston P, Al-Awqati Q, Mayhew M, Hoe M;

XX WPI; 2001-663092/76.

XX DR Anti cancer vaccine for the treatment of melanoma comprises a heat shock
XX PT protein and a melanoma antigen i.e. tyrosinase.

XX PS Disclosure; Page 29; 150pp; English.

XX The invention relates to a method of induction of an immune response,
CC comprising administration of an immunotherapeutic composition, comprising
CC a heat shock protein, and a melanoma antigen, where the melanoma antigen
CC is selected from tyrosinase, tyrosinase related protein 1, tyrosinase
CC related protein 2, gp 100, MAGE antigens, BAGE antigens, NYEs01, MART
CC antigens, GM2, antigenic portions and combinations of these. The melanoma
CC antigen is covalently bound to a javelin molecule, where the melanoma
CC antigen bound to the javelin molecule is non-covalently bound to the heat
CC shock protein. The composition is useful for inducing an immune response
CC for the treatment of melanoma. AAU71980-AAU72481 represent melanoma
CC antigen peptides of the invention
XX
SQ Sequence 32 AA;

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.014; 0; Gaps 0;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 285
AAE13451
ID AAE13451 standard; peptide; 38 AA.

XX AC AAE13451;

DT 12-FEB-2002 (first entry)

DE Chicken MHC class II peptide antigen #3.

XX Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
KW major histocompatibility complex; MHC; therapy; immune response;
KW malignancy; chicken.

XX OS Gallus gallus.

XX FH Key Location/Qualifiers

FT Region 1..8 /note= "Javelin sequence"

FT Region 9..11 /note= "Linker"

FT Region 12..27 /note= "MHC class II epitope"

FT Region 28..30 /note= "Linker"

FT Region 31..38 /note= "Javelin sequence"

XX PN WO200179259-A1.

XX PD 25-OCT-2001.

XX PF 17-APR-2001; 2001WO-US012567.

XX PR 17-APR-2000; 2000US-0197462P.

XX (ROTH/) ROTHMAN J E.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.

XX PI Rothman JE, Mayhew M, Hoe M;

XX WPI; 2002-017594/02.

XX A new antigenic complex comprising epitopes non-covalently joined to a
XX PT heat shock protein by a molecular tether designated a javelin are useful
XX PT to treat or prevent infectious disease or malignancy.

XX PS Disclosure; Page 13; 47pp; English.

XX The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is chicken MHC class II peptide antigen

XX SQ Sequence 38 AA;

Query Match 100.0%; Score 64; DB 5; Length 38;

Best Local Similarity 100.0%; Pred. No. 0.016; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 286
AAE13460
ID AAE13460 standard; protein; 100 AA.
XX
AC AAE13460;
XX
DT 12-FEB-2002 (first entry)
XX
DE Chicken ovalbumin derived protein domain #3.
XX
KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
KW major histocompatibility complex; MHC; therapy; immune response;
KW malignancy; chicken.
XX
OS Gallus gallus.
XX
FH Key Location/Qualifiers
FT Region 58. .65
FT /note= "MHC class I epitope"
FT Region 66. .81
FT /note= "MHC class II epitope"
FT Region 93. .100
FT /note= "Javelin sequence"
XX
PN WO200179259-A1.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012567.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
PA (ROTH/) ROTHMAN J E.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Rothman JE, Mayhew M, Hoe M;
XX
XX WPI; 2002-017594/02.
XX
XX A new antigenic complex comprising epitopes non-covalently joined to a
PT heat shock protein by a molecular tether designated a javelin are useful
PT to treat or prevent infectious disease or malignancy.
XX
PS Disclosure; Page 14; 47pp; English.
XX
CC The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is chicken ovalbumin derived protein domain
XX
SQ Sequence 100 AA;
Query Match 100.0%; Score 64; DB 5; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.044;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 93 HWDFAWPW 100

RESULT 286
AAE13461
ID AAE13461 standard; protein; 103 AA.
XX

RESULT 287
AAE13458
ID AAE13458 standard; protein; 100 AA.
XX
AC AAE13458;
XX
DT 12-FEB-2002 (first entry)
XX
DE Chicken ovalbumin derived protein domain #1.
XX
KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
KW major histocompatibility complex; MHC; therapy; immune response;
KW malignancy; chicken.
XX
OS Gallus gallus.
XX
FH Key Location/Qualifiers
FT Region 1. .8
FT /note= "Javelin sequence"
FT Region 66. .73
FT /note= "MHC class I epitope"
FT Region 74. .89
FT /note= "MHC class II epitope"
XX
PN WO200179259-A1.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012567.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
PA (ROTH/) ROTHMAN J E.
PA (MAYH/) MAYHEW M.
PA (HOEM/) HOE M.
XX
PI Rothman JE, Mayhew M, Hoe M;
XX
XX WPI; 2002-017594/02.
XX
XX A new antigenic complex comprising epitopes non-covalently joined to a
PT heat shock protein by a molecular tether designated a javelin are useful
PT to treat or prevent infectious disease or malignancy.
XX
PS Disclosure; Page 14; 47pp; English.
XX
CC The present invention relates to an antigenic complex, comprising a
CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
CC a tethering molecule referred to as javelin which has affinity for the
CC HSP under physiological conditions, where the epitopes are covalently
CC joined to the tethering molecule and one epitope is major
CC histocompatibility complex class I (MHC) and the other MHC class II. The
CC antigenic complex is used to induce immune responses directed towards the
CC treatment or prevention of infectious diseases and malignancies. The
CC present sequence is chicken ovalbumin derived protein domain
XX
SQ Sequence 100 AA;
Query Match 100.0%; Score 64; DB 5; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.044;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 288
AAE13461
ID AAE13461 standard; protein; 103 AA.
XX

AC AAE13461;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 DE Chicken ovalbumin derived protein domain #4.
 XX
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.
 XX
 OS Gallus gallus.
 XX
 FH Key Location/Qualifiers
 FT Region 58..65
 FT /note= "MHC class I epitope"
 FT Region 66..81
 FT /note= "MHC class II epitope"
 FT Region 93..95
 FT /note= "Linker sequence"
 FT Region 96..103
 FT /note= "Javelin sequence"
 XX
 PN WO200179259-A1.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012567.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEN/) HOE M.
 XX
 PI Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 XX
 PT A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX
 PS Disclosure; Page 14; 47pp; English.
 XX
 CC The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken ovalbumin derived protein domain
 XX Sequence 103 AA;
 SQ
 Query Match 100.0%; Score 64; DB 5; Length 103;
 Best Local Similarity 100.0%; Pred. No. 0.045;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAFW 8
 DB 96 HWDFAFW 103
 RESULT 289
 AAE13459
 ID AAE13459 standard; protein; 103 AA.
 XX
 AC AAE13459;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 KW Chicken ovalbumin derived protein domain #5.
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.

DE Chicken ovalbumin derived protein domain #2.
 XX
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 KW malignancy; chicken.
 XX
 OS Gallus gallus.
 XX
 FH Key Location/Qualifiers
 FT Region 1..8
 FT /note= "Javelin sequence"
 FT Region 9..11
 FT /note= "Linker"
 FT Region 69..76
 FT /note= "MHC class I epitope"
 FT Region 77..92
 FT /note= "MHC class II epitope"
 XX
 PN WO200179259-A1.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012567.
 XX
 PR 17-APR-2000; 2000US-0197462P.
 XX
 PA (ROTH/) ROTHMAN J E.
 PA (MAYH/) MAYHEW M.
 PA (HOEN/) HOE M.
 XX
 PI Rothman JE, Mayhew M, Hoe M;
 XX WPI; 2002-017594/02.
 XX
 PT A new antigenic complex comprising epitopes non-covalently joined to a
 PT heat shock protein by a molecular tether designated a javelin are useful
 PT to treat or prevent infectious disease or malignancy.
 XX
 PS Disclosure; Page 14; 47pp; English.
 XX
 CC The present invention relates to an antigenic complex, comprising a
 CC number of epitopes non-covalently joined to a heat shock protein (HSP) by
 CC a tethering molecule referred to as javelin which has affinity for the
 CC HSP under physiological conditions, where the epitopes are covalently
 CC joined to the tethering molecule and one epitope is major
 CC histocompatibility complex class I (MHC) and the other MHC class II. The
 CC antigenic complex is used to induce immune responses directed towards the
 CC treatment or prevention of infectious diseases and malignancies. The
 CC present sequence is chicken ovalbumin derived protein domain
 XX Sequence 103 AA;
 SQ
 Query Match 100.0%; Score 64; DB 5; Length 103;
 Best Local Similarity 100.0%; Pred. No. 0.045;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 HWDFAFW 8
 DB 1 HWDFAFW 8
 RESULT 290
 AAE13462
 ID AAE13462 standard; protein; 108 AA.
 XX
 AC AAE13462;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 KW Chicken ovalbumin derived protein domain #5.
 KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
 KW major histocompatibility complex; MHC; therapy; immune response;
 XX malignancy; chicken.

```

KW malignancy; chicken.
XX Gallus gallus.
XX
FH Key Location/Qualifiers
OS Region 1..8
XX /note= "Javelin sequence"
FH Region 9..11
XX /note= "Linker"
FT Region 69..76
FT /note= "MHC class I epitope"
FT Region 77..92
FT /note= "MHC class II epitope"
FT Region 104..111
FT /note= "Javelin sequence"
XX
XX WO200179259-A1.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012567.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (ROTH/) ROTHMAN J E.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Rothman JE, Mayhew M, Hoe M;
XX
XX WPI; 2002-017594/02.
XX
XX A new antigenic complex comprising epitopes non-covalently joined to a
XX heat shock protein by a molecular tether designated a javelin are useful
XX to treat or prevent infectious disease or malignancy.
XX
XX Disclosure; Page 15; 47pp; English.
XX
XX The present invention relates to an antigenic complex, comprising a
XX number of epitopes non-covalently joined to a heat shock protein (HSP) by
XX a tethering molecule referred to as javelin which has affinity for the
XX HSP under physiological conditions, where the epitopes are covalently
XX joined to the tethering molecule and one epitope is major
XX histocompatibility complex class I (MHC) and the other MHC class II. The
XX antigenic complex is used to induce immune responses directed towards the
XX treatment or prevention of infectious diseases and malignancies. The
XX present sequence is chicken ovalbumin derived protein domain
XX
XX Sequence 108 AA;
XX
XX Query Match 100.0%; Score 64; DB 5; Length 108;
XX Best Local Similarity 100.0%; Pred. No. 0.047;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 HWDFAWPW 8
XX |||||
XX Db 1 HWDFAWPW 8
XX
XX RESULT 291
XX AAEL13463
XX ID AAEL13463 standard; protein; 111 AA.
XX
XX AC AAEL13463;
XX
XX DT 12-FEB-2002 (first entry)
XX
XX DE Chicken ovalbumin derived protein domain #6.
XX
XX KW Antigenic complex; epitope; heat shock protein; HSP; tether; javelin;
XX KW major histocompatibility complex; MHC; therapy; immune response;
XX KW malignancy; chicken.
XX
XX OS Gallus gallus.
XX

```

```

FH Key Location/Qualifiers
FT Region 1..8
FT /note= "Javelin sequence"
FT Region 9..11
FT /note= "Linker"
FT Region 69..76
FT /note= "MHC class I epitope"
FT Region 77..92
FT /note= "MHC class II epitope"
FT Region 104..111
FT /note= "Javelin sequence"
XX
XX WO200179259-A1.
XX
XX 25-OCT-2001.
XX
XX 17-APR-2001; 2001WO-US012567.
XX
XX 17-APR-2000; 2000US-0197462P.
XX
XX (ROTH/) ROTHMAN J E.
XX (MAYH/) MAYHEW M.
XX (HOEM/) HOE M.
XX
XX Rothman JE, Mayhew M, Hoe M;
XX
XX WPI; 2002-017594/02.
XX
XX A new antigenic complex comprising epitopes non-covalently joined to a
XX heat shock protein by a molecular tether designated a javelin are useful
XX to treat or prevent infectious disease or malignancy.
XX
XX Disclosure; Page 15; 47pp; English.
XX
XX The present invention relates to an antigenic complex, comprising a
XX number of epitopes non-covalently joined to a heat shock protein (HSP) by
XX a tethering molecule referred to as javelin which has affinity for the
XX HSP under physiological conditions, where the epitopes are covalently
XX joined to the tethering molecule and one epitope is major
XX histocompatibility complex class I (MHC) and the other MHC class II. The
XX antigenic complex is used to induce immune responses directed towards the
XX treatment or prevention of infectious diseases and malignancies. The
XX present sequence is chicken ovalbumin derived protein domain
XX
XX Sequence 111 AA;
XX
XX Query Match 100.0%; Score 64; DB 5; Length 111;
XX Best Local Similarity 100.0%; Pred. No. 0.048;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1 HWDFAWPW 8
XX |||||
XX Db 1 HWDFAWPW 8
XX
XX Search completed: March 24, 2006, 12:35:07
XX Job time : 191 secs

```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 07:44:44 ; Search time 39 Seconds
(without alignments)
19,737 Million cell updates/sec

Title: US-10-053-520-143
Perfect score: 64
Sequence: 1 HWDFAWPW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_80.*
1: PIR1.*
2: PIR2.*
3: PIR3.*
4: PIR4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	44	68.8	1529	2 A59189	ATP-binding casset
2	43	67.2	349	2 G36470	Wnt-7a protein - m
3	42	65.6	340	2 B83262	hypothetical prote
4	42	65.6	567	2 A71463	probable sulfate t
5	42	65.6	575	2 T11753	mullerian inhibiti
6	41	64.1	331	2 T13932	SP16 protein, poll
7	41	64.1	717	2 T06041	hypothetical prote
8	41	64.1	1015	1 TQECT	transposase - Esch
9	40	62.5	237	2 AG3474	carbamoyl-phosphat
10	40	62.5	352	2 T08469	endo-1,4-beta-xyla
11	40	62.5	482	2 T01762	hypothetical prote
12	40	62.5	532	2 S62748	A-alpha X protein
13	40	62.5	537	2 S62749	A-alpha X protein
14	40	62.5	538	2 S62750	A-alpha X protein
15	40	62.5	545	2 B88479	protein F47D12.9 {
16	39.5	61.7	689	2 AC1927	hypothetical prote
17	39	60.9	154	2 JC6036	integral membrane
18	39	60.9	217	2 B91116	hypothetical prote
19	39	60.9	217	2 B85961	hypothetical prote
20	39	60.9	296	2 T03562	conserved hypothet
21	39	60.9	298	2 D75481	aldose epimerase f
22	39	60.9	309	2 C65088	hypothetical prote
23	39	60.9	417	2 A36965	malonyl-CoA decarb
24	39	60.9	418	2 AG2872	conserved hypothet
25	39	60.9	420	2 H97648	cinnamoyl ester hy
26	39	60.9	444	2 S57989	probable membrane
27	39	60.9	459	2 T36531	probable two-compo
28	39	60.9	487	2 B39490	subtilisin-like pr
29	39	60.9	509	2 B83002	drug efflux transp

30	39	60.9	513	2 A82432	sodium/solute symp
31	39	60.9	515	2 G70941	hypothetical prote
32	39	60.9	521	2 T34482	hypothetical prote
33	39	60.9	1034	2 A95262	probable formate d
34	38.5	60.2	310	2 F91032	probable transport
35	38.5	60.2	310	2 G85876	probable transport
36	38.5	60.2	310	2 A65008	hypothetical 34.5
37	38	59.4	80	2 B83128	hypothetical prote
38	38	59.4	219	2 G82611	hypothetical prote
39	38	59.4	225	2 T25957	hypothetical prote
40	38	59.4	283	2 T04056	hypothetical prote
41	38	59.4	326	2 T04055	hypothetical prote
42	38	59.4	330	2 B82822	NADH2 dehydrogenas
43	38	59.4	330	2 T51834	transcription fact
44	38	59.4	414	2 T03996	hypothetical prote
45	38	59.4	459	2 S42647	photosystem II chl

ALIGNMENTS

RESULT 1

A59189
ATP-binding cassette transporter - human (fragment)
N;Alternate names: KIAA1062 protein
C;Species: Homo sapiens (man)
C;Date: 18-Feb-2000 #sequence_revision 18-Feb-2000 #text_change 31-Dec-2004
C;Accession: A59189
R;Kikuno, R.; Nagase, T.; Ishikawa, K.; Hirose, M.; Miyajima, N.; Tanaka, A.; Kotani, F.
DNA Res. 6, 197-205, 1999
A;Title: Prediction of the coding sequences of unidentified human genes. XIV. The complete
A;Reference number: 222961; MUID:99397452; PMID:10470851
A;Accession: A59189
A;Status: preliminary; not compared with conceptual translation
A;Molecule type: mRNA
A;Residues: 1-1529 <KIK>
A;Cross-references: UNIPROT:Q9HC28, UNIPARC:UPI000017A0E0; GB:AB028985; NID:g5689460; PII
A;Experimental source: chromosome 9; clone hj03579; clone lib pBluescriptII SK plus; tise
C;Genetics:
A;Map position: 9
A;Note: KIAA1062

Query Match 68.8%; Score 44; DB 2; Length 1529;
Best Local Similarity 57.1%; Pred. No. 70;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAPWP 8
|:::|
Db 39 WENSWPW 45

RESULT 2

G36470
Wnt-7a protein - mouse
C;Species: Mus musculus (house mouse)
C;Date: 19-Apr-1991 #sequence_revision 19-Apr-1991 #text_change 09-Jul-2004
C;Accession: G36470
R;Gavin, B.J.; McMahon, J.A.; McMahon, A.P.
Genes Dev. 4, 2319-2332, 1990
A;Title: Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult m
A;Reference number: A36470; MUID:91122634; PMID:2279700
A;Accession: G36470
A;Status: preliminary
A;Molecule type: mRNA
A;Residues: 1-349 <GAV>
A;Cross-references: UNIPROT:P24383; UNIPARC:UPI0000029D72; GB:M89801; NID:g202409; PII
C;Superfamily: int-1 transforming protein

Query Match 67.2%; Score 43; DB 2; Length 349;
Best Local Similarity 62.5%; Pred. No. 22;
Matches 5; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Qy 1 HWDFAWPW 8
 Db 301 HWNLTWFW 308

RESULT 8
 TOEFT
 transposase - Escherichia coli transposon Tn3
 C:Species: Escherichia coli
 C>Date: 30-Jun-1980 #sequence_revision 15-Oct-1982 #text_change 09-Jul-2004
 C:Accession: A03538
 R:Hefron, F.; McCarthy, B.J.; Ohtsubo, H.; Ohtsubo, E.
 Cell 18, 1153-1163, 1979
 A:Title: DNA sequence analysis of the transposon Tn3: three genes and three sites involved in transposition
 A:Reference number: A90784; MUID:80090058; PMID:391406
 A:Accession: A03538
 A:Molecule type: DNA
 A:Residues: 1-1015 <HEF>
 A:Cross-references: UNIPROT:P03008; UNIPARC:UPI00001370D7
 C:Comment: This protein is required for transposition of transposon Tn3.
 C:Genetics:
 A:Start codon: GTG
 C:Superfamily: transposase Tn3
 C:Keywords: DNA binding; DNA replication

Query Match 64.1%; Score 41; DB 1; Length 1015;
 Best Local Similarity 83.3%; Pred. No. 1.3e+02;
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 DFAPWPW 8
 Db 128 EFAPWPW 133

RESULT 9
 AG3474
 carbamoyl-phosphate synthase (glutamine-hydrolysing) (BC 6.3.5.5) [imported] - Brucella
 C:Species: Brucella melitensis
 C>Date: 01-Feb-2002 #sequence_revision 01-Feb-2002 #text_change 09-Jul-2004
 C:Accession: AG3474
 R:DeVecchio, V.G.; Kapatal, V.; Redkar, R.J.; Patra, G.; Mujer, C.; Los, T.; Ivanova, M.; Mazur, M.; Goldsman, E.; Selkov, E.; Elzer, P.H.; Hagius, S.; O'Callaghan, D.; Letes, R.; Proc. Natl. Acad. Sci. U.S.A. 99, 443-448, 2002
 A:Title: The genome sequence of the facultative intracellular pathogen Brucella melitensis
 A:Reference number: AD3252; PMID:1175668
 A:Accession: AG3474
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-237 <KUR>
 A:Cross-references: UNIPROT:Q8YEU6; UNIPARC:UPI00000581D9; GB:AE008917; PIDN:AAU52962.1;
 A:Experimental source: strain 16M
 C:Genetics:
 A:Gene: BME11781
 A:Map position: I
 C:Keywords: ligase

Query Match 62.5%; Score 40; DB 2; Length 237;
 Best Local Similarity 71.4%; Pred. No. 41;
 Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 WDFAPWP 8
 Db 45 FSFAWPW 51

RESULT 10
 T08469
 endo-1,4-beta-xylanase (EC 3.2.1.8) - Dictyoglomus thermophilum
 C:Species: Dictyoglomus thermophilum
 C>Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 31-Dec-2004
 C:Accession: T08469
 R:Gibbs, M.D.; Reeves, R.A.; Bergquist, P.L.

Appl. Environ. Microbiol. 61, 4403-4408, 1995
 A:Title: Cloning, sequencing, and expression of a xylanase gene from the extreme thermophilic bacterium *Dictyoglomus thermophilum*
 A:Reference number: Z16432; MUID:96086022; PMID:8534104
 A:Accession: T08469
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-352 <GIB>
 A:Cross-references: UNIPROT:Q12603; UNIPARC:UPI000013907F; EMBL:L39866; NID:g973982; PIDN:G973982
 A:Experimental source: strain Rt46B.1
 C:Genetics:
 A:Note: xyna
 C:Function:
 A:Description: hydrolyzes xylan to xylotriase and xylobiose but could not hydrolyze xylooligosaccharides
 C:Superfamily: xylanase; Streptomyces endo-1,4-beta-xylanase A homology
 C:Keywords: glycosidase; hydrolase; polysaccharide degradation
 F:60-352/Domain: Streptomyces endo-1,4-beta-xylanase A homology <SXY>

Query Match 62.5%; Score 40; DB 2; Length 352;
 Best Local Similarity 71.4%; Pred. No. 61;
 Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 HWDFAWP 7
 Db 233 HWTLAMP 239

RESULT 11
 T01762
 hypothetical protein A_IG002P16.6 - Arabidopsis thaliana
 C:Species: Arabidopsis thaliana (mouse-ear cress)
 C>Date: 19-Feb-1999 #sequence_revision 19-Feb-1999 #text_change 09-Jul-2004
 C:Accession: T01762
 R:Miller, N.; Beck, C.; Kramer, J.
 submitted to the EMBL Data Library, June 1997
 A:Description: The sequence of A. thaliana IG002P16.
 A:Reference number: Z14421
 A:Accession: T01762
 A:Status: translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-482 <ML>
 A:Cross-references: UNIPROT:O04629; UNIPARC:UPI00000A2ABB; EMBL:AF007270; NID:g2191157; I
 C:Genetics:
 A:Gene: ATSP:A_IG002P16.6
 A:Map position: 5
 A:Introns: 15/2; 86/3; 108/1; 179/3; 238/3; 263/3; 301/1; 396/2; 433/3

Query Match 62.5%; Score 40; DB 2; Length 482;
 Best Local Similarity 83.3%; Pred. No. 85;
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAPWP 7
 Db 123 WNFAPW 128

RESULT 12
 S62748
 A-alpha X protein (allele 1) - bracket fungus (Schizophyllum commune)
 C:Species: Schizophyllum commune
 C>Date: 24-Aug-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004
 C:Accession: S62748
 R:Marion, A.L.; Bartholomew, K.A.; Wu, J.; Yang, H.; Novotny, C.P.; Ullrich, R.C.
 Curr. Genet. 29, 143-149, 1996
 A:Title: The A-alpha mating-type locus of Schizophyllum commune: structure and function
 A:Reference number: S62748; MUID:96418876; PMID:8821661
 A:Accession: S62748
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown
 A:Molecule type: DNA
 A:Residues: 1-532 <MAR>
 A:Cross-references: UNIPROT:Q02464; UNIPARC:UPI000006ACA9; EMBL:U13942; NID:g537620; PIDN:G537620
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1994
 C:Genetics:
 A:Introns: 21/3

C;Superfamily: A-alpha X protein

Query Match 62.5%; Score 40; DB 2; Length 532;

Best Local Similarity 83.3%; Pred. No. 94; Mismatches 0; Indels 1; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 197 WDFQWP 202

RESULT 13

S62749

A-alpha X protein (allele 3) - bracket fungus (Schizopyllum commune)

C;Species: Schizopyllum commune

C;Date: 24-Aug-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004

C;Accession: S62749

R;Marion, A.L.; Bartholomew, K.A.; Wu, J.; Yang, H.; Novotny, C.P.; Ullrich, R.C.

Curr. Genet. 29, 143-149, 1996

A;Title: The A-alpha mating-type locus of Schizopyllum commune: structure and function

A;Reference number: S62748; MUID:96418876; PMID:8821661

A;Accession: S62749

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-537 <MAR>

A;Cross-references: UNIPROT:Q02466; UNIPARC:UPI000006BE39; EMBL:U13943; NID:9537622; PID

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1994

C;Genetics:

A;Introns: 21/3

C;Superfamily: A-alpha X protein

Query Match

Best Local Similarity 62.5%; Score 40; DB 2; Length 537;

Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 197 WDFQWP 202

RESULT 14

S62750

A-alpha X protein (allele 4) - bracket fungus (Schizopyllum commune)

C;Species: Schizopyllum commune

C;Date: 24-Aug-1996 #sequence_revision 13-Mar-1997 #text_change 09-Jul-2004

C;Accession: S62750

R;Marion, A.L.; Bartholomew, K.A.; Wu, J.; Yang, H.; Novotny, C.P.; Ullrich, R.C.

Curr. Genet. 29, 143-149, 1996

A;Title: The A-alpha mating-type locus of Schizopyllum commune: structure and function

A;Reference number: S62748; MUID:96418876; PMID:8821661

A;Accession: S62750

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-538 <MAR>

A;Cross-references: UNIPROT:Q02467; UNIPARC:UPI000006D65; EMBL:U13944; NID:9537624; PID

A;Note: the nucleotide sequence was submitted to the EMBL Data Library, August 1994

C;Genetics:

A;Introns: 21/3

C;Superfamily: A-alpha X protein

Query Match

Best Local Similarity 62.5%; Score 40; DB 2; Length 538;

Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 197 WDFQWP 202

RESULT 15

B88479

protein F47D12.9 [imported] - Caenorhabditis elegans

C;Species: Caenorhabditis elegans

C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 09-Jul-2004

C;Accession: B88479

R;Anonymous, The C. elegans Sequencing Consortium.

Science 282, 2012-2018, 1998

A;Title: Genome sequence of the nematode C. elegans: a platform for investigating biology

A;Reference number: A75000; MUID:99069613; PMID:9851916

A;Note: see websites genome.wustl.edu/gsc/C_elegans/ and www.sanger.ac.uk/Projects/C_eleg

A;Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999; and

A;Accession: B88479

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-545 <STO>

A;Cross-references: UNIPROT:Q09392; UNIPARC:UPI000013BF71; GB:chr_III; PIDN:AAA64320.1; I

C;Genetics:

A;Gene: F47D12.9

A;Map position: 3

Query Match

Best Local Similarity 62.5%; Score 40; DB 2; Length 545;

Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAMP 7

|||||

Db 446 WDFRWP 451

Search completed: March 24, 2006, 07:49:05

Job time : 42 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 07:41:01 ; Search time 231 Seconds
(without alignments)
24.434 Million cell updates/sec

Title: US-10-053-520-143
Perfect score: 64
Sequence: 1 HWDFAWPW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2166443 seqs, 705528306 residues

Total number of hits satisfying chosen parameters: 2166443

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	46	71.9	581	2	Q4IGV1_GIBZE
2	45	70.3	254	2	Q8GQ64_PSEAE
3	45	70.3	419	2	Q4KKC3_PSEFS
4	45	70.3	526	2	Q529W2_WAGFR
5	44	68.8	142	2	Q5NZ03_AZOSE
6	44	68.8	283	2	Q8DM48_SYNEL
7	44	68.8	301	2	Q4NB48_WMICC
8	44	68.8	323	2	Q7XD95_ORYSA
9	44	68.8	323	2	Q8W368_ORYSA
10	44	68.8	1440	2	Q5W905_HUMAN
11	44	68.8	1771	2	Q76MW7_HUMAN
12	44	68.8	2434	1	ABCA2_RAT
13	44	68.8	2435	2	Q5SPV5_HUMAN
14	44	68.8	2436	1	ABCA2_HUMAN
15	44	68.8	2436	2	Q9HC28_HUMAN
16	43	67.2	136	2	Q94G11_ORYSA
17	43	67.2	285	1	Y2301_STRCO
18	43	67.2	287	2	Q82B30_STRAW
19	43	67.2	306	2	Q4UU05_XANCP
20	43	67.2	306	2	Q8P944_XANCP
21	43	67.2	349	1	WNT7A_MOUSE
22	43	67.2	379	2	Q851B1_ORYSA
23	43	67.2	517	2	Q74D39_GEOSL
24	42	65.6	253	2	Q93SK7_MYXXA
25	42	65.6	327	2	Q5QXN1_IDILO
26	42	65.6	335	2	Q4ITT0_AZOVI
27	42	65.6	340	2	Q9HZD5_PSEAE
28	42	65.6	352	2	Q4ZVQ6_PSESY
29	42	65.6	358	2	Q4KD40_PSEFS
30	42	65.6	394	2	Q5GTX5_XANOR
31	42	65.6	404	2	Q8PSP8_METWA

32	42	65.6	416	2	Q8TPP8_METAC
33	42	65.6	566	2	Q5L5D0_CHLAB
34	42	65.6	566	2	Q822D6_CHLCV
35	42	65.6	567	2	Q84864_CHLTR
36	42	65.6	575	1	MIS_FIG
37	42	65.6	605	2	Q9PL63_CHLMU
38	42	65.6	642	2	Q9FC03_STRCO
39	42	65.6	648	1	SVT_SILPO
40	42	65.6	650	2	Q6BA80_9PROT
41	42	65.6	887	2	Q4T919_TETNG
42	42	65.6	887	2	Q6VG34_SIVCZ
43	41.5	64.8	317	2	Q84E45_BACCI
44	41	64.1	145	2	Q8JUY9_9PAPI
45	41	64.1	181	2	Q61TE0_CAEBR

ALIGNMENTS

RESULT 1
Q4IGV1_GIBZE
ID Q4IGV1_GIBZE PRELIMINARY; PRT; 581 AA.
AC Q4IGV1;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DB Hypothetical protein.
GN ORFNames-PG03527.1;
OS Gibberella zeae PH-1.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Hypocreomycetidae; Nectriaceae; Gibberella.
OX NCBI_TaxID=229533;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=PH-1;
RA Birren B., Nusbaum C., Abouelleil A., Allen N., Anderson S.,
RA Arachi H.M., Barna N., Bastien V., Bloom T., Boguslavsky L.,
RA Boukhgalter B., Butler J., Calvo S.E., Camarata J., Chang J.,
RA Choepel V., Collymore A., Cook A., Cooke P., Corum B., DeArellano K.,
RA Diaz J.S., Dodge S., Dooley K., Dorris L., Elkins T., Engels R.,
RA Erickson J., Faro S., Ferreira P., Fitzgerald M., Gage D., Galagan J.,
RA Gardyna S., Gnerre S., Graham L., Grand-Pierre N., Hafez N.,
RA Hagopian D., Hagos B., Hall J., Horton L., Hulme W., Iliev I.,
RA Jaffe D., Johnson R., Jones C., Kamal M., Kamat A., Karatas A.,
RA Kells C., Landers T., Levine R., Lindblad-Toh K., Liu G., Lui A.,
RA Ma L.-J., Mabbitt R., MacLean C., Macdonald P., Major J., Manning J.,
RA Matthews C., Mauceli E., McCarthy M., Meldrim J., Meneus L.,
RA Mihova T., Mlenga V., Murphy T., Naylor J., Nguyen C., Nicol R.,
RA Nielsen C.B., Norbu C., O'Connor T., O'Donnell P., O'Neill D.,
RA Oliver J., Peterson K., Phunkhang P., Pierre N., Purcell S.,
RA Rachupka A., Ramasamy U., Raymond C., Retta R., Rise C., Rogov P.,
RA Roman J., Schauer S., Schupbach R., Seaman S., Severy P., Smirnov S.,
RA Smith C., Spencer B., Stange-Thomann N., Stojanovic N., Stubbs M.,
RA Talanas J., Testaye S., Theodore J., Topham K., Travers M.,
RA Vassiliou H., Venkataraman V.S., Viel R., Vo A., Wang S., Wilson B.,
RA Wu X., Wyman D., Young G., Zainoun J., Zembek L., Zimmer A., Zody M.,
RA Lander E.,
RT "Fusarium graminearum genome sequence."
RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
preliminary data.
CC EMBL; AAC01000159; EAA72493.1; -; Genomic_DNA.
DR Hypothetical protein.
KW Hypothetical protein.
SQ SEQUENCE 581 AA; 65440 MW; BF94CE0445C6D35D CRC64;

Query Match 71.9%; Score 46; DB 2; Length 581;

Best Local Similarity 71.4%; Pred. No. 1.5e+02;

Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2 WDFAPWP 8

Db 545 WELAWPW 551

```

RESULT 2
Q8GQ64_PSEAE
ID Q8GQ64_PSEAE PRELIMINARY; PRT; 254 AA.
AC Q8GQ64;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Hypothetical protein ORF C46.
GN Names=ORF C46;
OS Pseudomonas aeruginosa.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=287;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=C;
RX MEDLINE=22313472; PubMed=12426355;
RA DOI=10.1128/JB.184.23.6665-6680.2002;
RA Larbig K.D., Christmann A., Johann A., Klockgether J., Hartsch T.,
RA Merkl R., Wiehlmann L., Fritz H.J., Tummler B.;
RT "Gene islands integrated into tRNA(Gly) genes confer genome diversity
RT on a Pseudomonas aeruginosa clone.";
RL J. Bacteriol. 184:6665-6680(2002).
DR EMBL; AF440523; AAN62139.1; -; Genomic DNA.
DR GO; GO:003288; C:periplasmic space (sensu Gram-negative Bact. . .; IEA.
DR GO; GO:0015035; F:protein disulfide oxidoreductase activity; IEA.
KW Hypothetical protein.
SQ SEQUENCE 254 AA; 27649 MW; 212C116B689B8069 CRC64;

Query Match 70.3%; Score 45; DB 2; Length 254;
Best Local Similarity 71.4%; Pred. No. 96;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFANPW 8
DB 20 WQFRPW 26

RESULT 3
Q4KKC3_PSEF5
ID Q4KKC3_PSEF5 PRELIMINARY; PRT; 419 AA.
AC Q4KKC3;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Intercellular adhesion protein A.
GN Names=ICA; ORFNames=PFL_0163;
OS Pseudomonas fluorescens (strain Pf-5).
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
OC Pseudomonadaceae; Pseudomonas.
OX NCBI_TaxID=220564;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=PF-5;
RX PubMed=15980861; DOI=10.1038/nbt1110;
RA Paulsen I.T., Press C., Ravel J., Kobayashi D., Myers G.S.,
RA Mavrodì D., DeBoy R.T., Seehadri R., Ren Q., Madupu R., Dodson R.J.,
RA Durkin S., Brinkac L.M., Daugherty S.C., Sullivan S.A., Rosovitz M.,
RA Gwinn M.D., Zhou L., Nelson W.C., Weidman J., Watkins K., Tran K.,
RA Khouri H.M., Pierson E., Pierson L. III, Thomashow L., Loper J.;
RT "Complete genome sequence of the plant commensal Pseudomonas
RT fluorescens Pf-5.";
RL Nat. Biotechnol. 23:873-878(2005).
DR EMBL; CP000076; AAY95575.1; -; Genomic DNA.
DR NCBI_TaxID=220564;
SQ SEQUENCE 419 AA; 48273 MW; C1784CCE0AF1B252 CRC64;

Query Match 70.3%; Score 45; DB 2; Length 419;
Best Local Similarity 62.5%; Pred. No. 1.5e+02;
Matches 5; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8

```

```

DB ||: |||
25 HWERHWPW 32

RESULT 4
Q529W2_MAGGR
ID Q529W2_MAGGR PRELIMINARY; PRT; 526 AA.
AC Q529W2;
DT 13-SEP-2005 (TrEMBLrel. 31, Created)
DT 13-SEP-2005 (TrEMBLrel. 31, Last sequence update)
DT 13-SEP-2005 (TrEMBLrel. 31, Last annotation update)
DE Hypothetical protein.
GN ORFNames=MG0272.4; 70-15.
OS Magnaporthe grisea 70-15.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetes incertae sedis; Magnaportheaceae; Magnaporthe.
OX NCBI_TaxID=242507;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=70-15;
RA Birren B., Nuebaum C., Abebe A., Abouelleil A., Adekoya E.,
RA Ait-zahra M., Allen N., Allen T., An P., Anderson M., Anderson S.,
RA Arachchi H., Armbruster J., Bachantsang P., Baldwin J., Barry A.,
RA Bayul T., Blichsteyn B., Bloom T., Blye J., Boguslavskiy L.,
RA Borowsky M., Boukhgalter B., Brunache A., Butler J., Calixte N.,
RA Calvo S., Camarata J., Campo K., Chang J., Cheshatsang Y., Citroen M.,
RA Collymore A., Considine T., Cook A., Cooke P., Corum B., Cuomo C.,
RA David R., Dawoe T., Degray S., Dodge S., Dooley K., Dorje P.,
RA Dorjee K., Dorris L., Duffey N., Dupes A., Elkins T., Engels R.,
RA Erickson J., Farina A., Faro S., Ferreira P., Fischer H.,
RA Fitzgerald M., Foley K., Gage D., Galagan J., Gearin G., Gnerre S.,
RA Gnirke A., Goyette A., Graham J., Grandbois E., Gyaltsen K., Hafez N.,
RA Hagopian D., Hagos B., Hall J., Hatcher B., Heller A., Higgins H.,
RA Honan T., Horn A., Houde N., Hughes L., Hulme W., Husby E., Iliev I.,
RA Jaffe D., Jones C., Kamal M., Kamat A., Kamvysellis M., Karlsson E.,
RA Kelle C., Kieu A., Kiener P., Kodira C., Kulbokas E., Labutti K.,
RA Lama D., Landers T., Leger J., Levine S., Lewis D., Lewis T.,
RA Lindblad-toh K., Liu X., Lokyitsang T., Lokyitsang Y., Lucien O.,
RA Lui A., Ma L.J., Mabbitt R., Macdonald J., Maclean C., Major J.,
RA Manning J., Marabella R., Maru K., Matthews C., Mauceli E.,
RA McCarthy M., McDonough S., Mcghee T., Meldrim J., Meneus L.,
RA Mesirov J., Mihalev A., Mihova T., Mikkelsen T., Mlenga V., Moru K.,
RA Mozes J., Mulrain L., Munson G., Naylor J., Neues C., Nguyen C.,
RA Nguyen N., Nguyen T., Nicol R., Nielsen C., Nizzari M., Norbu C.,
RA Norbu N., O'donnell P., Okoawo O., O'leary S., Omotosho B.,
RA O'Neill K., Ogman S., Parker S., Perrin D., Phunkhang P., Pignani B.,
RA Purcell S., Rachupka T., Ramasamy U., Rameau R., Ray V., Raymond C.,
RA Retta R., Richardson S., Rise C., Rodriguez J., Rogers J., Rogov P.,
RA Rutnan M., Schupbach R., Seaman C., Settipalli S., Sharpe T.,
RA Sheridan J., Sherpa N., Shi J., Smirnov S., Smith C., Sougnez C.,
RA Spencer B., Stalker J., Stange-thomann N., Stavropoulos S.,
RA Stetsen K., Stone C., Stone S., Stubbs M., Talamas J., Tchuinga P.,
RA Tenzing P., Tesfaye S., Theodore J., Thoulteang Y., Topham K.,
RA Towey S., Tsamla T., Tsomo N., Vallee D., Vassiliev H.,
RA Venkataraman V., Vinson J., Vo A., Wade C., Wang S., Wangchuk T.,
RA Wangdi T., Whittaker C., Wilkinson J., Wu Y., Wyman D., Yadav S.,
RA Yang S., Yang X., Yeager S., Yee E., Young G., Zainoun J., Zembeck L.,
RA Zimmer A., Zody M., Lander E.;
RT "The genome sequence of Magnaporthe grisea.";
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
[2]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=70-15;
RA Dean R., Mitchell T., Brown D., Pan H., Thon M.;
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
[3]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=70-15;
RA Zhu H., Blackmon B.;
RL Submitted (OCT-2003) to the EMBL/GenBank/DBJ databases.
CC -1- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.

```

```
CC -1- CATALYTIC ACTIVITY: Obtusifoliol + 3 O(2) + 3 NADPH = 4-alpha-methyl-5-alpha-ergosta-8,14,24(28)-trien-3-beta-ol + formate + 3 NADP(+) + 3 H(2)O.
```

```
CC CC
```

```
CC -1- SIMILARITY: Belongs to the cytochrome P450 family.
```

```
CC EMBL: AACU01000440; EAA54287.1; -; Genomic_DNA.
```

```
CC InterPro: IPR001128; Cytochrome_P450.
```

```
DR InterPro: IPR002403; EP450IV.
```

```
DR Pfam: PF00067; p450; 1.
```

```
DR PRINTS: PR00465; EP450IV.
```

```
KW Heme; Hypothetical protein; Lipid synthesis; Membrane; Monooxygenase;
```

```
KW Oxidoreductase; Steroid biosynthesis; Sterol biosynthesis.
```

```
SQ SEQUENCE 526 AA; 60058 MW; DE5A6DE5E3F27EBB CRC64;
```

```
Query Match 70.3%; Score 45; DB 2; Length 526;
```

```
Best Local Similarity 100.0%; Pred.No.1.9e+02;
```

```
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2 WDFANPW 7 |||||
```

```
DB 484 WDFANPW 489
```

```
RESULT 5
```

```
QSNZ03_AZOSE PRELIMINARY; PRT; 142 AA.
```

```
AC QSNZ03;
```

```
DT 01-FEB-2005 (TrEMBLrel. 29, Created)
```

```
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
```

```
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
```

```
DE Noer (C-terminal domain).
```

```
GN Name=nosr; OrderedLocusNames=AZOSEAJ35860; ORFNames=eBB224;
```

```
OS Azococcus sp. (strain EBN1).
```

```
OC Bacteria; Proteobacteria; Betaproteobacteria; Rhodocycales;
```

```
OC Rhodocyclaceae; Azococcus.
```

```
OX NCBI_TaxID=76114;
```

```
[1]
```

```
RN NUCLEOTIDE SEQUENCE.
```

```
RC STRAIN=EBN1;
```

```
RX PubMed=15551059; DOI=10.1007/s00203-004-0742-9;
```

```
RA Rabus R., Kube M., Heider J., Beck A., Heitmann K., Widdel F., Reinhardt R.; "The genome sequence of an anaerobic aromatic-degrading denitrifying bacterium, strain EBN1.";
```

```
RL Arch. Microbiol. 183:27-36(2005).
```

```
DR EMBL: CR555306; CAI09711.1; -; Genomic_DNA.
```

```
KW Complete proteome.
```

```
SQ SEQUENCE 142 AA; 15770 MW; 8733EBB6E312A50D CRC64;
```

```
Query Match 68.8%; Score 44; DB 2; Length 142;
```

```
Best Local Similarity 71.4%; Pred.No.79;
```

```
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2 WDFANPW 8 |||||
```

```
DB 30 WDHLWPW 36
```

```
RESULT 6
```

```
Q8DM48_SYNEL PRELIMINARY; PRT; 283 AA.
```

```
ID Q8DM48 SYNEL
```

```
AC Q8DM48;
```

```
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
```

```
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
```

```
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
```

```
DE Sulfate transport system permease protein.
```

```
GN Name=cyst; OrderedLocusNames=tlr0275;
```

```
OS Synechococcus elongatus (Thermosynechococcus elongatus).
```

```
OC Bacteria; Cyanobacteria; Chroococcales; Synechococcus.
```

```
OX NCBI_TaxID=32046;
```

```
[1]
```

```
RN NUCLEOTIDE SEQUENCE.
```

```
RC STRAIN=BF-1;
```

```
RX MEDLINE=22225144; PubMed=12240834;
```

Best Local Similarity 71.4%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFAWPW 8
|||
240 WDATWFW 246

RESULT 8
Q7XD95_ORYSA
ID Q7XD95_ORYSA PRELIMINARY; PRT; 323 AA.
AC Q7XD95;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein.
GN ORFNames=OSJNBa0029C15.22;
OS Oryza sativa (japonica cultivar-group).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoidae; Oryzaceae; Oryza.
OX NCBI_TaxID=39947;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA The Rice Chromosome 10 Sequencing Consortium;
RT "In-depth view of structure, activity, and evolution of rice
chromosome 10.";
RL Science 300:1566-1569(2003).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Buell C.R., Wang R.A., McCombie W.R., Messing J., Yuan Q.;
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB017107; AAP54347.1; -; Genomic_DNA.
DR Gramine; Q7XD95; -;
KW Hypothetical protein.

QY 2 WDFAWPW 8
|||
69 WFFSWFW 75

Query Match 68.8%; Score 44; DB 2; Length 323;
Best Local Similarity 71.4%; Pred. No. 1.7e+02;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

RESULT 9
Q8W368_ORYSA
ID Q8W368_ORYSA PRELIMINARY; PRT; 323 AA.
AC Q8W368;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein OSJNBa0029C15.22.
GN Name=OSJNBa0029C15.22;
OS Oryza sativa (rice).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC Ehrhartoidae; Oryzaceae; Oryza.
OX NCBI_TaxID=4530;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Buell C.R., Yuan Q., Ouyang S., Liu J., Moffat K.S., Hill J.N.,
RA Gansberger K., Brenner M., Burgess S., Hance M., Shvartsbeyn M.,
RA Taitzin T., Riggs F., Hsiao J., Ziemann V., Blunt S., Pai G.,
RA VanAken S.E., Utterback T.R., Feldblyum T.V., Kalb E., Quackenbush J.,
RA Salzberg S.L., White O., Fraser C.M.;
RL Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Buell R.;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC087182; AAL59037.1; -; Genomic_DNA.

DR Gramine; Q8W368; -;
KW Hypothetical protein.
SQ SEQUENCE 323 AA; 33440 MW; 5D63175DA9CD17D8 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 323;
Best Local Similarity 71.4%; Pred. No. 1.7e+02;
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAWPW 8
|||
69 WFFSWFW 75

RESULT 10
Q5W9G5_HUMAN
ID Q5W9G5_HUMAN PRELIMINARY; PRT; 1440 AA.
AC Q5W9G5;
DT 01-FEB-2005 (TrEMBLrel. 29, Created)
DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE KIAA1062 splice variant 1 (fragment).
GN Name=KIAA1062;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Brain;
RA Homma K., Kikuno R.F., Nagase T., Ohara O., Nishikawa K.;
RT "Alternative Splice Variants Encoding Unstable Protein Domains Exist
in the Human Brain.";
RL J. Mol. Biol. 343:1207-1220(2004).
CC -!- SIMILARITY: Belongs to the ABC transporter family.
DR EMBL; AB177854; BAD66832.1; -; mRNA.
DR Ensembl; ENSG00000107311; Homo sapiens.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0016887; F:ATPase activity; IEA.
DR GO; GO:0000166; F:nucleotide binding; IEA.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transp_like.
DR InterPro; IPR006209; EGF_like.
DR InterPro; IPR002345; Lipocalin.
DR Pfam; PF00005; ABC_tran; 1.
DR ProDom; PD000006; ABC_transporter; 1.
DR SMART; SM00382; AAA; 1.
DR PROSITE; PS00211; ABC_TRANSPORTER_1; UNKNOWN_1.
DR PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.
KW ATP-binding; Nucleotide-binding.
FT NON_TER 1
SQ SEQUENCE 1440 AA; 159853 MW; 27F20F0D7E87B8FD CRC64;

Query Match 68.8%; Score 44; DB 2; Length 1440;
Best Local Similarity 57.1%; Pred. No. 6.5e+02;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAWPW 8
|||
295 WFFSWFW 301

RESULT 11
Q76MW7_HUMAN
ID Q76MW7_HUMAN PRELIMINARY; PRT; 1771 AA.
AC Q76MW7;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE KIAA1062 protein (Fragment).
GN Name=KIAA1062;

OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Brain;
 RA MEDLINE=9397452; PubMed=10470851;
 RX Kikuno R., Nagase T., Ishikawa K.-I., Hiroseawa M., Miyajima N.,
 RA Tanaka A., Kotani H., Nomura N., Ohara O.;
 RT "Prediction of the coding sequences of unidentified human genes. XIV.
 RT The complete sequences of 100 new cDNA clones from brain which code
 RT for large proteins in vitro.";
 RL DNA Res. 6:197-205(1999).
 CC -1- SIMILARITY: Belongs to the ABC transporter family.
 DR ENBL; AB028985; BA83014.2; -; mRNA.
 DR Ensembl; ENSRG00000107331; Homo sapiens.
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0016887; F:ATPase activity; IEA.
 DR GO; GO:0000166; F:nucleotide binding; IEA.
 DR InterPro; IPR003593; AAA_ATPase.
 DR InterPro; IPR003439; ABC_transp_like.
 DR InterPro; IPR006209; EGF_like.
 DR InterPro; IPR002345; Lipocalin.
 DR Pfam; PF00005; ABC_tran; 2.
 DR ProDom; PD000006; ABC transporter; 2.
 DR SMART; SM00382; AAA; 2.
 DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
 DR PROSITE; PS00893; ABC_TRANSPORTER_2; 2.
 DR PROSITE; PS00022; EGF_1; UNKNOWN 1.
 DR PROSITE; PS00213; LIPOCALIN; UNKNOWN 1.
 KW ATP-binding; Nucleotide-binding.
 FT NON_TER 1 1
 SQ SEQUENCE 1771 AA; 197369 MW; B2CCFB4C7C092D13 CRC64;
 Query Match 68.8%; Score 44; DB 2; Length 1771;
 Best Local Similarity 57.1%; Pred. No. 7.8e+02;
 Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 Qy 2 WDFANPW 8
 Db 281 WEWSWPW 287
 RESULT 12
 ID ABCA2_RAT STANDARD; PRT; 2434 AA.
 AC Q9ESR3;
 DT 25-OCT-2004 (Rel. 45, Created)
 DT 25-OCT-2004 (Rel. 45, Last sequence update)
 DT 13-SEP-2005 (Rel. 48, Last annotation update)
 DE ATP-binding cassette sub-family A member 2 (ATP-binding cassette
 DE transporter 2) (ATP-binding cassette 2).
 GN Name=Abca2; Synonyms=Abc2;
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
 OC Muridea; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP NUCLEOTIDE SEQUENCE, TISSUE SPECIFICITY, AND GLYCOSYLATION.
 RC TISSUE=Brain;
 RX MEDLINE=20427713; PubMed=10970803; DOI=10.1042/0264-6021:3500865;
 RA Zhao L.-X., Zhou C.-J., Tanaka A., Nakata M., Hirabayashi T.,
 RA Amachi T., Shioda S., Ueda K., Inagaki N.;
 RT "Cloning, characterization and tissue distribution of the rat ATP-
 RT binding cassette (ABC) transporter Abca2/ABCA2.";
 RL Biochem. J. 350:865-872(2000).
 CC -1- FUNCTION: Probable transporter, its natural substrate has not been
 CC found yet. May have a role in macrophage lipid metabolism and
 CC neural development.
 CC -1- SUBCELLULAR LOCATION: Integral membrane protein (Potential).

CC -1- TISSUE SPECIFICITY: Expressed at high levels in brain, at moderate
 CC levels in heart, kidney and lung, and at low levels in skeletal
 CC muscle, stomach, spleen, colon and pancreas. Not detected in the
 CC liver or small intestine. In brain, highly expressed in white
 CC matter and detected in oligodendrocytes.
 CC -1- PTM: N-glycosylated.
 CC -1- SIMILARITY: Belongs to the ABC transporter family. ABCA subfamily.
 CC -1- SIMILARITY: Contains 2 ABC transporter domains.
 CC -----
 CC This Swiss-Prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the ENBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use as long as its content is in no way modified and this statement is not
 CC removed.
 CC -----
 DR ENBL; AB037937; BAB16596.1; -; mRNA.
 DR Ensembl; ENSRG000000014268; Rattus norvegicus.
 DR RGD; 620238; Abca2.
 DR GO; GO:0043190; C:ATP-binding cassette (ABC) transporter complex; ISS.
 DR GO; GO:0016021; C:integral to membrane; NAS.
 DR GO; GO:0005524; F:ATP binding; IEA.
 DR GO; GO:0006629; F:lipid metabolism; NAS.
 DR GO; GO:0006810; P:transport; NAS.
 DR InterPro; IPR003593; AAA_ATPase.
 DR InterPro; IPR003439; ABC_transp_like.
 DR Pfam; PF00005; ABC_tran; 2.
 DR ProDom; PD000006; ABC transporter; 2.
 DR SMART; SM00382; AAA; 2.
 DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
 DR PROSITE; PS00893; ABC_TRANSPORTER_2; 2.
 KW ATP-binding; Glycoprotein; Nucleotide-binding; Repeat; Transmembrane;
 Transport.
 FT NON_TER 1 1
 FT TRANSMEM 22 42 Potential.
 FT TRANSMEM 54 74 Potential.
 FT TRANSMEM 699 719 Potential.
 FT TRANSMEM 750 770 Potential.
 FT TRANSMEM 782 802 Potential.
 FT TRANSMEM 813 833 Potential.
 FT TRANSMEM 857 877 Potential.
 FT TRANSMEM 893 913 Potential.
 FT TRANSMEM 1461 1481 Potential.
 FT TRANSMEM 1793 1813 Potential.
 FT TRANSMEM 1842 1862 Potential.
 FT TRANSMEM 1873 1893 Potential.
 FT TRANSMEM 1906 1926 Potential.
 FT TRANSMEM 1992 2012 Potential.
 FT DOMAIN 990 1221 ABC transporter 1.
 FT DOMAIN 2051 2286 ABC transporter 2.
 FT NP_BIND 1024 1031 ATP 1 (By similarity).
 FT NP_BIND 2088 2095 ATP 2 (By similarity).
 FT CARBOHYD 14 14 N-linked (GlcNAc...)
 FT CARBOHYD 89 89 N-linked (GlcNAc...)
 FT CARBOHYD 168 168 N-linked (GlcNAc...)
 FT CARBOHYD 173 173 N-linked (GlcNAc...)
 FT CARBOHYD 305 305 N-linked (GlcNAc...)
 FT CARBOHYD 368 368 N-linked (GlcNAc...)
 FT CARBOHYD 379 379 N-linked (GlcNAc...)
 FT CARBOHYD 420 420 N-linked (GlcNAc...)
 FT CARBOHYD 432 432 N-linked (GlcNAc...)
 FT CARBOHYD 476 476 N-linked (GlcNAc...)
 FT CARBOHYD 484 484 N-linked (GlcNAc...)
 FT CARBOHYD 494 494 N-linked (GlcNAc...)
 FT CARBOHYD 530 530 N-linked (GlcNAc...)
 FT CARBOHYD 549 549 N-linked (GlcNAc...)
 FT CARBOHYD 590 590 N-linked (GlcNAc...)
 FT CARBOHYD 600 600 N-linked (GlcNAc...)
 FT CARBOHYD 628 628 N-linked (GlcNAc...)
 FT CARBOHYD 1247 1247 N-linked (GlcNAc...)
 FT CARBOHYD 1496 1496 N-linked (GlcNAc...)
 FT CARBOHYD 1549 1549 N-linked (GlcNAc...)
 FT CARBOHYD 1557 1557 N-linked (GlcNAc...)
 FT CARBOHYD 1613 1613 N-linked (GlcNAc...)
 FT CARBOHYD 1678 1678 N-linked (GlcNAc...)

FT CARBOHYD 1776 1776 N-linked (GLcNAc...) (Potential).
FT CARBOHYD 2055 2055 N-linked (GLcNAc...) (Potential).
SQ SEQUENCE 2434 AA; 270928 MW; CD424A9C4F63513F CRC64;

Query Match 68.8%; Score 44; DB 1; Length 2434;

Best Local Similarity 57.1%; Pred. No. 1e+03;

Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAPWP 8

Db 945 WEWSWPW 951

RESULT 13

Q5SPY5 HUMAN

ID Q5SPY5_HUMAN PRELIMINARY; PRT; 2435 AA.

AC Q5SPY5;

DT 01-FEB-2005 (TrEMBLrel. 29, Created)

DT 01-FEB-2005 (TrEMBLrel. 29, Last sequence update)

DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)

DE ATP-binding cassette, sub-family A (ABC1), member 2.

GN Names-ABCA2; ORNames=RP11-229P13.8-002;

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;

OC Homo.

OC NCBI_TaxID=9606;

OX [1]

RN NUCLEOTIDE SEQUENCE.

RA Lloyd D.;

RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.

CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).

CC -1- SIMILARITY: Belongs to the ABC transporter family.

DR EMBL; AL080752; Call12768.1; -; Genomic_DNA.

DR Ensembl; ENSG00000107331; Homo sapiens.

DR GO; GO:0016021; C:integral to membrane; IEA.

DR GO; GO:0005524; F:ATP binding; IEA.

DR GO; GO:0016887; F:ATPase activity; IEA.

DR GO; GO:0000166; F:nucleotide binding; IEA.

DR InterPro; IPR003593; AAA ATPase.

DR InterPro; IPR003439; ABC transp_like.

DR InterPro; IPR006209; EGF like.

DR InterPro; IPR002345; Lipocalin.

DR Pfam; PF00005; ABC tran; 2.

DR ProDom; PD000006; ABC transporter; 2.

DR SMART; SM00382; AAA; 2.

DR PROSITE; PS00211; ABC TRANSPORTER_1; UNKNOWN_1.

DR PROSITE; PS50893; ABC TRANSPORTER_2; 2.

DR PROSITE; PS00022; EGF_1; UNKNOWN_1.

DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.

KW ATP-binding; Nucleotide-binding; Repeat; Transmembrane.

SQ SEQUENCE 2435 AA; 269873 MW; 0C4ABE9087B8C5C4 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 2435;

Best Local Similarity 57.1%; Pred. No. 1e+03;

Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2 WDFAPWP 8

Db 945 WEWSWPW 951

RESULT 14

ABCA2 HUMAN

ID ABCA2_HUMAN STANDARD; PRT; 2436 AA.

AC Q9BZC7;

DT 16-OCT-2001 (Rel. 40, Created)

DT 16-OCT-2001 (Rel. 40, Last sequence update)

DT 13-SEP-2005 (Rel. 48, Last annotation update)

DE ATP-binding cassette sub-family A member 2 (ATP-binding cassette

transporter 2) (ATP-binding cassette 2).

GN Names-ABCA2; Synonyms=ABCB2;

OS Homo sapiens (Human).

Q5

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.

OC NCBI_TaxID=9606;

OX [1]

RN NUCLEOTIDE SEQUENCE.

RA Kaminski W.E., Plehler A., Pullmann K., Porsch-Oezcuvermez M.,

RA Duong C., Bared G.M., Buchler C., Schmitz G.;

RT "Complete coding sequence, promoter region, and genomic structure of

the human ABCA2 gene and evidence for sterol-dependent regulation in

macrophages.";

RL Biochem. Biophys. Res. Commun. 281:249-258(2001).

CC -1- FUNCTION: Probable transporter, its natural substrate has not been

CC -1- FUNCTION: May have a role in macrophage lipid metabolism and

CC neural development.

CC -1- SUBCELLULAR LOCATION: Integral membrane protein (Potential).

CC -1- SIMILARITY: Belongs to the ABC transporter family. ABCA subfamily.

CC -1- SIMILARITY: Contains 2 ABC transporter domains.

CC This Swiss-Prot entry is copyright. It is produced through a collaboration

between the Swiss Institute of Bioinformatics and the EMBL outstation -

the European Bioinformatics Institute. There are no restrictions on its

use as long as its content is in no way modified and this statement is not

removed.

DR EMBL; AF327705; AAK14335.1; -; Genomic_DNA.

DR EMBL; AF327658; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327659; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327660; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327661; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327662; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327663; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327664; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327665; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327666; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327667; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327668; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327669; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327670; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327671; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327672; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327673; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327674; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327675; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327676; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327677; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327678; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327679; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327680; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327681; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327682; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327683; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327684; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327685; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327686; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327687; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327688; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327689; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327690; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327691; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327692; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327693; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327694; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327695; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327696; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327697; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327698; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327699; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327700; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327701; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327702; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327703; AAK14335.1; JOINED; Genomic_DNA.

DR EMBL; AF327704; AAK4335.1; JOINED; Genomic_DNA.
DR Ensembl; ENSG00000107331; Homo sapiens.
DR HGNC; HGNC:32; ABCA2.
DR MIM; 600047; -.
DR GO; GO:0043190; C:ATP-binding cassette (ABC) transporter complex; NAS.
DR GO; GO:0016021; C:integral to membrane; NAS.
DR GO; GO:006629; P:lipid metabolism; NAS.
DR GO; GO:0006810; P:transport; NAS.
DR InterPro; IPR003439; ABC transp_like.
DR Pfam; PF00005; ABC_tran_2.
DR ProDom; PD000006; ABC transporter; 2.
DR SMART; SM00382; AAA_2.
DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR PROSITE; PS00893; ABC_TRANSPORTER_2; 2.
KW ATP-binding; Glycoprotein; Nucleotide-binding; Repeat; Transmembrane;
Transport.
FT TRANSMEM 22 42 Potential.
FT TRANSMEM 54 74 Potential.
FT TRANSMEM 700 720 Potential.
FT TRANSMEM 751 771 Potential.
FT TRANSMEM 783 803 Potential.
FT TRANSMEM 814 834 Potential.
FT TRANSMEM 858 878 Potential.
FT TRANSMEM 894 914 Potential.
FT TRANSMEM 1457 1477 Potential.
FT TRANSMEM 1793 1813 Potential.
FT TRANSMEM 1842 1862 Potential.
FT TRANSMEM 1873 1893 Potential.
FT TRANSMEM 1906 1926 Potential.
FT TRANSMEM 1992 2012 Potential.
FT DOMAIN 991 1222 ABC transporter 1.
FT DOMAIN 2051 2286 ABC transporter 2.
FT NP_BIND 1025 1032 ATP 1 (Potential).
FT NP_BIND 2088 2095 ATP 2 (Potential).
FT CARBOHYD 14 14 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 90 90 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 169 169 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 174 174 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 306 306 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 369 369 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 380 380 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 421 421 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 433 433 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 477 477 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 485 485 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 495 495 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 531 531 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 545 545 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 591 591 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 601 601 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 629 629 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1409 1409 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1497 1497 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1550 1550 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1558 1558 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1613 1613 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1678 1678 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 1776 1776 N-linked (GlcNAc...) (Potential).
FT CARBOHYD 2055 2055 N-linked (GlcNAc...) (Potential).
SQ SEQUENCE 2436 AA; 269974 MW; 9E6688D8615DE06D CRC64;

Query Match 68.8%; Score 44; DB 1; Length 2436;
Best Local Similarity 57.1%; Pred. No. le+03;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAWPW 8
|:|:|:|:|
Db 946 WENSWPW 952

RESULT 15
Q9HC28_HUMAN

ID AC Q9HC28 HUMAN PRELIMINARY; PRT; 2436 AA.
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-FEB-2005 (TrEMBLrel. 29, Last annotation update)
DE ATP-binding cassette sub-family A member 2 (ABCA2)
DE ABCA2).
GN Name=ABCA2;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Brain;
RX MEDLINE=21205831; PubMed=11309290;
RA Vulevic B., Chen Z., Boyd J.T., Davis W. Jr., Walsh E.S.,
Belinsky M.G., Tew K.D.;
RT "Cloning and characterization of human adenosine 5'-triphosphate-
binding cassette, sub-family A, transporter 2 (ABCA2).";
Cancer Res. 61:3339-3347(2001).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=21092814; PubMed=1178988; DOI=10.1006/bbrc.2001.4305;
RA Kaminski W.E., Piehler A., Pullmann K., Porsch-Oezcuermmez M.,
Duong C., Bared G.M., Buchler C., Schmitz G.;
RT "Complete coding sequence, promoter region, and genomic structure of
the human ABCA2 gene and evidence for sterol-dependent regulation in
macrophages.";
RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
CC -1- SUBCELLULAR LOCATION: Integral membrane protein (By similarity).
CC -1- SIMILARITY: Belongs to the ABC transporter family.
DR EMBL; AF178941; AAC09372.1; -; mRNA.
DR EMBL; AF327657; AAK14334.1; -; mRNA.
DR PIR; A59189; A59189.
DR Ensembl; ENSG00000107331; Homo sapiens.
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0005524; F:ATP binding; IEA.
DR GO; GO:0016887; F:ATPase activity; IEA.
DR GO; GO:0000166; F:nucleotide binding; IEA.
DR InterPro; IPR003593; AAA_ATPase.
DR InterPro; IPR003439; ABC_transp_like.
DR InterPro; IPR006209; EGF-like.
DR InterPro; IPR002345; Lipocalin.
DR Pfam; PF00005; ABC_tran; 2.
DR ProDom; PD000006; ABC transporter; 2.
DR SMART; SM00382; AAA; 2.
DR PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR PROSITE; PS00893; ABC_TRANSPORTER_2; 2.
DR PROSITE; PS00022; EGF_1; UNKNOWN_I.
DR PROSITE; PS00213; LIPOCALIN; UNKNOWN_1.
KW ATP-binding; Nucleotide-binding; Repeat; Transmembrane.
SQ SEQUENCE 2436 AA; 269958 MW; E0443AF14EA25D1 CRC64;

Query Match 68.8%; Score 44; DB 2; Length 2436;
Best Local Similarity 57.1%; Pred. No. le+03;
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAWPW 8
|:|:|:|:|
Db 946 WENSWPW 952

Search completed: March 24, 2006, 07:48:21
Job time : 235 secs

THIS PAGE BLANK (USPTO)

RESULT 1
US-09-794-529B-1
; Sequence 1, Application US/09794529B
; Patent No. 6641812

```
;
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: mouse
;
; FEATURE:
; OTHER INFORMATION: heat shock binding sequence
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-529B-1

Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 2
US-09-794-517A-1
; Sequence 1, Application US/09794517A
; Patent No. 6656679
```

```
;
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: mouse
;
; FEATURE:
; OTHER INFORMATION: heat shock binding sequence
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-517A-1

Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 3
US-09-011-645E-1
; Sequence 1, Application US/09011645E
; Patent No. 6663868
```

GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-011-645E-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 4
US-09-794-832-1
Sequence 1, Application US/09794832
Patent No. 6673348
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-832-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 5
US-09-680-806A-1
Sequence 1, Application US/09680806A
Patent No. 6719974
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680,806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-680-806A-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
RESULT 6
US-09-552-868-1
Sequence 1, Application US/09552868
Patent No. 6761892
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-552-868-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
RESULT 7
US-09-636-295-1
Sequence 1, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-636-295-1
Query Match 100.0%; Score 64; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 4.6e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 8
US-09-794-529B-8
Sequence 8, Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-529B-8
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
RESULT 9
US-09-794-529B-9
Sequence 9, Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, P. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-529B-9
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8
RESULT 10
US-09-794-517A-8
; Sequence 8, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, P. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517A
FILING DATE: 19-Oct-2001
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/13
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-517A-8
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
DB 12 HWDFAWPW 19
RESULT 11
US-09-794-517A-9
; Sequence 9, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517A
FILING DATE: 19-Oct-2001
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/13
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-517A-9
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDPAWPW 8
Db 1 HWDPAWPW 8
RESULT 12
US-09-011-645E-8
; Sequence 8, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-011-645E-8
Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDPAWPW 8
Db 12 HWDPAWPW 19
RESULT 13
US-09-011-645E-9
; Sequence 9, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich

HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/011.645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002.479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002.490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-011-645E-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 14
US-09-794-832-8
Sequence 8, Application US/09794832
Patent No. 6673348
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002.479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002.490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-832-8

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 15
US-09-794-832-9
Sequence 9, Application US/09794832
Patent No. 6673348
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

; TAKECHI, Yoshizumi
 ; MAYHEW, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
 ; Immunotherapies
 ; NUMBER OF SEQUENCES: 30
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Kenyon & Kenyon
 ; STREET: One Broadway
 ; CITY: New York
 ; STATE: NY
 ; COUNTRY: US
 ; ZIP: 10004
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
 ; COMPUTER: IBM compatible
 ; OPERATING SYSTEM: MS DOS
 ; SOFTWARE: Word Perfect
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/794,832
 ; FILING DATE: 27-Feb-2001
 ; CLASSIFICATION: <Unknown>
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/011,645
 ; FILING DATE: 13-Feb-1998
 ; APPLICATION NUMBER: 60/002,479
 ; FILING DATE: August 18, 1995
 ; APPLICATION NUMBER: 60/002,490
 ; FILING DATE: August 18, 1995
 ; APPLICATION NUMBER: PCT/US96/13363
 ; FILING DATE: August 16, 1996
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: DeLucia, Richard L.
 ; REGISTRATION NUMBER: 28,839
 ; REFERENCE/DOCKET NUMBER: 11746/1
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212) 425-7200
 ; TELEFAX: (212) 425-5288
 ; TELEX: <Unknown>
 ; INFORMATION FOR SEQ ID NO: 9:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 19
 ; TYPE: amino acid
 ; STRANDEDNESS: <Unknown>
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; HYPOTHETICAL: no
 ; FRAGMENT TYPE: internal
 ; ORIGINAL SOURCE:
 ; ORGANISM: <Unknown>
 ; FEATURE:
 ; OTHER INFORMATION:
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
 ; US-09-794-832-9

Query Match 100.0%; Score 64; DB 2; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0027;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 1 HWDFAWPW 8

RESULT 16
 US-09-680-806A-8
 ; Sequence 8, Application US/09680806A
 ; Patent No. 6719974
 ; GENERAL INFORMATION:
 ; APPLICANT: Sloan-Kettering Institute for Cancer Research
 ; ROTHMAN, James E.
 ; HARTL, F. Ulrich
 ; HOE, Mee H.
 ; HOUGHTON, Alan

; TAKECHI, Yoshizumi
 ; MAYHEW, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
 ; Immunotherapies
 ; NUMBER OF SEQUENCES: 30
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Kenyon & Kenyon
 ; STREET: One Broadway
 ; CITY: New York
 ; STATE: NY
 ; COUNTRY: US
 ; ZIP: 10004
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
 ; COMPUTER: IBM compatible
 ; OPERATING SYSTEM: MS DOS
 ; SOFTWARE: Word Perfect
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/680,806A
 ; FILING DATE: 05-Oct-2000
 ; CLASSIFICATION: 424
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/002,479
 ; FILING DATE: August 18, 1995
 ; APPLICATION NUMBER: 60/002,490
 ; FILING DATE: August 18, 1995
 ; APPLICATION NUMBER: PCT/US96/13363
 ; FILING DATE: August 16, 1996
 ; APPLICATION NUMBER: 09/011,645
 ; FILING DATE: February 13, 1998
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: DeLucia, Richard L.
 ; REGISTRATION NUMBER: 28,839
 ; REFERENCE/DOCKET NUMBER: 11746/10
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212) 425-7200
 ; TELEFAX: (212) 425-5288
 ; TELEX: <Unknown>
 ; INFORMATION FOR SEQ ID NO: 8:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 19
 ; TYPE: amino acid
 ; STRANDEDNESS: <Unknown>
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 ; HYPOTHETICAL: no
 ; FRAGMENT TYPE: internal
 ; ORIGINAL SOURCE:
 ; ORGANISM: <Unknown>
 ; FEATURE:
 ; OTHER INFORMATION:
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
 ; US-09-680-806A-8

Query Match 100.0%; Score 64; DB 2; Length 19;
 Best Local Similarity 100.0%; Pred. No. 0.0027;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 Db 12 HWDFAWPW 19

RESULT 17
 US-09-680-806A-9
 ; Sequence 9, Application US/09680806A
 ; Patent No. 6719974
 ; GENERAL INFORMATION:
 ; APPLICANT: Sloan-Kettering Institute for Cancer Research
 ; ROTHMAN, James E.
 ; HARTL, F. Ulrich
 ; HOE, Mee H.
 ; HOUGHTON, Alan

;; TAKECHI, Yoshizumi
;; MAYHEW, Mark
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;; Immunotherapies
;;
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Kenyon & Kenyon
;; STREET: One Broadway
;; CITY: New York
;; STATE: NY
;; COUNTRY: US
;; ZIP: 10004
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;; COMPUTER: IBM compatible
;; OPERATING SYSTEM: MS DOS
;; SOFTWARE: Word Perfect
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/680,806A
;; FILING DATE: 05-Oct-2000
;; CLASSIFICATION: 424
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/002,479
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: 60/002,490
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: PCT/US96/13363
;; FILING DATE: August 16, 1996
;; APPLICATION NUMBER: 09/011,645
;; FILING DATE: February 13, 1998
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Delucia, Richard L.
;; REGISTRATION NUMBER: 28,839
;; REFERENCE/DOCKET NUMBER: 11746/10
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212) 425-7200
;; TELEFAX: (212) 425-5288
;; TELEX: <Unknown>
;;
;; INFORMATION FOR SEQ ID NO: 9:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19
;; TYPE: amino acid
;; STRANDEDNESS: <Unknown>
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; HYPOTHETICAL: no
;; FRAGMENT TYPE: internal
;; ORIGINAL SOURCE:
;; ORGANISM: <Unknown>
;; FEATURE:
;; OTHER INFORMATION:
;; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-680-806A-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 18
US-09-552-868-8
; Sequence 8, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan

;; TAKECHI, Yoshizumi
;; MAYHEW, Mark
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;; Immunotherapies
;;
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Kenyon & Kenyon
;; STREET: One Broadway
;; CITY: New York
;; STATE: NY
;; COUNTRY: US
;; ZIP: 10004
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;; COMPUTER: IBM compatible
;; OPERATING SYSTEM: MS DOS
;; SOFTWARE: Word Perfect
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/552,868
;; FILING DATE: 20-Apr-2000
;; CLASSIFICATION: 424
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/002,479
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: 60/002,490
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: PCT/US96/13363
;; FILING DATE: August 16, 1996
;; APPLICATION NUMBER: 09/011,645
;; FILING DATE: February 13, 1998
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Delucia, Richard L.
;; REGISTRATION NUMBER: 28,839
;; REFERENCE/DOCKET NUMBER: 11746/8
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212) 425-7200
;; TELEFAX: (212) 425-5288
;; TELEX: <Unknown>
;;
;; INFORMATION FOR SEQ ID NO: 8:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19
;; TYPE: amino acid
;; STRANDEDNESS: <Unknown>
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; HYPOTHETICAL: no
;; FRAGMENT TYPE: internal
;; ORIGINAL SOURCE:
;; ORGANISM: <Unknown>
;; FEATURE:
;; OTHER INFORMATION:
;; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-552-868-8

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 19
US-09-552-868-9
; Sequence 9, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-552-868-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 20
US-09-636-295-8
Sequence 8, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-636-295-8

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 21
US-09-636-295-9
Sequence 9, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan

;;
;; TAKECHI, Yoshizumi
;; MAYHEW, Mark
;;
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;; Immunotherapies
;;
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Kenyon & Kenyon
;; STREET: One Broadway
;; CITY: New York
;; STATE: NY
;; COUNTRY: US
;; ZIP: 10004
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;; COMPUTER: IBM compatible
;; OPERATING SYSTEM: MS DOS
;; SOFTWARE: Word Perfect
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/636,295
;; FILING DATE: 10-Aug-2000
;; CLASSIFICATION: 424
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/002,479
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: 60/002,490
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: PCT/US96/13363
;; FILING DATE: August 16, 1996
;; APPLICATION NUMBER: 09/011,645
;; FILING DATE: February 13, 1998
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Delucia, Richard L.
;; REGISTRATION NUMBER: 28,839
;; REFERENCE/DOCKET NUMBER: 11746/9
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212) 425-7200
;; TELEFAX: (212) 425-5288
;; TELEX: <Unknown>
;;
;; INFORMATION FOR SEQ ID NO: 9:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19
;; TYPE: amino acid
;; STRANDEDNESS: <Unknown>
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; HYPOTHETICAL: no
;; FRAGMENT TYPE: internal
;; ORIGINAL SOURCE:
;; ORGANISM: <Unknown>
;;
;; FEATURE:
;; OTHER INFORMATION:
;; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-636-295-9

Query Match 100.0%; Score 64; DB 2; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.0027;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
|||
Db 1 HWDFAPWP 8

RESULT 22
US-09-794-529B-10
; Sequence 10 Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan

;;
;; TAKECHI, Yoshizumi
;; MAYHEW, Mark
;;
;; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;; Immunotherapies
;;
;; NUMBER OF SEQUENCES: 30
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Kenyon & Kenyon
;; STREET: One Broadway
;; CITY: New York
;; STATE: NY
;; COUNTRY: US
;; ZIP: 10004
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;; COMPUTER: IBM compatible
;; OPERATING SYSTEM: MS DOS
;; SOFTWARE: Word Perfect
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/794,529B
;; FILING DATE: 09-Jan-2002
;; CLASSIFICATION: 536
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/002,479
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: 60/002,490
;; FILING DATE: August 18, 1995
;; APPLICATION NUMBER: PCT/US96/13363
;; FILING DATE: August 16, 1996
;; APPLICATION NUMBER: 09/011,645
;; FILING DATE: February 13, 1998
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Delucia, Richard L.
;; REGISTRATION NUMBER: 28,839
;; REFERENCE/DOCKET NUMBER: 11746/11
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (212) 425-7200
;; TELEFAX: (212) 425-5288
;; TELEX: <Unknown>
;;
;; INFORMATION FOR SEQ ID NO: 10:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: amino acid
;; STRANDEDNESS: <Unknown>
;; TOPOLOGY: linear
;; MOLECULE TYPE: peptide
;; HYPOTHETICAL: yes
;; FRAGMENT TYPE: internal
;; ORIGINAL SOURCE:
;; ORGANISM: <Unknown>
;;
;; FEATURE:
;; OTHER INFORMATION: hybrid peptide for human papilloma
;; virus vaccine
;; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-529B-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
|||
Db 13 HWDFAPWP 20

RESULT 23
US-09-794-529B-11
; Sequence 11 Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.

HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-529B-11
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 24
US-09-794-529B-12
Sequence 12, Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich

HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-529B-12
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 25
US-09-794-529B-13
Sequence 13, Application US/09794529B
Patent No. 6641812
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.

APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-529B-15

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 28
US-09-794-529B-16
; Sequence 16, Application US/09794529B
; Patent No. 6641812

GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529B
FILING DATE: 09-Jan-2002
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-529B-16

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 29
US-09-794-529B-17
; Sequence 17, Application US/09794529B

; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-529B-17

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 30

US-09-794-529B-18

; Sequence 18, Application US/09794529B
; Patent No. 6641812
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529B
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-529B-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 31

US-09-794-529B-19
; Sequence 19, Application US/09794529B
; Patent No. 6641812

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,529B

FILING DATE: 09-Jan-2002

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/11

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 19:

US-09-794-529B-19

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 32

US-09-794-517A-10

; Sequence 10, Application US/09794517A

; Patent No. 6656679

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,517A

FILING DATE: 19-Oct-2001

CLASSIFICATION: 536

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/13

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 10:

US-09-794-517A-10

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 13 HWDFAWPW 20

RESULT 33
US-09-794-517A-11
; Sequence 11, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-517A-11

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAFWP 8
| | | | | | | |
.Db 1 HWDFAFWP 8

RESULT 34
US-09-794-517A-12
; Sequence 12, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-517A-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAFWP 8
| | | | | | | |

```
Db          13 HWDFAWPW 20

RESULT 35
US-09-794-517A-13
; Sequence 13, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-794-517A-13

Query Match          100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8

RESULT 36
US-09-794-517A-14
; Sequence 14, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-517A-14

Query Match          100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 HWDFAWPM 8
Db 13 HWDFAWPM 20

RESULT 37
US-09-794-517A-15
; Sequence 15, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-517A-15
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
Db 1 HWDFAWPM 8

RESULT 38
US-09-794-517A-16
; Sequence 16, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-517A-16
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 13 HWDFAWPW 20

RESULT 39

US-09-794-517A-17

; Sequence 17, Application US/09794517A

; Patent No. 6656679

; GENERAL INFORMATION:

; APPLICANT: Sloan-Kettering Institute for Cancer Research

; ROTHMAN, James E.

; HARTL, F. Ulrich

; HOE, Mee H.

; HOUGHTON, Alan

; TAKECHI, Yoshizumi

; MAYHEW, Mark

; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

; NUMBER OF SEQUENCES: 30

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Kenyon & Kenyon

; STREET: One Broadway

; CITY: New York

; STATE: NY

; COUNTRY: US

; ZIP: 10004

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

; COMPUTER: IBM compatible

; OPERATING SYSTEM: MS DOS

; SOFTWARE: Word Perfect

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/794,517A

; FILING DATE: 19-Oct-2001

; CLASSIFICATION: 536

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/002,479

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: 60/002,490

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: PCT/US96/13363

; FILING DATE: August 16, 1996

; APPLICATION NUMBER: 09/011,645

; FILING DATE: February 13, 1998

; ATTORNEY/AGENT INFORMATION:

; NAME: Delucia, Richard L.

; REGISTRATION NUMBER: 28,839

; REFERENCE/DOCKET NUMBER: 11746/13

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 425-7200

; TELEFAX: (212) 425-5288

; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 17:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20

; TYPE: amino acid

; STRANDEDNESS: <Unknown>

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; HYPOTHETICAL: yes

; FRAGMENT TYPE: internal

; ORIGINAL SOURCE:

; ORGANISM: <Unknown>

; FEATURE:

; OTHER INFORMATION: hybrid peptide for human papilloma

; virus vaccine

; SEQUENCE DESCRIPTION: SEQ ID NO: 17:

US-09-794-517A-17

Query Match

100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 40

US-09-794-517A-18

; Sequence 18, Application US/09794517A

; Patent No. 6656679

; GENERAL INFORMATION:

; APPLICANT: Sloan-Kettering Institute for Cancer Research

; ROTHMAN, James E.

; HARTL, F. Ulrich

; HOE, Mee H.

; HOUGHTON, Alan

; TAKECHI, Yoshizumi

; MAYHEW, Mark

; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

; NUMBER OF SEQUENCES: 30

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Kenyon & Kenyon

; STREET: One Broadway

; CITY: New York

; STATE: NY

; COUNTRY: US

; ZIP: 10004

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

; COMPUTER: IBM compatible

; OPERATING SYSTEM: MS DOS

; SOFTWARE: Word Perfect

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/794,517A

; FILING DATE: 19-Oct-2001

; CLASSIFICATION: 536

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/002,479

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: 60/002,490

; FILING DATE: August 18, 1995

; APPLICATION NUMBER: PCT/US96/13363

; FILING DATE: August 16, 1996

; APPLICATION NUMBER: 09/011,645

; FILING DATE: February 13, 1998

; ATTORNEY/AGENT INFORMATION:

; NAME: Delucia, Richard L.

; REGISTRATION NUMBER: 28,839

; REFERENCE/DOCKET NUMBER: 11746/13

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 425-7200

; TELEFAX: (212) 425-5288

; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 18:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20

; TYPE: amino acid

; STRANDEDNESS: <Unknown>

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; HYPOTHETICAL: yes

; FRAGMENT TYPE: internal

; ORIGINAL SOURCE:

; ORGANISM: <Unknown>

; FEATURE:

; OTHER INFORMATION: hybrid peptide for human papilloma

; virus vaccine

; SEQUENCE DESCRIPTION: SEQ ID NO: 18:

US-09-794-517A-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 13 HWDFAWPW 20

RESULT 41

US-09-794-517A-19
; Sequence 19, Application US/09794517A
; Patent No. 6656679
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517A
; FILING DATE: 19-Oct-2001
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/13
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-794-517A-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 42

US-09-011-645E-10
; Sequence 10, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-011-645E-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 43
US-09-011-645E-11
; Sequence 11, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-011-645E-11

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 44
US-09-011-645E-12
; Sequence 12, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-011-645E-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 13 HWDFAWFW 20

RESULT 45

US-09-011-645E-13
; Sequence 13, Application US/09011645E
; Patent No. 6663868

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/011.645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 13:

US-09-011-645E-13

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 46

US-09-011-645E-14
; Sequence 14, Application US/09011645E
; Patent No. 6663868

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/011.645E
FILING DATE: 13-Feb-1998
CLASSIFICATION: 424
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:

LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 14:

US-09-011-645E-14

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 47
US-09-011-645E-15
; Sequence 15, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-011-645E-15
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 48
US-09-011-645E-16
; Sequence 16, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-011-645E-16
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

```
Db          13 HWDFAWPW 20

RESULT 49
US-09-011-645E-17
; Sequence 17, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-011-645E-17

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
.Db     1 HWDFAWPW 8

RESULT 50
US-09-011-645E-18
; Sequence 18, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-011-645E-18

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
.Db     1 HWDFAWPW 20
```

RESULT 51

US-09-011-645E-19
; Sequence 19, Application US/09011645E
; Patent No. 6663868
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645E
; FILING DATE: 13-Feb-1998
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-011-645E-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 52

US-09-794-832-10
; Sequence 10, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-832-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 53
US-09-794-832-11
; Sequence 11, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-832-11

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAFPW 8
|||||||

.Db 1 HWDFAFPW 8

RESULT 54
US-09-794-832-12
; Sequence 12, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-832-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAFPW 8
|||||||

Db 13 HWDFAWFW 20

RESULT 55

US-09-794-832-13

Sequence 13, Application US/09794832

Patent No. 6673348

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,832

FILING DATE: 27-Feb-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/011,645

FILING DATE: 13-Feb-1998

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/1

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 13:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 13:

US-09-794-832-13

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8

Db 1 HWDFAWFW 8

RESULT 56

US-09-794-832-14

Sequence 14, Application US/09794832

Patent No. 6673348

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,832

FILING DATE: 27-Feb-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/011,645

FILING DATE: 13-Feb-1998

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/1

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine

SEQUENCE DESCRIPTION: SEQ ID NO: 14:

US-09-794-832-14

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDPAWPW 8
Db 13 HWDPAWPW 20

RESULT 57

US-09-794-832-15
; Sequence 15, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-832-15
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDPAWPW 8
Db 1 HWDPAWPW 8

RESULT 58

US-09-794-832-16
; Sequence 16, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-832-16
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 59

US-09-794-832-17
; Sequence 17, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-832-17

Query Match 100.0%; Score 64; DB 2; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 60

US-09-794-832-18
; Sequence 18, Application US/09794832
; Patent No. 6673348
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-832-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 61

US-09-794-832-19
; Sequence 19, Application US/09794832
; Patent No. 6673348

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESCHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 19:

SEQUENCE CHARACTERISTICS:

LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 19:

US-09-794-832-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 62

US-09-680-806A-10
; Sequence 10, Application US/09680806A
; Patent No. 6719974

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESCHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/680,806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 10:

SEQUENCE CHARACTERISTICS:

LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 10:

US-09-680-806A-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 63

US-09-680-806A-11
; Sequence 11, Application US/09680806A
; Patent No. 6719974

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/680,806A

FILING DATE: 05-Oct-2000

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/10

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

virus vaccine

; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-680-806A-11

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 64

US-09-680-806A-12

; Sequence 12, Application US/09680806A

; Patent No. 6719974

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOE, Mee H.

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/680,806A

FILING DATE: 05-Oct-2000

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/10

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: amino acid

STRANDEDNESS: <Unknown>

TOPOLOGY: linear

MOLECULE TYPE: peptide

HYPOTHETICAL: yes

FRAGMENT TYPE: internal

ORIGINAL SOURCE:

ORGANISM: <Unknown>

FEATURE:

OTHER INFORMATION: hybrid peptide for human papilloma

```
;
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-680-806A-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 65
US-09-680-806A-13
; Sequence 13, Application US/09680806A
; Patent No. 6719974
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/680.806A
; FILING DATE: 05-Oct-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:

;
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-680-806A-13

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 66
US-09-680-806A-14
; Sequence 14, Application US/09680806A
; Patent No. 6719974
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/680.806A
; FILING DATE: 05-Oct-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/10
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
```


MOLECULE TYPE: yes
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-680-806A-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
DB 13 HWDFAWPW 20

RESULT 71
US-09-680-806A-19
; Sequence 19, Application US/09680806A
; Patent No. 671974
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/680.806A
FILING DATE: 05-Oct-2000
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/10
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear

MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-680-806A-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
DB 1 HWDFAWPW 8

RESULT 72
US-09-552-868-10
; Sequence 10, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552.868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>

```

;
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-552-868-10
```

```

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 HWDFAPW 8
        |||||
Db      13 HWDFAPW 20
```

```

RESULT 73
US-09-552-868-11
; Sequence 11, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
```

```

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies
```

```

NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESS: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
```

```

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
```

```

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
```

```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
```

```

ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
```

```

INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
```

```

;
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-552-868-11
```

```

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 HWDFAPW 8
        |||||
Db      1 HWDFAPW 8
```

```

RESULT 74
US-09-552-868-12
; Sequence 12, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
```

```

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies
```

```

NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESS: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
```

```

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
```

```

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
```

```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
```

```

ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
```

```

INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
```


TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-552-868-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 75

US-09-552-868-13
Sequence 13, Application US/09552868
Patent No. 6761892
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
SEQUENCE CHARACTERISTICS:
INFORMATION FOR SEQ ID NO: 13:

LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-552-868-13

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 76

US-09-552-868-14
Sequence 14, Application US/09552868
Patent No. 6761892
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/552,868
FILING DATE: 20-Apr-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/8
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 14:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-552-868-14

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDPAWPW 8
Db 13 HWDPAWPW 20

RESULT 77

US-09-552-868-15
; Sequence 15, Application US/09552868
; Patent No. 6761892

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/552,868

FILING DATE: 20-Apr-2000

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/8

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-552-868-15

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDPAWPW 8
Db 1 HWDPAWPW 8

RESULT 78

US-09-552-868-16

; Sequence 16, Application US/09552868

; Patent No. 6761892

GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.

HARTL, F. Ulrich

HOUGHTON, Alan

TAKECHI, Yoshizumi

MAYHEW, Mark

TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon

STREET: One Broadway

CITY: New York

STATE: NY

COUNTRY: US

ZIP: 10004

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible

OPERATING SYSTEM: MS DOS

SOFTWARE: Word Perfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/552,868

FILING DATE: 20-Apr-2000

CLASSIFICATION: 424

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/002,479

FILING DATE: August 18, 1995

APPLICATION NUMBER: 60/002,490

FILING DATE: August 18, 1995

APPLICATION NUMBER: PCT/US96/13363

FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645

FILING DATE: February 13, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Delucia, Richard L.

REGISTRATION NUMBER: 28,839

REFERENCE/DOCKET NUMBER: 11746/8

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 425-7200

TELEFAX: (212) 425-5288

```

;
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-552-868-16

```

```

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAPW 8
Db      13 HWDFAPW 20

```

```

RESULT 79
US-09-552-868-17
; Sequence 17, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/552,868
; FILING DATE: 20-Apr-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/8
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200

```

```

;
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-552-868-17

```

```

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAPW 8
Db      1 HWDFAPW 8

```

```

RESULT 80
US-09-552-868-18
; Sequence 18, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/552,868
; FILING DATE: 20-Apr-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/8
; TELECOMMUNICATION INFORMATION:

```

; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-552-868-18

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
Db 13 HWDFAWPM 20
|||||

RESULT 81
US-09-552-868-19
; Sequence 19, Application US/09552868
; Patent No. 6761892
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/552.868
; FILING DATE: 20-Apr-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/8

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-552-868-19

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPM 8
Db 1 HWDFAWPM 8
|||||

RESULT 82
US-09-636-295-10
; Sequence 10, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, P. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839

; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-636-295-10

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 83
US-09-636-295-11
; Sequence 11, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.

; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-636-295-11
Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 84
US-09-636-295-12
; Sequence 12, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:

```
;
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-636-295-12

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 85
US-09-636-295-13
; Sequence 13, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
```

```
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-636-295-13

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 86
US-09-636-295-14
; Sequence 14, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
```

APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-636-295-14

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 87

US-09-636-295-15
Sequence 15, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996

APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/9
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-636-295-15

Query Match 100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 88

US-09-636-295-16
Sequence 16, Application US/09636295
Patent No. 6773707
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/636,295
FILING DATE: 10-Aug-2000
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996

```
;
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
;   NAME: Delucia, Richard L.
;   REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (212) 425-7200
;   TELEFAX: (212) 425-5288
;   TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: amino acid
;   STRANDEDNESS: <Unknown>
;   TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
;   ORGANISM: <Unknown>
; FEATURE:
;   OTHER INFORMATION: hybrid peptide for human papilloma
;   virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-636-295-16
Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      13 HWDFAPWP 20
      |||||
      |||||

RESULT 89
US-09-636-295-17
; Sequence 17, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
;   ROTHMAN, James E.
;   HARTL, F. Ulrich
;   HOE, Mee H.
;   HOUGHTON, Alan
;   TAKECHI, Yoshizumi
;   MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;   Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Kenyon & Kenyon
;   STREET: One Broadway
;   CITY: New York
;   STATE: NY
;   COUNTRY: US
;   ZIP: 10004
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;   COMPUTER: IBM compatible
;   OPERATING SYSTEM: MS DOS
;   SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/636,295
;   FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 60/002,479
;   FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
;
```

```
;
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
;   NAME: Delucia, Richard L.
;   REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (212) 425-7200
;   TELEFAX: (212) 425-5288
;   TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: amino acid
;   STRANDEDNESS: <Unknown>
;   TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
;   ORGANISM: <Unknown>
; FEATURE:
;   OTHER INFORMATION: hybrid peptide for human papilloma
;   virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-636-295-17
Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8
      |||||
      |||||

RESULT 90
US-09-636-295-18
; Sequence 18, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
;   ROTHMAN, James E.
;   HARTL, F. Ulrich
;   HOE, Mee H.
;   HOUGHTON, Alan
;   TAKECHI, Yoshizumi
;   MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;   Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Kenyon & Kenyon
;   STREET: One Broadway
;   CITY: New York
;   STATE: NY
;   COUNTRY: US
;   ZIP: 10004
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;   COMPUTER: IBM compatible
;   OPERATING SYSTEM: MS DOS
;   SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/636,295
;   FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 60/002,479
;   FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
;
```



```

; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-636-295-18

```

```

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      13 HWDFAPWP 20

```

RESULT 91

```

US-09-636-295-19
; Sequence 19, Application US/09636295
; Patent No. 6773707
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/636,295
; FILING DATE: 10-Aug-2000
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995

```

```

; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/9
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-636-295-19

```

```

Query Match      100.0%; Score 64; DB 2; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.0028;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8

```

```

Search completed: March 24, 2006, 12:35:57
Job time : 46 secs

```

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 12:36:12 ; Search time 165 Seconds
(without alignments)
20.258 Million cell updates/sec

Title: US-10-053-520-143

Perfect score: 64

Sequence: 1 HWDFAWFW 8

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 438

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 100%

Maximum Match 100%

Listing first 1000 summaries

Database : Published Applications_AA_Main:

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep:*

3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep:*

4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep:*

5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep:*

6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	64	100.0	8	3	US-09-794-517-1
2	64	100.0	8	3	US-09-794-529-1
3	64	100.0	8	3	US-09-794-832-1
4	64	100.0	8	4	US-10-052-578-143
5	64	100.0	8	4	US-10-053-520-143
6	64	100.0	8	4	US-10-170-713A-1
7	64	100.0	8	4	US-10-171-734-1
8	64	100.0	8	4	US-10-053-498B-143
9	64	100.0	8	4	US-10-258-147-3
10	64	100.0	8	4	US-10-258-146A-1
11	64	100.0	8	4	US-10-328-953-3
12	64	100.0	8	4	US-10-367-580-1
13	64	100.0	8	4	US-10-367-593-1
14	64	100.0	8	4	US-10-367-594-1
15	64	100.0	8	4	US-10-367-654-1
16	64	100.0	8	4	US-10-367-658-1
17	64	100.0	8	4	US-10-367-668-1
18	64	100.0	8	4	US-10-258-144-36
19	64	100.0	8	4	US-10-367-674-1
20	64	100.0	8	5	US-10-776-521B-358
21	64	100.0	8	5	US-10-820-067A-267
22	64	100.0	8	5	US-10-820-067A-869
23	64	100.0	9	4	US-10-258-146A-175
24	64	100.0	9	4	US-10-258-146A-176
25	64	100.0	12	4	US-10-258-146A-171
26	64	100.0	12	4	US-10-258-146A-172
27	64	100.0	16	4	US-10-258-144-277

28	64	100.0	16	4	US-10-258-144-278	Sequence 278, App
29	64	100.0	17	4	US-10-258-144-208	Sequence 208, App
30	64	100.0	17	4	US-10-258-144-209	Sequence 209, App
31	64	100.0	17	4	US-10-258-144-217	Sequence 217, App
32	64	100.0	17	4	US-10-258-144-218	Sequence 218, App
33	64	100.0	17	4	US-10-258-144-227	Sequence 227, App
34	64	100.0	17	4	US-10-258-144-228	Sequence 228, App
35	64	100.0	17	4	US-10-258-144-237	Sequence 237, App
36	64	100.0	17	4	US-10-258-144-238	Sequence 238, App
37	64	100.0	17	4	US-10-258-144-247	Sequence 247, App
38	64	100.0	17	4	US-10-258-144-248	Sequence 248, App
39	64	100.0	17	4	US-10-258-144-257	Sequence 257, App
40	64	100.0	17	4	US-10-258-144-258	Sequence 258, App
41	64	100.0	17	4	US-10-258-144-287	Sequence 287, App
42	64	100.0	17	4	US-10-258-144-288	Sequence 288, App
43	64	100.0	17	4	US-10-258-144-297	Sequence 297, App
44	64	100.0	17	4	US-10-258-144-298	Sequence 298, App
45	64	100.0	17	4	US-10-258-144-317	Sequence 317, App
46	64	100.0	17	4	US-10-258-144-318	Sequence 318, App
47	64	100.0	17	4	US-10-258-144-327	Sequence 327, App
48	64	100.0	17	4	US-10-258-144-328	Sequence 328, App
49	64	100.0	17	4	US-10-258-144-387	Sequence 387, App
50	64	100.0	17	4	US-10-258-144-388	Sequence 388, App
51	64	100.0	17	4	US-10-258-144-417	Sequence 417, App
52	64	100.0	17	4	US-10-258-144-418	Sequence 418, App
53	64	100.0	17	4	US-10-258-144-427	Sequence 427, App
54	64	100.0	17	4	US-10-258-144-428	Sequence 428, App
55	64	100.0	17	4	US-10-258-144-437	Sequence 437, App
56	64	100.0	17	4	US-10-258-144-438	Sequence 438, App
57	64	100.0	17	4	US-10-258-144-467	Sequence 467, App
58	64	100.0	17	4	US-10-258-144-468	Sequence 468, App
59	64	100.0	17	4	US-10-258-144-497	Sequence 497, App
60	64	100.0	17	4	US-10-258-144-498	Sequence 498, App
61	64	100.0	18	4	US-10-258-144-267	Sequence 267, App
62	64	100.0	18	4	US-10-258-144-268	Sequence 268, App
63	64	100.0	18	4	US-10-258-144-307	Sequence 307, App
64	64	100.0	18	4	US-10-258-144-308	Sequence 308, App
65	64	100.0	18	4	US-10-258-144-337	Sequence 337, App
66	64	100.0	18	4	US-10-258-144-338	Sequence 338, App
67	64	100.0	18	4	US-10-258-144-347	Sequence 347, App
68	64	100.0	18	4	US-10-258-144-348	Sequence 348, App
69	64	100.0	18	4	US-10-258-144-357	Sequence 357, App
70	64	100.0	18	4	US-10-258-144-358	Sequence 358, App
71	64	100.0	18	4	US-10-258-144-367	Sequence 367, App
72	64	100.0	18	4	US-10-258-144-368	Sequence 368, App
73	64	100.0	18	4	US-10-258-144-377	Sequence 377, App
74	64	100.0	18	4	US-10-258-144-378	Sequence 378, App
75	64	100.0	18	4	US-10-258-144-397	Sequence 397, App
76	64	100.0	18	4	US-10-258-144-398	Sequence 398, App
77	64	100.0	18	4	US-10-258-144-407	Sequence 407, App
78	64	100.0	18	4	US-10-258-144-408	Sequence 408, App
79	64	100.0	18	4	US-10-258-144-447	Sequence 447, App
80	64	100.0	18	4	US-10-258-144-448	Sequence 448, App
81	64	100.0	18	4	US-10-258-144-457	Sequence 457, App
82	64	100.0	18	4	US-10-258-144-458	Sequence 458, App
83	64	100.0	18	4	US-10-258-144-477	Sequence 477, App
84	64	100.0	18	4	US-10-258-144-478	Sequence 478, App
85	64	100.0	18	4	US-10-258-144-487	Sequence 487, App
86	64	100.0	18	4	US-10-258-144-488	Sequence 488, App
87	64	100.0	19	3	US-09-794-517-8	Sequence 8, Appli
88	64	100.0	19	3	US-09-794-517-9	Sequence 9, Appli
89	64	100.0	19	3	US-09-794-529-9	Sequence 9, Appli
90	64	100.0	19	3	US-09-794-529-9	Sequence 9, Appli
91	64	100.0	19	3	US-09-794-832-8	Sequence 8, Appli
92	64	100.0	19	3	US-09-794-832-9	Sequence 9, Appli
93	64	100.0	19	4	US-10-052-578-321	Sequence 321, App
94	64	100.0	19	4	US-10-053-520-321	Sequence 321, App
95	64	100.0	19	4	US-10-170-713A-8	Sequence 8, Appli
96	64	100.0	19	4	US-10-170-713A-9	Sequence 9, Appli
97	64	100.0	19	4	US-10-171-734-8	Sequence 8, Appli
98	64	100.0	19	4	US-10-171-734-9	Sequence 9, Appli
99	64	100.0	19	4	US-10-053-498B-321	Sequence 321, App
100	64	100.0	19	4	US-10-258-147-16	Sequence 16, Appli

101	64	100.0	19	4	US-10-258-147-17
102	64	100.0	19	4	US-10-258-147-22
103	64	100.0	19	4	US-10-258-147-23
104	64	100.0	19	4	US-10-367-580-8
105	64	100.0	19	4	US-10-367-580-9
106	64	100.0	19	4	US-10-367-593-8
107	64	100.0	19	4	US-10-367-593-9
108	64	100.0	19	4	US-10-367-594-8
109	64	100.0	19	4	US-10-367-594-9
110	64	100.0	19	4	US-10-367-654-8
111	64	100.0	19	4	US-10-367-654-9
112	64	100.0	19	4	US-10-367-658-8
113	64	100.0	19	4	US-10-367-658-9
114	64	100.0	19	4	US-10-367-668-8
115	64	100.0	19	4	US-10-367-668-9
116	64	100.0	19	4	US-10-258-144-274
117	64	100.0	19	4	US-10-258-144-275
118	64	100.0	19	4	US-10-367-674-8
119	64	100.0	19	4	US-10-367-674-9
120	64	100.0	19	5	US-10-776-521B-368
121	64	100.0	19	5	US-10-776-521B-376
122	64	100.0	19	5	US-10-776-521B-379
123	64	100.0	20	3	US-09-794-517-10
124	64	100.0	20	3	US-09-794-517-11
125	64	100.0	20	3	US-09-794-517-12
126	64	100.0	20	3	US-09-794-517-13
127	64	100.0	20	3	US-09-794-517-14
128	64	100.0	20	3	US-09-794-517-15
129	64	100.0	20	3	US-09-794-517-16
130	64	100.0	20	3	US-09-794-517-17
131	64	100.0	20	3	US-09-794-517-18
132	64	100.0	20	3	US-09-794-517-19
133	64	100.0	20	3	US-09-794-529-10
134	64	100.0	20	3	US-09-794-529-11
135	64	100.0	20	3	US-09-794-529-12
136	64	100.0	20	3	US-09-794-529-13
137	64	100.0	20	3	US-09-794-529-14
138	64	100.0	20	3	US-09-794-529-15
139	64	100.0	20	3	US-09-794-529-16
140	64	100.0	20	3	US-09-794-529-17
141	64	100.0	20	3	US-09-794-529-18
142	64	100.0	20	3	US-09-794-529-19
143	64	100.0	20	3	US-09-794-832-10
144	64	100.0	20	3	US-09-794-832-11
145	64	100.0	20	3	US-09-794-832-12
146	64	100.0	20	3	US-09-794-832-13
147	64	100.0	20	3	US-09-794-832-14
148	64	100.0	20	3	US-09-794-832-15
149	64	100.0	20	3	US-09-794-832-16
150	64	100.0	20	3	US-09-794-832-17
151	64	100.0	20	3	US-09-794-832-18
152	64	100.0	20	3	US-09-794-832-19
153	64	100.0	20	4	US-10-170-713A-10
154	64	100.0	20	4	US-10-170-713A-11
155	64	100.0	20	4	US-10-170-713A-12
156	64	100.0	20	4	US-10-170-713A-13
157	64	100.0	20	4	US-10-170-713A-14
158	64	100.0	20	4	US-10-170-713A-15
159	64	100.0	20	4	US-10-170-713A-16
160	64	100.0	20	4	US-10-170-713A-17
161	64	100.0	20	4	US-10-170-713A-18
162	64	100.0	20	4	US-10-170-713A-19
163	64	100.0	20	4	US-10-171-734-10
164	64	100.0	20	4	US-10-171-734-11
165	64	100.0	20	4	US-10-171-734-12
166	64	100.0	20	4	US-10-171-734-13
167	64	100.0	20	4	US-10-171-734-14
168	64	100.0	20	4	US-10-171-734-15
169	64	100.0	20	4	US-10-171-734-16
170	64	100.0	20	4	US-10-171-734-17
171	64	100.0	20	4	US-10-171-734-18
172	64	100.0	20	4	US-10-171-734-19
173	64	100.0	20	4	US-10-258-147-25

Sequence 17, Appl	174	64	100.0	20	4	US-10-258-147-26
Sequence 22, Appl	175	64	100.0	20	4	US-10-367-580-10
Sequence 23, Appl	176	64	100.0	20	4	US-10-367-580-11
Sequence 8, Appl	177	64	100.0	20	4	US-10-367-580-12
Sequence 8, Appl	178	64	100.0	20	4	US-10-367-580-13
Sequence 8, Appl	179	64	100.0	20	4	US-10-367-580-14
Sequence 9, Appl	180	64	100.0	20	4	US-10-367-580-15
Sequence 8, Appl	181	64	100.0	20	4	US-10-367-580-16
Sequence 9, Appl	182	64	100.0	20	4	US-10-367-580-17
Sequence 8, Appl	183	64	100.0	20	4	US-10-367-580-18
Sequence 8, Appl	184	64	100.0	20	4	US-10-367-580-19
Sequence 8, Appl	185	64	100.0	20	4	US-10-367-593-10
Sequence 8, Appl	186	64	100.0	20	4	US-10-367-593-11
Sequence 8, Appl	187	64	100.0	20	4	US-10-367-593-12
Sequence 9, Appl	188	64	100.0	20	4	US-10-367-593-13
Sequence 9, Appl	189	64	100.0	20	4	US-10-367-593-14
Sequence 274, App	190	64	100.0	20	4	US-10-367-594-10
Sequence 275, App	191	64	100.0	20	4	US-10-367-594-11
Sequence 8, Appl	192	64	100.0	20	4	US-10-367-594-12
Sequence 9, Appl	193	64	100.0	20	4	US-10-367-594-13
Sequence 368, App	194	64	100.0	20	4	US-10-367-594-14
Sequence 376, App	195	64	100.0	20	4	US-10-367-594-15
Sequence 379, App	196	64	100.0	20	4	US-10-367-594-16
Sequence 10, Appl	197	64	100.0	20	4	US-10-367-594-17
Sequence 11, Appl	198	64	100.0	20	4	US-10-367-594-18
Sequence 12, Appl	199	64	100.0	20	4	US-10-367-594-19
Sequence 14, Appl	200	64	100.0	20	4	US-10-367-654-10
Sequence 15, Appl	201	64	100.0	20	4	US-10-367-654-11
Sequence 16, Appl	202	64	100.0	20	4	US-10-367-654-12
Sequence 17, Appl	203	64	100.0	20	4	US-10-367-654-13
Sequence 18, Appl	204	64	100.0	20	4	US-10-367-654-14
Sequence 19, Appl	205	64	100.0	20	4	US-10-367-654-15
Sequence 10, Appl	206	64	100.0	20	4	US-10-367-654-16
Sequence 11, Appl	207	64	100.0	20	4	US-10-367-654-17
Sequence 12, Appl	208	64	100.0	20	4	US-10-367-654-18
Sequence 13, Appl	209	64	100.0	20	4	US-10-367-654-19
Sequence 14, Appl	210	64	100.0	20	4	US-10-367-654-20
Sequence 15, Appl	211	64	100.0	20	4	US-10-367-654-21
Sequence 16, Appl	212	64	100.0	20	4	US-10-367-654-22
Sequence 17, Appl	213	64	100.0	20	4	US-10-367-654-23
Sequence 18, Appl	214	64	100.0	20	4	US-10-367-654-24
Sequence 19, Appl	215	64	100.0	20	4	US-10-367-654-25
Sequence 10, Appl	216	64	100.0	20	4	US-10-367-658-10
Sequence 11, Appl	217	64	100.0	20	4	US-10-367-658-11
Sequence 12, Appl	218	64	100.0	20	4	US-10-367-658-12
Sequence 13, Appl	219	64	100.0	20	4	US-10-367-658-13
Sequence 14, Appl	220	64	100.0	20	4	US-10-367-658-14
Sequence 15, Appl	221	64	100.0	20	4	US-10-367-658-15
Sequence 16, Appl	222	64	100.0	20	4	US-10-367-658-16
Sequence 17, Appl	223	64	100.0	20	4	US-10-367-658-17
Sequence 18, Appl	224	64	100.0	20	4	US-10-367-658-18
Sequence 19, Appl	225	64	100.0	20	4	US-10-367-658-19
Sequence 10, Appl	226	64	100.0	20	4	US-10-367-668-10
Sequence 11, Appl	227	64	100.0	20	4	US-10-367-668-11
Sequence 12, Appl	228	64	100.0	20	4	US-10-367-668-12
Sequence 13, Appl	229	64	100.0	20	4	US-10-367-668-13
Sequence 14, Appl	230	64	100.0	20	4	US-10-367-668-14
Sequence 15, Appl	231	64	100.0	20	4	US-10-367-668-15
Sequence 16, Appl	232	64	100.0	20	4	US-10-367-668-16
Sequence 17, Appl	233	64	100.0	20	4	US-10-367-668-17
Sequence 18, Appl	234	64	100.0	20	4	US-10-367-668-18
Sequence 19, Appl	235	64	100.0	20	4	US-10-367-668-19
Sequence 10, Appl	236	64	100.0	20	4	US-10-258-144-212
Sequence 11, Appl	237	64	100.0	20	4	US-10-258-144-214
Sequence 12, Appl	238	64	100.0	20	4	US-10-258-144-215
Sequence 13, Appl	239	64	100.0	20	4	US-10-258-144-224
Sequence 14, Appl	240	64	100.0	20	4	US-10-258-144-225
Sequence 15, Appl	241	64	100.0	20	4	US-10-258-144-234
Sequence 16, Appl	242	64	100.0	20	4	US-10-258-144-235
Sequence 17, Appl	243	64	100.0	20	4	US-10-258-144-244
Sequence 18, Appl	244	64	100.0	20	4	US-10-258-144-245
Sequence 19, Appl	245	64	100.0	20	4	US-10-258-144-255
Sequence 25, Appl	246	64	100.0	20	4	US-10-258-144-284

Sequence 26, Appl	Sequence 10, Appl
Sequence 11, Appl	Sequence 11, Appl
Sequence 12, Appl	Sequence 12, Appl
Sequence 13, Appl	Sequence 13, Appl
Sequence 14, Appl	Sequence 14, Appl
Sequence 15, Appl	Sequence 15, Appl
Sequence 16, Appl	Sequence 16, Appl
Sequence 17, Appl	Sequence 17, Appl
Sequence 18, Appl	Sequence 18, Appl
Sequence 19, Appl	Sequence 19, Appl
Sequence 20, Appl	Sequence 20, Appl
Sequence 21, Appl	Sequence 21, Appl
Sequence 22, Appl	Sequence 22, Appl
Sequence 23, Appl	Sequence 23, Appl
Sequence 24, Appl	Sequence 24, Appl
Sequence 25, Appl	Sequence 25, Appl
Sequence 284, App	

247	64	100.0	20	4	US-10-258-144-285	Sequence 285, App	320	64	100.0	25	4	US-10-258-144-359	Sequence 259, App
248	64	100.0	20	4	US-10-258-144-294	Sequence 294, App	321	64	100.0	25	4	US-10-258-144-263	Sequence 263, App
249	64	100.0	20	4	US-10-258-144-295	Sequence 295, App	322	64	100.0	25	4	US-10-258-144-289	Sequence 289, App
250	64	100.0	20	4	US-10-258-144-314	Sequence 314, App	323	64	100.0	25	4	US-10-258-144-293	Sequence 293, App
251	64	100.0	20	4	US-10-258-144-315	Sequence 315, App	324	64	100.0	25	4	US-10-258-144-299	Sequence 299, App
252	64	100.0	20	4	US-10-258-144-324	Sequence 324, App	325	64	100.0	25	4	US-10-258-144-303	Sequence 303, App
253	64	100.0	20	4	US-10-258-144-325	Sequence 325, App	326	64	100.0	25	4	US-10-258-144-319	Sequence 319, App
254	64	100.0	20	4	US-10-258-144-384	Sequence 384, App	327	64	100.0	25	4	US-10-258-144-323	Sequence 323, App
255	64	100.0	20	4	US-10-258-144-395	Sequence 385, App	328	64	100.0	25	4	US-10-258-144-329	Sequence 329, App
256	64	100.0	20	4	US-10-258-144-414	Sequence 414, App	329	64	100.0	25	4	US-10-258-144-333	Sequence 333, App
257	64	100.0	20	4	US-10-258-144-415	Sequence 415, App	330	64	100.0	25	4	US-10-258-144-389	Sequence 389, App
258	64	100.0	20	4	US-10-258-144-424	Sequence 424, App	331	64	100.0	25	4	US-10-258-144-393	Sequence 393, App
259	64	100.0	20	4	US-10-258-144-425	Sequence 425, App	332	64	100.0	25	4	US-10-258-144-419	Sequence 419, App
260	64	100.0	20	4	US-10-258-144-434	Sequence 434, App	333	64	100.0	25	4	US-10-258-144-423	Sequence 423, App
261	64	100.0	20	4	US-10-258-144-435	Sequence 435, App	334	64	100.0	25	4	US-10-258-144-429	Sequence 429, App
262	64	100.0	20	4	US-10-258-144-464	Sequence 464, App	335	64	100.0	25	4	US-10-258-144-433	Sequence 433, App
263	64	100.0	20	4	US-10-258-144-465	Sequence 465, App	336	64	100.0	25	4	US-10-258-144-439	Sequence 439, App
264	64	100.0	20	4	US-10-258-144-494	Sequence 494, App	337	64	100.0	25	4	US-10-258-144-443	Sequence 443, App
265	64	100.0	20	4	US-10-258-144-495	Sequence 495, App	338	64	100.0	25	4	US-10-258-144-469	Sequence 469, App
266	64	100.0	20	4	US-10-367-674-10	Sequence 10, App	339	64	100.0	25	4	US-10-258-144-473	Sequence 473, App
267	64	100.0	20	4	US-10-367-674-11	Sequence 11, App	340	64	100.0	25	4	US-10-258-144-499	Sequence 499, App
268	64	100.0	20	4	US-10-367-674-12	Sequence 12, App	341	64	100.0	26	4	US-10-258-144-269	Sequence 269, App
269	64	100.0	20	4	US-10-367-674-13	Sequence 13, App	342	64	100.0	26	4	US-10-258-144-273	Sequence 273, App
270	64	100.0	20	4	US-10-367-674-14	Sequence 14, App	343	64	100.0	26	4	US-10-258-144-309	Sequence 309, App
271	64	100.0	20	4	US-10-367-674-15	Sequence 15, App	344	64	100.0	26	4	US-10-258-144-313	Sequence 313, App
272	64	100.0	20	4	US-10-367-674-16	Sequence 16, App	345	64	100.0	26	4	US-10-258-144-339	Sequence 339, App
273	64	100.0	20	4	US-10-367-674-17	Sequence 17, App	346	64	100.0	26	4	US-10-258-144-343	Sequence 343, App
274	64	100.0	20	4	US-10-367-674-18	Sequence 18, App	347	64	100.0	26	4	US-10-258-144-349	Sequence 349, App
275	64	100.0	20	4	US-10-367-674-19	Sequence 19, App	348	64	100.0	26	4	US-10-258-144-353	Sequence 353, App
276	64	100.0	20	5	US-10-776-521B-369	Sequence 369, App	349	64	100.0	26	4	US-10-258-144-359	Sequence 359, App
277	64	100.0	20	5	US-10-776-521B-371	Sequence 371, App	350	64	100.0	26	4	US-10-258-144-363	Sequence 363, App
278	64	100.0	20	5	US-10-776-521B-373	Sequence 373, App	351	64	100.0	26	4	US-10-258-144-369	Sequence 369, App
279	64	100.0	20	5	US-10-776-521B-374	Sequence 374, App	352	64	100.0	26	4	US-10-258-144-373	Sequence 373, App
280	64	100.0	20	5	US-10-820-067A-878	Sequence 878, App	353	64	100.0	26	4	US-10-258-144-379	Sequence 379, App
281	64	100.0	21	4	US-10-258-144-264	Sequence 264, App	354	64	100.0	26	4	US-10-258-144-383	Sequence 383, App
282	64	100.0	21	4	US-10-258-144-265	Sequence 265, App	355	64	100.0	26	4	US-10-258-144-399	Sequence 399, App
283	64	100.0	21	4	US-10-258-144-304	Sequence 304, App	356	64	100.0	26	4	US-10-258-144-403	Sequence 403, App
284	64	100.0	21	4	US-10-258-144-305	Sequence 305, App	357	64	100.0	26	4	US-10-258-144-409	Sequence 409, App
285	64	100.0	21	4	US-10-258-144-334	Sequence 334, App	358	64	100.0	26	4	US-10-258-144-413	Sequence 413, App
286	64	100.0	21	4	US-10-258-144-335	Sequence 335, App	359	64	100.0	26	4	US-10-258-144-449	Sequence 449, App
287	64	100.0	21	4	US-10-258-144-344	Sequence 344, App	360	64	100.0	26	4	US-10-258-144-453	Sequence 453, App
288	64	100.0	21	4	US-10-258-144-345	Sequence 345, App	361	64	100.0	26	4	US-10-258-144-459	Sequence 459, App
289	64	100.0	21	4	US-10-258-144-354	Sequence 354, App	362	64	100.0	26	4	US-10-258-144-479	Sequence 479, App
290	64	100.0	21	4	US-10-258-144-355	Sequence 355, App	363	64	100.0	26	4	US-10-258-144-483	Sequence 483, App
291	64	100.0	21	4	US-10-258-144-364	Sequence 364, App	364	64	100.0	26	4	US-10-258-144-489	Sequence 489, App
292	64	100.0	21	4	US-10-258-144-365	Sequence 365, App	365	64	100.0	26	4	US-10-258-144-493	Sequence 493, App
293	64	100.0	21	4	US-10-258-144-374	Sequence 374, App	366	64	100.0	27	4	US-10-258-147-19	Sequence 19, App
294	64	100.0	21	4	US-10-258-144-375	Sequence 375, App	367	64	100.0	27	4	US-10-258-147-20	Sequence 20, App
295	64	100.0	21	4	US-10-258-144-394	Sequence 394, App	368	64	100.0	27	4	US-10-258-144-463	Sequence 463, App
296	64	100.0	21	4	US-10-258-144-395	Sequence 395, App	369	64	100.0	30	4	US-10-258-147-18	Sequence 18, App
297	64	100.0	21	4	US-10-258-144-404	Sequence 404, App	370	64	100.0	30	4	US-10-258-147-24	Sequence 24, App
298	64	100.0	21	4	US-10-258-144-405	Sequence 405, App	371	64	100.0	30	4	US-10-258-144-276	Sequence 276, App
299	64	100.0	21	4	US-10-258-144-444	Sequence 444, App	372	64	100.0	30	4	US-10-258-144-281	Sequence 281, App
300	64	100.0	21	4	US-10-258-144-445	Sequence 445, App	373	64	100.0	31	4	US-10-258-147-27	Sequence 27, App
301	64	100.0	21	4	US-10-258-144-454	Sequence 454, App	374	64	100.0	31	4	US-10-258-144-213	Sequence 213, App
302	64	100.0	21	4	US-10-258-144-455	Sequence 455, App	375	64	100.0	31	4	US-10-258-144-216	Sequence 216, App
303	64	100.0	21	4	US-10-258-144-474	Sequence 474, App	376	64	100.0	31	4	US-10-258-144-221	Sequence 221, App
304	64	100.0	21	4	US-10-258-144-475	Sequence 475, App	377	64	100.0	31	4	US-10-258-144-226	Sequence 226, App
305	64	100.0	21	4	US-10-258-144-484	Sequence 484, App	378	64	100.0	31	4	US-10-258-144-231	Sequence 231, App
306	64	100.0	21	4	US-10-258-144-485	Sequence 485, App	379	64	100.0	31	4	US-10-258-144-236	Sequence 236, App
307	64	100.0	21	4	US-10-258-144-485	Sequence 485, App	380	64	100.0	31	4	US-10-258-144-241	Sequence 241, App
308	64	100.0	24	4	US-10-776-521B-378	Sequence 378, App	381	64	100.0	31	4	US-10-258-144-246	Sequence 246, App
309	64	100.0	24	4	US-10-258-144-279	Sequence 279, App	382	64	100.0	31	4	US-10-258-144-251	Sequence 251, App
310	64	100.0	25	4	US-10-258-144-280	Sequence 280, App	383	64	100.0	31	4	US-10-258-144-256	Sequence 256, App
311	64	100.0	25	4	US-10-258-144-211	Sequence 211, App	384	64	100.0	31	4	US-10-258-144-261	Sequence 261, App
312	64	100.0	25	4	US-10-258-144-219	Sequence 219, App	385	64	100.0	31	4	US-10-258-144-286	Sequence 286, App
313	64	100.0	25	4	US-10-258-144-223	Sequence 223, App	386	64	100.0	31	4	US-10-258-144-291	Sequence 291, App
314	64	100.0	25	4	US-10-258-144-229	Sequence 229, App	387	64	100.0	31	4	US-10-258-144-296	Sequence 296, App
315	64	100.0	25	4	US-10-258-144-233	Sequence 233, App	388	64	100.0	31	4	US-10-258-144-301	Sequence 301, App
316	64	100.0	25	4	US-10-258-144-239	Sequence 239, App	389	64	100.0	31	4	US-10-258-144-316	Sequence 316, App
317	64	100.0	25	4	US-10-258-144-243	Sequence 243, App	390	64	100.0	31	4	US-10-258-144-321	Sequence 321, App
318	64	100.0	25	4	US-10-258-144-249	Sequence 249, App	391	64	100.0	31	4	US-10-258-144-326	Sequence 326, App
319	64	100.0	25	4	US-10-258-144-253	Sequence 253, App	392	64	100.0	31	4	US-10-258-144-331	Sequence 331, App

```
393 64 100.0 31 4 US-10-258-144-386 Sequence 386, App
394 64 100.0 31 4 US-10-258-144-391 Sequence 391, App
395 64 100.0 31 4 US-10-258-144-416 Sequence 416, App
396 64 100.0 31 4 US-10-258-144-421 Sequence 421, App
397 64 100.0 31 4 US-10-258-144-426 Sequence 426, App
398 64 100.0 31 4 US-10-258-144-431 Sequence 431, App
399 64 100.0 31 4 US-10-258-144-436 Sequence 436, App
400 64 100.0 31 4 US-10-258-144-441 Sequence 441, App
401 64 100.0 31 4 US-10-258-144-466 Sequence 466, App
402 64 100.0 31 4 US-10-258-144-471 Sequence 471, App
403 64 100.0 31 4 US-10-258-144-496 Sequence 496, App
404 64 100.0 31 4 US-10-258-144-501 Sequence 501, App
405 64 100.0 31 5 US-10-258-144-501 Sequence 519, App
406 64 100.0 32 4 US-10-258-144-266 Sequence 266, App
407 64 100.0 32 4 US-10-258-144-271 Sequence 271, App
408 64 100.0 32 4 US-10-258-144-306 Sequence 306, App
409 64 100.0 32 4 US-10-258-144-311 Sequence 311, App
410 64 100.0 32 4 US-10-258-144-336 Sequence 336, App
411 64 100.0 32 4 US-10-258-144-341 Sequence 341, App
412 64 100.0 32 4 US-10-258-144-346 Sequence 346, App
413 64 100.0 32 4 US-10-258-144-351 Sequence 351, App
414 64 100.0 32 4 US-10-258-144-356 Sequence 356, App
415 64 100.0 32 4 US-10-258-144-361 Sequence 361, App
416 64 100.0 32 4 US-10-258-144-366 Sequence 366, App
417 64 100.0 32 4 US-10-258-144-371 Sequence 371, App
418 64 100.0 32 4 US-10-258-144-376 Sequence 376, App
419 64 100.0 32 4 US-10-258-144-381 Sequence 381, App
420 64 100.0 32 4 US-10-258-144-396 Sequence 396, App
421 64 100.0 32 4 US-10-258-144-401 Sequence 401, App
422 64 100.0 32 4 US-10-258-144-406 Sequence 406, App
423 64 100.0 32 4 US-10-258-144-411 Sequence 411, App
424 64 100.0 32 4 US-10-258-144-446 Sequence 446, App
425 64 100.0 32 4 US-10-258-144-451 Sequence 451, App
426 64 100.0 32 4 US-10-258-144-456 Sequence 456, App
427 64 100.0 32 4 US-10-258-144-461 Sequence 461, App
428 64 100.0 32 4 US-10-258-144-476 Sequence 476, App
429 64 100.0 32 4 US-10-258-144-481 Sequence 481, App
430 64 100.0 32 4 US-10-258-144-486 Sequence 486, App
431 64 100.0 32 4 US-10-258-144-491 Sequence 491, App
432 64 100.0 38 4 US-10-258-147-21 Sequence 21, Appl
433 64 100.0 100 4 US-10-258-147-28 Sequence 28, Appl
434 64 100.0 100 4 US-10-258-147-30 Sequence 30, Appl
435 64 100.0 103 4 US-10-258-147-29 Sequence 29, Appl
436 64 100.0 103 4 US-10-258-147-31 Sequence 31, Appl
437 64 100.0 108 4 US-10-258-147-32 Sequence 32, Appl
438 64 100.0 111 4 US-10-258-147-33 Sequence 33, Appl
```

ALIGNMENTS

```
RESULT 1
US-09-794-517-1
; Sequence 1, Application US/09794517
; Publication NO. US200300217941
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: mouse
; FEATURE:
; OTHER INFORMATION: heat shock binding sequence
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-517-1
Query Match 100.0%; Score 64; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. NO. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8
RESULT 2
US-09-794-529-1
; Sequence 1, Application US/09794529
; Publication NO. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
```

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-529-1

Query Match 100.0%; Score 64; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 3
US-09-794-832-1
Sequence 1, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
IMMUNOTHERAPIES
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 8
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: no
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: mouse
FEATURE:
OTHER INFORMATION: heat shock binding sequence
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-794-832-1

Query Match 100.0%; Score 64; DB 3; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 4
US-10-052-578-143
Sequence 143, Application US/10052578
Publication No. US20030134787A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
MAYHEW, Mark
HOE, Mee H.
HOUGHTON, Alan
HARTL, Ulrich
OUEFELLI, Ouathak
MOROI, Yoichi
TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
FILE REFERENCE: 11746/46003
CURRENT APPLICATION NUMBER: US/10/052,578
CURRENT FILING DATE: 2002-01-17
PRIOR APPLICATION NUMBER: 08/961,707
PRIOR FILING DATE: 1997-10-31
NUMBER OF SEQ ID NOS: 321
SOFTWARE: WordPerfect 8.0 for Windows
SEQ ID NO 143
LENGTH: 8
TYPE: PRT

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide in ml3 coliphage
US-10-052-578-143

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 5
US-10-053-520-143
; Sequence 143, Application US/10053520
; Publication No. US20030166530A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Hartl, Ulrich
; APPLICANT: Querfelli, Ouathek
; APPLICANT: Morol, Yoichi
; TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
; FILE REFERENCE: 11746/46004
; CURRENT APPLICATION NUMBER: US/10/053,520
; PRIOR FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 08/961,707
; PRIOR FILING DATE: 1997-10-31
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 143
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide in ml3 coliphage
US-10-053-520-143

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 6
US-10-170-713A-1
; Sequence 1, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: TAKECHI, Yoshizumi
; APPLICANT: MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide in ml3 coliphage
US-10-052-578-143

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 7
US-10-171-734-1
; Sequence 1, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: TAKECHI, Yoshizumi
; APPLICANT: MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US

```

```

; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: mouse
; FEATURE:
; OTHER INFORMATION: heat shock binding sequence
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-170-713A-1

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 7
US-10-171-734-1
; Sequence 1, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: TAKECHI, Yoshizumi
; APPLICANT: MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US

```



```

;
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: mouse
;
; FEATURE:
; OTHER INFORMATION: heat shock binding sequence
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
;
; US-10-171-734-1
;
; Query Match 100.0%; Score 64; DB 4; Length 8;
; Best Local Similarity 100.0%; Pred.No.1.7e+06;
; Matches 8; Conservative 0; Mismatches 0; Indels 0;
;
; QY 1 HWDFAWPW 8
; |||||
; DB 1 HWDFAWPW 8
;
; RESULT 8
; US-10-053-498B-143
; Sequence 143, Application US/10053498B
; Publication No. US20030194409A1
;
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Hartl, Ulrich
; APPLICANT: Querfelli, Ouathek
; APPLICANT: Morol, Yoichi
;
; TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
; FILE REFERENCE: 11746/46002
; CURRENT APPLICATION NUMBER: US/10/053,498B
; CURRENT FILING DATE: 2002-01-17
; PRIOR APPLICATION NUMBER: 08/961,707
; PRIOR FILING DATE: 1997-10-31

```

```
; ORGANISM: human
US-10-258-146A-1

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 11
US-10-328-953-3
; Sequence 3, Application US/10328953
; Publication No. US20040071656A1
; GENERAL INFORMATION:
; APPLICANT: Wieland, Felix
; TITLE OF INVENTION: Modulation of Heat-Shock-Protein-Based Immunotherapies
; FILE REFERENCE: 11390/46101
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/342,570
; PRIOR FILING DATE: 2001-12-26
; PRIOR APPLICATION NUMBER: US 60/343,884
; PRIOR FILING DATE: 2001-12-28
; PRIOR APPLICATION NUMBER: US 60/372,620
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: US 60/399,342
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/414,834
; PRIOR FILING DATE: 2002-09-28
; NUMBER OF SEQ ID NOS: 331
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 3
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-328-953-3

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 12
US-10-367-580-1
; Sequence 1, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 13
US-10-367-593-1
; Sequence 1, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-1

Query Match      100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
      |||||
Db      1 HWDFAPWP 8

RESULT 14
US-10-367-594-1
; Sequence 1, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
```

; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-1

Query Match 100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 15
US-10-367-654-1
; Sequence 1, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-1

Query Match 100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 16
US-10-367-658-1
; Sequence 1, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 1
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-1

Query Match 100.0%; Score 64; DB 4; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 17
US-10-367-668-1
; Sequence 1, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363

; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 1
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-668-1

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 Db 1 HWDFAPWP 8

RESULT 18

US-10-258-144-36
 ; Sequence 36, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awqati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 36
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: ml3 coliphage insert
 US-10-258-144-36

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 Db 1 HWDFAPWP 8

RESULT 19

US-10-367-674-1
 ; Sequence 1, Application US/10367674
 ; Publication No. US20040127684A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/4610211
 ; CURRENT APPLICATION NUMBER: US/10/367,674
 ; CURRENT FILING DATE: 2003-02-14

; PRIOR APPLICATION NUMBER: US 10/170,738
 ; PRIOR FILING DATE: 2002-06-13
 ; PRIOR APPLICATION NUMBER: US 09/552,868
 ; PRIOR FILING DATE: 2000-04-20
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 1
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-674-1

Query Match 100.0%; Score 64; DB 4; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 Db 1 HWDFAPWP 8

RESULT 20

US-10-776-521B-358
 ; Sequence 358, Application US/10776521B
 ; Publication No. US20050202033A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Fletcher, Jessica
 ; APPLICANT: Prince-Cohane, Kenya
 ; APPLICANT: Mehta, Sunil
 ; APPLICANT: Slusarewicz, Paul
 ; APPLICANT: Andjelic, Sofija
 ; APPLICANT: Barber, Brian
 ; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
 ; FILE REFERENCE: 8449-405-399
 ; CURRENT APPLICATION NUMBER: US/10/776,521B
 ; CURRENT FILING DATE: 2004-02-12
 ; PRIOR APPLICATION NUMBER: 60/503,417
 ; PRIOR FILING DATE: 2003-09-16
 ; PRIOR APPLICATION NUMBER: 60/463,746
 ; PRIOR FILING DATE: 2003-04-18
 ; PRIOR APPLICATION NUMBER: 60/462,469
 ; PRIOR FILING DATE: 2003-04-11
 ; PRIOR APPLICATION NUMBER: 60/447,142
 ; PRIOR FILING DATE: 2003-02-13
 ; NUMBER OF SEQ ID NOS: 419
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 358
 ; LENGTH: 8
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Heat shock protein binding domain
 US-10-776-521B-358

Query Match 100.0%; Score 64; DB 5; Length 8;
 Best Local Similarity 100.0%; Pred. No. 1.7e+06;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAPWP 8
 Db 1 HWDFAPWP 8

RESULT 21
US-10-820-067A-267
; Sequence 267, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 267
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: pentapeptide binding motif
US-10-820-067A-267

Query Match 100.0%; Score 64; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 22
US-10-820-067A-869
; Sequence 869, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 869
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heat shock-protein binding motif to form hybrid antigen
US-10-820-067A-869

Query Match 100.0%; Score 64; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 23
US-10-258-146A-175
; Sequence 175, Application US/10258146A
; Publication No. US20040052812A1
; GENERAL INFORMATION:
; APPLICANT: Mee Hoe
; APPLICANT: Frank Landsberger
; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL
; TITLE OF INVENTION: VACCINES
; FILE REFERENCE: 11390/46301
; CURRENT APPLICATION NUMBER: US/10/258,146A
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: PCT/US01/12568
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 175
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: obtained from a phage synthetic peptide library
US-10-258-146A-175

Query Match 100.0%; Score 64; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 2 HWDFAWPW 9

RESULT 24
US-10-258-146A-176
; Sequence 176, Application US/10258146A
; Publication No. US20040052812A1
; GENERAL INFORMATION:
; APPLICANT: Mee Hoe
; APPLICANT: Frank Landsberger
; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL
; TITLE OF INVENTION: VACCINES
; FILE REFERENCE: 11390/46301
; CURRENT APPLICATION NUMBER: US/10/258,146A
; CURRENT FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: PCT/US01/12568
; PRIOR FILING DATE: 2001-04-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 180
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 176
; LENGTH: 9
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: obtained from a phage synthetic peptide library
US-10-258-146A-176

Query Match 100.0%; Score 64; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 25

US-10-258-146A-171

; Sequence 171, Application US/10258146A

; Publication No. US20040052812A1

; GENERAL INFORMATION:

; APPLICANT: Mee Hoe

; APPLICANT: Frank Landsberger

; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL

; FILE REFERENCE: 11390/46301

; CURRENT APPLICATION NUMBER: US/10/258,146A

; CURRENT FILING DATE: 2003-09-05

; PRIOR APPLICATION NUMBER: PCT/US01/12568

; PRIOR FILING DATE: 2001-04-17

; PRIOR APPLICATION NUMBER: 60/197,462

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 171

; LENGTH: 12

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: obtained from a phage synthetic peptide library

US-10-258-146A-171

Query Match 100.0%; Score 64; DB 4; Length 12;

Best Local Similarity 100.0%; Pred. No. 0.047;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 5 HWDFAWPW 12

RESULT 26

US-10-258-146A-172

; Sequence 172, Application US/10258146A

; Publication No. US20040052812A1

; GENERAL INFORMATION:

; APPLICANT: Mee Hoe

; APPLICANT: Frank Landsberger

; TITLE OF INVENTION: HEAT SHOCK PROTEIN-BASED ANTIVIRAL

; FILE REFERENCE: 11390/46301

; CURRENT APPLICATION NUMBER: US/10/258,146A

; CURRENT FILING DATE: 2003-09-05

; PRIOR APPLICATION NUMBER: PCT/US01/12568

; PRIOR FILING DATE: 2001-04-17

; PRIOR APPLICATION NUMBER: 60/197,462

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 172

; LENGTH: 12

; TYPE: PRT

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: obtained from a phage synthetic peptide library

US-10-258-146A-172

Query Match 100.0%; Score 64; DB 4; Length 12;

Best Local Similarity 100.0%; Pred. No. 0.047;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8

RESULT 27

US-10-258-144-277

; Sequence 277, Application US/10258144

; Publication No. US20040101532A1

; GENERAL INFORMATION:

; APPLICANT: Houghton, Alan

; APPLICANT: Livingston, Phil

; APPLICANT: Al-Awqati, Qais

; APPLICANT: Mayhew, Mark

; APPLICANT: Hoe, Mee

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

; FILE REFERENCE: 11746/46401

; CURRENT APPLICATION NUMBER: US/10/258,144

; CURRENT FILING DATE: 2002-10-17

; PRIOR APPLICATION NUMBER: 60/197,642

; PRIOR FILING DATE: 2000-04-17

; NUMBER OF SEQ ID NOS: 502

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 277

; LENGTH: 16

; TYPE: PRT

; ORGANISM: Homo sapiens derivative

US-10-258-144-277

Query Match 100.0%; Score 64; DB 4; Length 16;

Best Local Similarity 100.0%; Pred. No. 0.059;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 28

US-10-258-144-278

; Sequence 278, Application US/10258144

; Publication No. US20040101532A1

; GENERAL INFORMATION:

; APPLICANT: Houghton, Alan

; APPLICANT: Livingston, Phil

; APPLICANT: Al-Awqati, Qais

; APPLICANT: Mayhew, Mark

; APPLICANT: Hoe, Mee

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

; FILE REFERENCE: 11746/46401

; CURRENT APPLICATION NUMBER: US/10/258,144

; CURRENT FILING DATE: 2002-10-17

; PRIOR APPLICATION NUMBER: 60/197,642

; PRIOR FILING DATE: 2000-04-17

; NUMBER OF SEQ ID NOS: 502

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 278

; LENGTH: 16

; TYPE: PRT

; ORGANISM: Homo sapiens derivative

US-10-258-144-278

Query Match 100.0%; Score 64; DB 4; Length 16;

Best Local Similarity 100.0%; Pred. No. 0.059;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 9 HWDFAWPW 16

RESULT 29

US-10-258-144-208
; Sequence 208, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 208
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-208

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 30
US-10-258-144-209
; Sequence 209, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 209
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-209

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

RESULT 31
US-10-258-144-217
; Sequence 217, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan

; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 217
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-217

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 32
US-10-258-144-218
; Sequence 218, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 218
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-218

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

RESULT 33
US-10-258-144-227
; Sequence 227, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

```
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 227
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-227

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDPAWPW 8
DB 1 HWDPAWPW 8

RESULT 34
US-10-258-144-228
; Sequence 228, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 228
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-228

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDPAWPW 8
DB 10 HWDPAWPW 17

RESULT 35
US-10-258-144-237
; Sequence 237, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
```

```
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 237
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-237

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDPAWPW 8
DB 1 HWDPAWPW 8

RESULT 36
US-10-258-144-238
; Sequence 238, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 238
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-238

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDPAWPW 8
DB 10 HWDPAWPW 17

RESULT 37
US-10-258-144-247
; Sequence 247, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 247
; LENGTH: 17
```


; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-247

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 38

US-10-258-144-248
; Sequence 248, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 248
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-248

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 10 HWDFAWPW 17

RESULT 39

US-10-258-144-257
; Sequence 257, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 257
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-257

Query Match 100.0%; Score 64; DB 4; Length 17;

Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 40
US-10-258-144-258
; Sequence 258, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 258
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-258

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 10 HWDFAWPW 17

RESULT 41
US-10-258-144-287
; Sequence 287, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 287
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-287

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |

```
Db      1 HWDFAWPW 8

RESULT 42
US-10-258-144-288
; Sequence 288, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 288
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-288

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 43
US-10-258-144-297
; Sequence 297, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 297
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-297

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 44
US-10-258-144-298
```

```
; Sequence 298, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 298
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-298

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 45
US-10-258-144-317
; Sequence 317, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 317
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-317

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
Db      10 HWDFAWPW 17

RESULT 46
US-10-258-144-318
; Sequence 318, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
```

```

; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 318
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-318

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

```

```

RESULT 47
US-10-258-144-327
; Sequence 327, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 327
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-327

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

```

```

RESULT 48
US-10-258-144-328
; Sequence 328, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA

```

```

; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 328
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-328

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

```

```

RESULT 49
US-10-258-144-387
; Sequence 387, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 387
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-387

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

```

```

RESULT 50
US-10-258-144-388
; Sequence 388, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17

```

```
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 388
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-388

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDPAWPP 8
DB      10 HWDPAWPP 17

RESULT 51
US-10-258-144-417
; Sequence 417, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 417
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-417

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDPAWPP 8
DB      10 HWDPAWPP 17
```

```
; ORGANISM: Homo sapiens derivative
US-10-258-144-418

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDPAWPP 8
DB      10 HWDPAWPP 17

RESULT 53
US-10-258-144-427
; Sequence 427, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 427
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-427

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDPAWPP 8
DB      10 HWDPAWPP 8

RESULT 54
US-10-258-144-428
; Sequence 428, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 428
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-428

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDPAWPP 8
DB      10 HWDPAWPP 8
```

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

RESULT 55

US-10-258-144-437
; Sequence 437, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 437
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-437

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 56

US-10-258-144-438
; Sequence 438, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 438
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-438

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

RESULT 57

US-10-258-144-467
; Sequence 467, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 467
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-467

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 58

US-10-258-144-468
; Sequence 468, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 468
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-468

Query Match 100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 10 HWDFAWPW 17

RESULT 59

US-10-258-144-497
; Sequence 497, Application US/10258144

```

; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 497
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-497

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
    |||||
Db 1 HWDFAWPW 8

```

```

RESULT 60
US-10-258-144-498
; Sequence 498, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 498
; LENGTH: 17
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-498

```

```

Query Match      100.0%; Score 64; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 0.062;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
    |||||
Db 10 HWDFAWPW 17

```

```

RESULT 61
US-10-258-144-267
; Sequence 267, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais

```

```

; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 267
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-267

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
    |||||
Db 1 HWDFAWPW 8

```

```

RESULT 62
US-10-258-144-268
; Sequence 268, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 268
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-268

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
    |||||
Db 11 HWDFAWPW 18

```

```

RESULT 63
US-10-258-144-307
; Sequence 307, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401

```

```

; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 307
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-307

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 64
US-10-258-144-308
; Sequence 308, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 308
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-308

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      11 HWDFAWPW 18

```

```

RESULT 65
US-10-258-144-337
; Sequence 337, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502

```

```

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 337
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-337

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 66
US-10-258-144-338
; Sequence 338, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 338
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-338

```

```

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      11 HWDFAWPW 18

```

```

RESULT 67
US-10-258-144-347
; Sequence 347, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 347
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative

```

US-10-258-144-347

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 68

US-10-258-144-348
; Sequence 348, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 348
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-348

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 11 HWDFAWPW 18

RESULT 69

US-10-258-144-357
; Sequence 357, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 357
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-357

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 70
US-10-258-144-358
; Sequence 358, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 358
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-358

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 11 HWDFAWPW 18

RESULT 71
US-10-258-144-367
; Sequence 367, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 367
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-367

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 72
US-10-258-144-368
; Sequence 368, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 368
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-368

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 73
US-10-258-144-377
; Sequence 377, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 377
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-377

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 74
US-10-258-144-378
; Sequence 378, Application US/10258144
; Publication No. US20040101532A1

; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 378
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-378

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 75
US-10-258-144-397
; Sequence 397, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 397
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-397

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 76
US-10-258-144-398
; Sequence 398, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark

```
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 398
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-398

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      11 HWDFAPWP 18

RESULT 77
US-10-258-144-407
; Sequence 407, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 407
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-407

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      11 HWDFAPWP 18

RESULT 78
US-10-258-144-408
; Sequence 408, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
```

```
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 408
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-408

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      11 HWDFAPWP 18

RESULT 79
US-10-258-144-447
; Sequence 447, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 447
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-447

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      11 HWDFAPWP 18

RESULT 80
US-10-258-144-448
; Sequence 448, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
```

```
; SEQ ID NO 448
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-448

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 81
US-10-258-144-457
; Sequence 457, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 457
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-457

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 82
US-10-258-144-458
; Sequence 458, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 458
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-458
```

```
Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 83
US-10-258-144-477
; Sequence 477, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 477
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-477

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 84
US-10-258-144-478
; Sequence 478, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 478
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-478

Query Match      100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 85
US-10-258-144-487
; Sequence 487, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 487
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-487

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 86
US-10-258-144-488
; Sequence 488, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 488
; LENGTH: 18
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-488

Query Match 100.0%; Score 64; DB 4; Length 18;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 11 HWDFAWPW 18

RESULT 87
US-09-794-517-8
; Sequence 8, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-517-8

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 88
US-09-794-517-9

; Sequence 9, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-517-9

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPW 8
| | | | |
Db 1 HWDFAPW 8

RESULT 89
US-09-794-529-8
; Sequence 8, Application US/09794529
; Publication No. US20030082197A1

; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-794-529-8

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPW 8
| | | | |
Db 12 HWDFAPW 19

RESULT 90
US-09-794-529-9
; Sequence 9, Application US/09794529
; Publication No. US20030082197A1

```
/
/ GENERAL INFORMATION:
/ APPLICANT: Sloan-Kettering Institute for Cancer Research
/ ROTHMAN, James E.
/ HARTL, F. Ulrich
/ HOE, Mee H.
/ HOUGHTON, Alan
/ TAKECHI, Yoshizumi
/ MAYHEW, Mark
/
/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
/ Immunotherapies
/
/ NUMBER OF SEQUENCES: 30
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Kenyon & Kenyon
/ STREET: One Broadway
/ CITY: New York
/ STATE: NY
/ COUNTRY: US
/ ZIP: 10004
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: MS DOS
/ SOFTWARE: Word Perfect
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/794,529
/ FILING DATE: 27-Feb-2001
/ CLASSIFICATION: <Unknown>
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/09/011,645
/ FILING DATE: 13-Feb-1998
/ APPLICATION NUMBER: 60/002,479
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: 60/002,490
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: PCT/US96/13363
/ FILING DATE: August 16, 1996
/
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Delucia, Richard L.
/ REGISTRATION NUMBER: 28,839
/ REFERENCE/DOCKET NUMBER: 11746/1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 425-7200
/ TELEFAX: (212) 425-5288
/ TELEX: <Unknown>
/
/ INFORMATION FOR SEQ ID NO: 9:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: no
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ ORGANISM: <Unknown>
/ FEATURE:
/ OTHER INFORMATION:
/ SEQUENCE DESCRIPTION: SEQ ID NO: 9:
/
/ US-09-794-529-9
/
/ Query Match 100.0%; Score 64; DB 3; Length 19;
/ Best Local Similarity 100.0%; Pred. No. 0.068;
/ Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 1 HWDFAWPW 8
/ Db 1 HWDFAWPW 8
/
/ RESULT 91
/ US-09-794-832-8
/ Sequence 8, Application US/09794832
/ Publication No. US20030082198A1
```

```
/
/ GENERAL INFORMATION:
/ APPLICANT: Sloan-Kettering Institute for Cancer Research
/ ROTHMAN, James E.
/ HARTL, F. Ulrich
/ HOE, Mee H.
/ HOUGHTON, Alan
/ TAKECHI, Yoshizumi
/ MAYHEW, Mark
/
/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
/ Immunotherapies
/
/ NUMBER OF SEQUENCES: 30
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Kenyon & Kenyon
/ STREET: One Broadway
/ CITY: New York
/ STATE: NY
/ COUNTRY: US
/ ZIP: 10004
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: MS DOS
/ SOFTWARE: Word Perfect
/
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/794,832
/ FILING DATE: 27-Feb-2001
/ CLASSIFICATION: <Unknown>
/
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/09/011,645
/ FILING DATE: 13-Feb-1998
/ APPLICATION NUMBER: 60/002,479
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: 60/002,490
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: PCT/US96/13363
/ FILING DATE: August 16, 1996
/
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Delucia, Richard L.
/ REGISTRATION NUMBER: 28,839
/ REFERENCE/DOCKET NUMBER: 11746/1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 425-7200
/ TELEFAX: (212) 425-5288
/ TELEX: <Unknown>
/
/ INFORMATION FOR SEQ ID NO: 8:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: no
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ ORGANISM: <Unknown>
/ FEATURE:
/ OTHER INFORMATION:
/ SEQUENCE DESCRIPTION: SEQ ID NO: 8:
/
/ US-09-794-832-8
/
/ Query Match 100.0%; Score 64; DB 3; Length 19;
/ Best Local Similarity 100.0%; Pred. No. 0.068;
/ Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 1 HWDFAWPW 8
/ Db 12 HWDFAWPW 19
/
/ RESULT 92
/ US-09-794-832-9
/ Sequence 9, Application US/09794832
/ Publication No. US20030082198A1
```

GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Hartl, Ulrich
; APPLICANT: Ouerfelli, Ouathak
; APPLICANT: Moroi, Yoichi
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-09-794-832-9

Query Match 100.0%; Score 64; DB 3; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 93

US-10-052-578-321
; Sequence 321, Application US/10052578
; Publication No. US2003013478/A1

GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Hartl, Ulrich
; APPLICANT: Ouerfelli, Ouathak
; APPLICANT: Moroi, Yoichi
; TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
; FILE REFERENCE: 11746/46003
; CURRENT APPLICATION NUMBER: US/10/052,578
; CURRENT FILING DATE: 2002-01-17
; PRIOR APPLICATION NUMBER: 08/961,707
; PRIOR FILING DATE: 1997-10-31
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 321
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hybrid peptide
US-10-052-578-321

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 12 HWDFAPWP 19

RESULT 94

US-10-053-520-321
; Sequence 321, Application US/10053520
; Publication No. US20030166530A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Hartl, Ulrich
; APPLICANT: Ouerfelli, Ouathak
; APPLICANT: Moroi, Yoichi
; TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
; FILE REFERENCE: 11746/46004
; CURRENT APPLICATION NUMBER: US/10/053,520
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 08/961,707
; PRIOR FILING DATE: 1997-10-31
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 321
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hybrid peptide
US-10-053-520-321

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 12 HWDFAPWP 19

RESULT 95

US-10-170-713A-8
; Sequence 8, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-10-170-713A-8

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. NO. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 12 HWDFAWFW 19

RESULT 96

US-10-170-713A-9
; Sequence 9, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-170-713A-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. NO. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 97

US-10-171-734-8
; Sequence 8, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-10-171-734-8

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
|||||||

RESULT 98
US-10-171-734-9
; Sequence 9, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: no
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION:
; SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-171-734-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
|||||||

Db 1 HWDFAWPW 8

RESULT 99
US-10-053-498B-321
; Sequence 321, Application US/10053498B
; Publication No. US20030194409A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; APPLICANT: Rothman, James E.
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Hartl, Ulrich
; APPLICANT: Querfelli, Quathek
; APPLICANT: Moroi, Yoichi
; TITLE OF INVENTION: CONJUGATE HEAT SHOCK PROTEIN-BINDING PEPTIDES
; FILE REFERENCE: 11746/46002
; CURRENT APPLICATION NUMBER: US/10/053,498B
; PRIOR FILING DATE: 2002-01-17
; PRIOR FILING DATE: 08/961,707
; NUMBER OF SEQ ID NOS: 321
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 321
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: hybrid peptide
US-10-053-498B-321

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
12 HWDFAWPW 19
Db

RESULT 100
US-10-258-147-16
; Sequence 16, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 60/197,462
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 16
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide from Gallus gallus ovalbumin
US-10-258-147-16

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
12 HWDFAWPW 19
Db

RESULT 101
US-10-258-147-17
; Sequence 17, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-17

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
1 HWDFAWPW 8
Db

RESULT 102
US-10-258-147-22
; Sequence 22, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Herpes Simplex virus
US-10-258-147-22

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
1 HWDFAWPW 8
Db

RESULT 103
US-10-258-147-23
; Sequence 23, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James

; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 23
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Javelinized peptide of Herpes Simplex virus
US-10-258-147-23

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 12 HWDFAWPW 19

RESULT 104

US-10-367-580-8
; Sequence 8, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-8

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 12 HWDFAWPW 19

RESULT 105

US-10-367-580-9

; Sequence 9, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 106

US-10-367-593-8
; Sequence 8, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-8

```
US-10-367-593-8
Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      12 HWDFAWPW 19

RESULT 107
US-10-367-593-9
; Sequence 9, Application US/10367593
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-9

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      12 HWDFAWPW 19

RESULT 108
US-10-367-594-8
; Sequence 8, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-8

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      12 HWDFAWPW 19

RESULT 109
US-10-367-594-9
; Sequence 9, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-9

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      12 HWDFAWPW 19

RESULT 110
US-10-367-654-8
; Sequence 8, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
;
US-10-367-654-8

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
        |||||
Db      12 HWDFAWPW 19

RESULT 111
US-10-367-654-9
; Sequence 9, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
;
US-10-367-654-9

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
        |||||
Db      1 HWDFAWPW 8

RESULT 112
US-10-367-658-8
; Sequence 8, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
;
US-10-367-658-8

Query Match      100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
        |||||
Db      12 HWDFAWPW 19

RESULT 113
US-10-367-658-9
; Sequence 9, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
```

```
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-9
```

```
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
```

```
RESULT 114
US-10-367-668-8
; Sequence 8, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-8
```

```
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19
```

```
RESULT 115
US-10-367-668-9
; Sequence 9, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-9
```

```
Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
```

```
RESULT 116
US-10-258-144-274
; Sequence 274, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 274
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-274
```

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 117
US-10-367-674-8
; Sequence 275, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 275
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-275

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 12 HWDFAWPW 19

RESULT 118
US-10-367-674-8
; Sequence 8, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479

; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 8
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-8

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 12 HWDFAWPW 19

RESULT 119
US-10-367-674-9
; Sequence 9, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 9
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-9

Query Match 100.0%; Score 64; DB 4; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 120
US-10-776-521B-368
; Sequence 368, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya

; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 368
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
; US-10-776-521B-368

Query Match 100.0%; Score 64; DB 5; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 121
US-10-776-521B-376
; Sequence 376, Application US/10/776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletchner, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 376
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
; US-10-776-521B-376

Query Match 100.0%; Score 64; DB 5; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 12 HWDFAWPW 19

RESULT 122
US-10-776-521B-379
; Sequence 379, Application US/10/776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletchner, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 379
; LENGTH: 19
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
; US-10-776-521B-379

Query Match 100.0%; Score 64; DB 5; Length 19;
Best Local Similarity 100.0%; Pred. No. 0.068;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 123
US-09-794-517-10
; Sequence 10, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage


```

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-517-10

```

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels

Qy 1 HWDFAWPW 8
13 HWDFAWPW 20
Dp

```

RESULT 124
US-09-794-517-11
; Sequence 11, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible

```

OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-517-11

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels

Qy	1	HWDF	AWPW	8
Db	1	HWDF <td>AWPW</td> <td>8</td>	AWPW	8

```

RESULT 125
US-09-794-517-12
; Sequence 12, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS

```

```

;
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-517-12

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 126
US-09-794-517-13
; Sequence 13, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:

```

```

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
;
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
;
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-794-517-13

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 127
US-09-794-517-14
; Sequence 14, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
;
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
;
; CURRENT APPLICATION DATA:

```

```
/ APPLICATION NUMBER: US/09/794,517
/ FILING DATE: 27-Feb-2001
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/011,645
/ FILING DATE: <Unknown>
/ APPLICATION NUMBER: 60/002,490
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: PCT/US96/13363
/ FILING DATE: August 16, 1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Delucia, Richard L.
/ REGISTRATION NUMBER: 28,839
/ REFERENCE/DOCKET NUMBER: 11746/1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 425-7200
/ TELEFAX: (212) 425-5288
/ TELEX: <Unknown>
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: yes
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ ORGANISM: <Unknown>
/ FEATURE:
/ OTHER INFORMATION: hybrid peptide for human papilloma
/ virus vaccine
/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-517-14
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 128
US-09-794-517-15
/ Sequence 15, Application US/09794517
/ Publication No. US20030021794A1
/ GENERAL INFORMATION:
/ APPLICANT: Sloan-Kettering Institute for Cancer Research
/ ROTHMAN, James E.
/ HARTL, F. Ulrich
/ HOE, Mee H.
/ HOUGHTON, Alan
/ TAKECHI, Yoshizumi
/ MAYHEW, Mark
/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
/ Immunotherapies
/ NUMBER OF SEQUENCES: 30
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Kenyon & Kenyon
/ STREET: One Broadway
/ CITY: New York
/ STATE: NY
/ COUNTRY: US
/ ZIP: 10004
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: MS DOS
/ SOFTWARE: Word Perfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/794,517
/ FILING DATE: 27-Feb-2001
```

```
/ FILING DATE: 27-Feb-2001
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 09/011,645
/ FILING DATE: <Unknown>
/ APPLICATION NUMBER: 60/002,490
/ FILING DATE: August 18, 1995
/ APPLICATION NUMBER: PCT/US96/13363
/ FILING DATE: August 16, 1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Delucia, Richard L.
/ REGISTRATION NUMBER: 28,839
/ REFERENCE/DOCKET NUMBER: 11746/1
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 425-7200
/ TELEFAX: (212) 425-5288
/ TELEX: <Unknown>
/ INFORMATION FOR SEQ ID NO: 15:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20
/ TYPE: amino acid
/ STRANDEDNESS: <Unknown>
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ HYPOTHETICAL: yes
/ FRAGMENT TYPE: internal
/ ORIGINAL SOURCE:
/ ORGANISM: <Unknown>
/ FEATURE:
/ OTHER INFORMATION: hybrid peptide for human papilloma
/ virus vaccine
/ SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-517-15
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 129
US-09-794-517-16
/ Sequence 16, Application US/09794517
/ Publication No. US20030021794A1
/ GENERAL INFORMATION:
/ APPLICANT: Sloan-Kettering Institute for Cancer Research
/ ROTHMAN, James E.
/ HARTL, F. Ulrich
/ HOE, Mee H.
/ HOUGHTON, Alan
/ TAKECHI, Yoshizumi
/ MAYHEW, Mark
/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
/ Immunotherapies
/ NUMBER OF SEQUENCES: 30
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Kenyon & Kenyon
/ STREET: One Broadway
/ CITY: New York
/ STATE: NY
/ COUNTRY: US
/ ZIP: 10004
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: MS DOS
/ SOFTWARE: Word Perfect
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/794,517
/ FILING DATE: 27-Feb-2001
```

```

;
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011.645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-517-16

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 13 HWDFAWPW 20

RESULT 130
US-09-794-517-17
; Sequence 17, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>

```

```

;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011.645
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-517-17

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
DB 1 HWDFAWPW 8

RESULT 131
US-09-794-517-18
; Sequence 18, Application US/09794517
; Publication No. US20030021794A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,517
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:

```

APPLICATION NUMBER: 09/011,645
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-517-18
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAPW 8
Db 13 HWDFAPW 20
RESULT 132
US-09-794-517-19
Sequence 19, Application US/09794517
Publication No. US20030021794A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,517
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645

FILING DATE: <Unknown>
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-794-517-19
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAPW 8
Db 1 HWDFAPW 8
RESULT 133
US-09-794-529-10
Sequence 10, Application US/09794529
Publication No. US20030082197A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998

```
;
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-529-10

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 13 HWDFAWFW 20

RESULT 134
US-09-794-529-11
; Sequence 11, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
```

```
;
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-529-11

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8

RESULT 135
US-09-794-529-12
; Sequence 12, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
```

APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-529-12

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 136
US-09-794-529-13
Sequence 13, Application US/09794529
Publication No. US20030082197A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-794-529-13

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 137
US-09-794-529-14
Sequence 14, Application US/09794529
Publication No. US20030082197A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,529
FILING DATE: 27-Feb-2001

```
;
;
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-529-14

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 13 HWDFAWFW 20
|||||

RESULT 138
US-09-794-529-15
; Sequence 15, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
```

```
;
;
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011.645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002.479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002.490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-529-15

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8
|||||

RESULT 139
US-09-794-529-16
; Sequence 16, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
```



```

; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-529-16

```

```

Query Match      100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 140
US-09-794-529-17
; Sequence 17, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,529
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-529-17

Query Match      100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 141
US-09-794-529-18
; Sequence 18, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS

```

```

;
;   SOFTWARE: Word Perfect
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/794,529
;   FILING DATE: 27-Feb-2001
;   CLASSIFICATION: <Unknown>
;
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US/09/011,645
;   FILING DATE: 13-Feb-1998
;   APPLICATION NUMBER: 60/002,479
;   FILING DATE: August 18, 1995
;   APPLICATION NUMBER: 60/002,490
;   FILING DATE: August 18, 1995
;   APPLICATION NUMBER: PCT/US96/13363
;   FILING DATE: August 16, 1996
;
;   ATTORNEY/AGENT INFORMATION:
;   NAME: DeLucia, Richard L.
;   REGISTRATION NUMBER: 28,839
;   REFERENCE/DOCKET NUMBER: 11746/1
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (212) 425-5288
;   TELEFAX: (212) 425-5288
;   TELEX: <Unknown>
;
;   INFORMATION FOR SEQ ID NO: 18:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 20
;     TYPE: amino acid
;     STRANDEDNESS: <Unknown>
;     TOPOLOGY: linear
;     MOLECULE TYPE: peptide
;     HYPOTHETICAL: yes
;     FRAGMENT TYPE: internal
;     ORIGINAL SOURCE:
;       ORGANISM: <Unknown>
;     FEATURE:
;       OTHER INFORMATION: hybrid peptide for human papilloma
;       virus vaccine
;     SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-529-18

Query Match      100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWFW 8
Db      13 HWDFAWFW 20
      |||||
      |||||

RESULT 142
US-09-794-529-19
; Sequence 19, Application US/09794529
; Publication No. US20030082197A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible

```

```

;
;   OPERATING SYSTEM: MS DOS
;   SOFTWARE: Word Perfect
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/794,529
;   FILING DATE: 27-Feb-2001
;   CLASSIFICATION: <Unknown>
;
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: US/09/011,645
;   FILING DATE: 13-Feb-1998
;   APPLICATION NUMBER: 60/002,479
;   FILING DATE: August 18, 1995
;   APPLICATION NUMBER: 60/002,490
;   FILING DATE: August 18, 1995
;   APPLICATION NUMBER: PCT/US96/13363
;   FILING DATE: August 16, 1996
;
;   ATTORNEY/AGENT INFORMATION:
;   NAME: DeLucia, Richard L.
;   REGISTRATION NUMBER: 28,839
;   REFERENCE/DOCKET NUMBER: 11746/1
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (212) 425-5288
;   TELEFAX: (212) 425-5288
;   TELEX: <Unknown>
;
;   INFORMATION FOR SEQ ID NO: 19:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH: 20
;     TYPE: amino acid
;     STRANDEDNESS: <Unknown>
;     TOPOLOGY: linear
;     MOLECULE TYPE: peptide
;     HYPOTHETICAL: yes
;     FRAGMENT TYPE: internal
;     ORIGINAL SOURCE:
;       ORGANISM: <Unknown>
;     FEATURE:
;       OTHER INFORMATION: hybrid peptide for human papilloma
;       virus vaccine
;     SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-794-529-19

Query Match      100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWFW 8
Db      1 HWDFAWFW 8
      |||||
      |||||

RESULT 143
US-09-794-832-10
; Sequence 10, Application US/09794832
; Publication No. US20030082198A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage

```

COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-794-832-10

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 144
US-09-794-832-11
Sequence 11, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-794-832-11

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 145
US-09-794-832-12
Sequence 12, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004

```

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-09-794-832-12

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 146
US-09-794-832-13
; Sequence 13, Application US/09794832
; Publication No. US20030082198A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US

```

```

;
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/794,832
; FILING DATE: 27-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,645
; FILING DATE: 13-Feb-1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Delucia, Richard L.
; REGISTRATION NUMBER: 28,839
; REFERENCE/DOCKET NUMBER: 11746/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-09-794-832-13

Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 147
US-09-794-832-14
; Sequence 14, Application US/09794832
; Publication No. US20030082198A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY

```

STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-794-832-14
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 148
US-09-794-832-15
Sequence 15, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York

STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 15:
US-09-794-832-15
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 149
US-09-794-832-16
Sequence 16, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway

;
;
;
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-794-832-16
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 150
US-09-794-832-17
Sequence 17, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
HOE, Mee H.
TAKESCHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon

;
;
;
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Delucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-09-794-832-17
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 151
US-09-794-832-18
Sequence 18, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOUGHTON, Alan
HOE, Mee H.
TAKESCHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:

ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-794-832-18
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 152
US-09-794-832-19
Sequence 19, Application US/09794832
Publication No. US20030082198A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies
NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/794,832
FILING DATE: 27-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/011,645
FILING DATE: 13-Feb-1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: DeLucia, Richard L.
REGISTRATION NUMBER: 28,839
REFERENCE/DOCKET NUMBER: 11746/1
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma
virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-09-794-832-19
Query Match 100.0%; Score 64; DB 3; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 153
US-10-170-713A-10
Sequence 10, Application US/10170713A
Publication No. US20030185842A1
GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
Immunotherapies

;/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;/ Immunotherapies
;/ NUMBER OF SEQUENCES: 30
;/ CORRESPONDENCE ADDRESS:
;/ ADDRESSEE: Kenyon & Kenyon
;/ STREET: One Broadway
;/ CITY: New York
;/ STATE: NY
;/ COUNTRY: US
;/ ZIP: 10004
;/ COMPUTER READABLE FORM:
;/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;/ COMPUTER: IBM compatible
;/ OPERATING SYSTEM: MS DOS
;/ SOFTWARE: Word Perfect
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/10/170,713A
;/ FILING DATE: 13-Jun-2002
;/ CLASSIFICATION: 424
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 09/011,645
;/ FILING DATE: February 13, 1998
;/ APPLICATION NUMBER: 60/002,479
;/ FILING DATE: August 18, 1995
;/ APPLICATION NUMBER: 60/002,490
;/ FILING DATE: August 18, 1995
;/ APPLICATION NUMBER: PCT/US96/13363
;/ FILING DATE: August 16, 1996
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Casson, Lawrence P.
;/ REGISTRATION NUMBER: 46,606
;/ REFERENCE/DOCKET NUMBER: 11746/461011
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (212) 425-7200
;/ TELEFAX: (212) 425-5288
;/ TELEX: <Unknown>
;/ INFORMATION FOR SEQ ID NO: 12:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20
;/ TYPE: amino acid
;/ STRANDEDNESS: <Unknown>
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ HYPOTHETICAL: yes
;/ FRAGMENT TYPE: internal
;/ ORIGINAL SOURCE:
;/ ORGANISM: <Unknown>
;/ FEATURE:
;/ OTHER INFORMATION: hybrid peptide for human papilloma
;/ virus vaccine
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-170-713A-12
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 156
US-10-170-713A-13
; Sequence 13, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi

;/ MAYHEW, Mark
;/ TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
;/ Immunotherapies
;/ NUMBER OF SEQUENCES: 30
;/ CORRESPONDENCE ADDRESS:
;/ ADDRESSEE: Kenyon & Kenyon
;/ STREET: One Broadway
;/ CITY: New York
;/ STATE: NY
;/ COUNTRY: US
;/ ZIP: 10004
;/ COMPUTER READABLE FORM:
;/ MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
;/ COMPUTER: IBM compatible
;/ OPERATING SYSTEM: MS DOS
;/ SOFTWARE: Word Perfect
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/10/170,713A
;/ FILING DATE: 13-Jun-2002
;/ CLASSIFICATION: 424
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 09/011,645
;/ FILING DATE: February 13, 1998
;/ APPLICATION NUMBER: 60/002,479
;/ FILING DATE: August 18, 1995
;/ APPLICATION NUMBER: 60/002,490
;/ FILING DATE: August 18, 1995
;/ APPLICATION NUMBER: PCT/US96/13363
;/ FILING DATE: August 16, 1996
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Casson, Lawrence P.
;/ REGISTRATION NUMBER: 46,606
;/ REFERENCE/DOCKET NUMBER: 11746/461011
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (212) 425-7200
;/ TELEFAX: (212) 425-5288
;/ TELEX: <Unknown>
;/ INFORMATION FOR SEQ ID NO: 13:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20
;/ TYPE: amino acid
;/ STRANDEDNESS: <Unknown>
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: peptide
;/ HYPOTHETICAL: yes
;/ FRAGMENT TYPE: internal
;/ ORIGINAL SOURCE:
;/ ORGANISM: <Unknown>
;/ FEATURE:
;/ OTHER INFORMATION: hybrid peptide for human papilloma
;/ virus vaccine
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 13:
US-10-170-713A-13
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 157
US-10-170-713A-14
; Sequence 14, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan

```
;
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
;
; US-10-170-713A-14
;
; Query Match 100.0%; Score 64; DB 4; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.071;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1 HWDFAPWP 8
; DB 13 HWDFAPWP 20
;
; RESULT 158
; US-10-170-713A-15
; Sequence 15, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
```

```
;
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
;
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/170,713A
; FILING DATE: 13-Jun-2002
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 15:
;
; US-10-170-713A-15
;
; Query Match 100.0%; Score 64; DB 4; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.071;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1 HWDFAPWP 8
; DB 1 HWDFAPWP 8
;
; RESULT 159
; US-10-170-713A-16
; Sequence 16, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
```

HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/170,713A
FILING DATE: 13-Jun-2002
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-170-713A-16
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 160
US-10-170-713A-17
; Sequence 17, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.

HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/170,713A
FILING DATE: 13-Jun-2002
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-170-713A-17
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 161
US-10-170-713A-18
; Sequence 18, Application US/10170713A
; Publication No. US20030185842A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research

ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/170,713A
FILING DATE: 13-Jun-2002
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-170-713A-18
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWFW 8
Db 13 HWDFAWFW 20
RESULT 162
US-10-170-713A-19
Sequence 19, Application US/10170713A
Publication No. US20030185842A1
GENERAL INFORMATION:

APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKECHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/170,713A
FILING DATE: 13-Jun-2002
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-10-170-713A-19
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWFW 8
Db 1 HWDFAWFW 8
RESULT 163
US-10-171-734-10
Sequence 10, Application US/10171734
Publication No. US20030185843A1

GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESCHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/171,734
FILING DATE: 14-Jan-2003
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 09/636,295
FILING DATE: August 10, 2000
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461031
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 10:

US-10-171-734-10
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 164

US-10-171-734-11
; Sequence 11, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
APPLICANT: Sloan-Kettering Institute for Cancer Research
ROTHMAN, James E.
HARTL, F. Ulrich
HOE, Mee H.
HOUGHTON, Alan
TAKESCHI, Yoshizumi
MAYHEW, Mark
TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Kenyon & Kenyon
STREET: One Broadway
CITY: New York
STATE: NY
COUNTRY: US
ZIP: 10004
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/171,734
FILING DATE: 14-Jan-2003
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/002,479
FILING DATE: August 18, 1995
APPLICATION NUMBER: 60/002,490
FILING DATE: August 18, 1995
APPLICATION NUMBER: PCT/US96/13363
FILING DATE: August 16, 1996
APPLICATION NUMBER: 09/011,645
FILING DATE: February 13, 1998
APPLICATION NUMBER: 09/636,295
FILING DATE: August 10, 2000
ATTORNEY/AGENT INFORMATION:
NAME: Casson, Lawrence P.
REGISTRATION NUMBER: 46,606
REFERENCE/DOCKET NUMBER: 11746/461031
TELEPHONE: (212) 425-7200
TELEFAX: (212) 425-5288
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: amino acid
STRANDEDNESS: <Unknown>
TOPOLOGY: linear
MOLECULE TYPE: peptide
HYPOTHETICAL: yes
FRAGMENT TYPE: internal
ORIGINAL SOURCE:
ORGANISM: <Unknown>
FEATURE:
OTHER INFORMATION: hybrid peptide for human papilloma virus vaccine
SEQUENCE DESCRIPTION: SEQ ID NO: 11:

US-10-171-734-11
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

```
QY      1 HWDEAWPW 8
Db      13 HWDEAWPW 20

RESULT 166
US-10-171-734-13
; Sequence 13, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 13:
;
; US-10-171-734-13
;
; Query Match      100.0%; Score 64; DB 4; Length 20;
; Best Local Similarity 100.0%; Pred. No. 0.071;
; Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 167
US-10-171-734-14
; Sequence 14, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:
; OTHER INFORMATION: hybrid peptide for human papilloma
; virus vaccine
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:

US-10-171-734-14
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 168
US-10-171-734-15
; Sequence 15, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: yes
; FRAGMENT TYPE: internal
; ORIGINAL SOURCE:
; ORGANISM: <Unknown>
; FEATURE:


```
,
, MOLECULE TYPE: peptide
, HYPOTHETICAL: yes
, FRAGMENT TYPE: internal
, ORIGINAL SOURCE:
, ORGANISM: <Unknown>
, FEATURE:
, OTHER INFORMATION: hybrid peptide for human papilloma
, virus vaccine
, SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-171-734-17
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
RESULT 171
US-10-171-734-18
; Sequence 18, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
```

```
,
, TYPE: amino acid
, STRANDEDNESS: <Unknown>
, TOPOLOGY: linear
, MOLECULE TYPE: peptide
, HYPOTHETICAL: yes
, FRAGMENT TYPE: internal
, ORIGINAL SOURCE:
, ORGANISM: <Unknown>
, FEATURE:
, OTHER INFORMATION: hybrid peptide for human papilloma
, virus vaccine
, SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-171-734-18
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
RESULT 172
US-10-171-734-19
; Sequence 19, Application US/10171734
; Publication No. US20030185843A1
; GENERAL INFORMATION:
; APPLICANT: Sloan-Kettering Institute for Cancer Research
; ROTHMAN, James E.
; HARTL, F. Ulrich
; HOE, Mee H.
; HOUGHTON, Alan
; TAKECHI, Yoshizumi
; MAYHEW, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and
; Immunotherapies
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kenyon & Kenyon
; STREET: One Broadway
; CITY: New York
; STATE: NY
; COUNTRY: US
; ZIP: 10004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/171,734
; FILING DATE: 14-Jan-2003
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/002,479
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: 60/002,490
; FILING DATE: August 18, 1995
; APPLICATION NUMBER: PCT/US96/13363
; FILING DATE: August 16, 1996
; APPLICATION NUMBER: 09/011,645
; FILING DATE: February 13, 1998
; APPLICATION NUMBER: 09/636,295
; FILING DATE: August 10, 2000
; ATTORNEY/AGENT INFORMATION:
; NAME: Casson, Lawrence P.
; REGISTRATION NUMBER: 46,606
; REFERENCE/DOCKET NUMBER: 11746/461031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 425-7200
; TELEFAX: (212) 425-5288
; TELEX: <Unknown>
```

```
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: amino acid
;   STRANDEDNESS: <Unknown>
;   TOPOLOGY: linear
;   MOLECULE TYPE: peptide
;   HYPOTHETICAL: yes
;   FRAGMENT TYPE: internal
;   ORIGINAL SOURCE:
;     ORGANISM: <Unknown>
;   FEATURE:
;     OTHER INFORMATION: hybrid peptide for human papilloma
;     virus vaccine
;   SEQUENCE DESCRIPTION: SEQ ID NO: 19:
US-10-171-734-19

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 173
US-10-258-147-25
; Sequence 25, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: Fast-Seq for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of gp100 human melanoma
; OTHER INFORMATION: antigen
US-10-258-147-25

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 174
US-10-258-147-26
; Sequence 26, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: Fast-Seq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of gp100 human melanoma
; OTHER INFORMATION: antigen
US-10-258-147-26

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 175
US-10-367-580-10
; Sequence 10, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takeshi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-10

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 176
US-10-367-580-11
; Sequence 11, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
```

; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 11
 ; LENGTH: 20
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-580-11

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.071;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 177
 US-10-367-580-12
 ; Sequence 12, Application US/10367580
 ; Publication No. US20040071720A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 12
 ; LENGTH: 20
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-580-12

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.071;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 HWDFAWPW 8
 |||||
 Db 13 HWDFAWPW 20

RESULT 178
 US-10-367-580-13
 ; Sequence 13, Application US/10367580
 ; Publication No. US20040071720A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490
 ; PRIOR FILING DATE: 1995-08-18
 ; PRIOR APPLICATION NUMBER: US 60/002,479
 ; PRIOR FILING DATE: 1995-08-18
 ; NUMBER OF SEQ ID NOS: 349
 ; SOFTWARE: WordPerfect 8.0 for Windows
 ; SEQ ID NO 13
 ; LENGTH: 20
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: synthetic peptide
 US-10-367-580-13

Query Match 100.0%; Score 64; DB 4; Length 20;
 Best Local Similarity 100.0%; Pred. No. 0.071;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 179
 US-10-367-580-14
 ; Sequence 14, Application US/10367580
 ; Publication No. US20040071720A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Rothman, James E.
 ; APPLICANT: Hartl, F. Ulrich
 ; APPLICANT: Hoe, Mee H.
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Takechi, Yoshizumi
 ; APPLICANT: Mayhew, Mark
 ; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
 ; FILE REFERENCE: 11746/461061
 ; CURRENT APPLICATION NUMBER: US/10/367,580
 ; PRIOR FILING DATE: 2003-02-14
 ; PRIOR APPLICATION NUMBER: US 09/794,832
 ; PRIOR FILING DATE: 2001-02-27
 ; PRIOR APPLICATION NUMBER: US 09/011,645
 ; PRIOR FILING DATE: 1998-02-13
 ; PRIOR APPLICATION NUMBER: PCT/US96/13363
 ; PRIOR FILING DATE: 1996-08-16
 ; PRIOR APPLICATION NUMBER: US 60/002,490

```

; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-14

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

QY      1 HWDFAWPW 8
      |||||
DB      13 HWDFAWPW 20

```

```

RESULT 180
US-10-367-580-15
; Sequence 15, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-15

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

QY      1 HWDFAWPW 8
      |||||
DB      1 HWDFAWPW 8

```

```

RESULT 181
US-10-367-580-16
; Sequence 16, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich

```

```

; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-16

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

QY      1 HWDFAWPW 8
      |||||
DB      13 HWDFAWPW 20

```

```

RESULT 182
US-10-367-580-17
; Sequence 17, Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-17

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;

```

```
; Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 183
US-10-367-580-18
; Sequence 18. Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-18

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 184
US-10-367-580-19
; Sequence 19. Application US/10367580
; Publication No. US20040071720A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461061
; CURRENT APPLICATION NUMBER: US/10/367,580
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,832
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
```

```
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-580-19

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 185
US-10-367-593-10
; Sequence 10. Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-10

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 186
US-10-367-593-11
; Sequence 11. Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
```

```
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-11

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPM 8
        |||||
Db       1 HWDFAWPM 8

RESULT 187
US-10-367-593-12
; Sequence 12, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-12

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPM 8
        |||||
Db       1 HWDFAWPM 8

RESULT 188
US-10-367-593-13
; Sequence 13, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-13

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPM 8
        |||||
Db       1 HWDFAWPM 8

RESULT 189
US-10-367-593-14
; Sequence 14, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
```

```
Db       13 HWDFAWPM 20

RESULT 188
US-10-367-593-13
; Sequence 13, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-13

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPM 8
        |||||
Db       1 HWDFAWPM 8

RESULT 189
US-10-367-593-14
; Sequence 14, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-14

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 190
US-10-367-593-15
; Sequence 15, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-15

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 191
US-10-367-593-16
; Sequence 16, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-16

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 192
US-10-367-593-17
; Sequence 17, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-17

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 193
US-10-367-593-18
; Sequence 18, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
```

```
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-16

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 192
US-10-367-593-17
; Sequence 17, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-17

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 8

RESULT 193
US-10-367-593-18
; Sequence 18, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
```

```

; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-18

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 194
US-10-367-593-19
; Sequence 19, Application US/10367593
; Publication No. US20040071721A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461012
; CURRENT APPLICATION NUMBER: US/10/367,593
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-593-19

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 195
US-10-367-594-10
; Sequence 10, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-10

```

```

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 196
US-10-367-594-11
; Sequence 11, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479

```


; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-11

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 197
US-10-367-594-12
; Sequence 12, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-12

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 198
US-10-367-594-13
; Sequence 13, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan

; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-13

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 199
US-10-367-594-14
; Sequence 14, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-14

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 200

US-10-367-594-15
; Sequence 15, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-15

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 201

US-10-367-594-16
; Sequence 16, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18

; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-16

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 202

US-10-367-594-17
; Sequence 17, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-17

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 203

US-10-367-594-18
; Sequence 18, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.

```
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-18

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      13 HWDFAWPW 20

RESULT 204
US-10-367-594-19
; Sequence 19, Application US/10367594
; Publication No. US20040071722A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461041
; CURRENT APPLICATION NUMBER: US/10/367,594
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/680,806
; PRIOR FILING DATE: 2000-10-05
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-594-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 205
US-10-367-654-10
; Sequence 10, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-10

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      13 HWDFAWPW 20

RESULT 206
US-10-367-654-11
; Sequence 11, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
```

;
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-11

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 207

US-10-367-654-12
; Sequence 12, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-12

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 208

US-10-367-654-13
; Sequence 13, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-13

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 209

US-10-367-654-14
; Sequence 14, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349

; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-14

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 210
US-10-367-654-15
; Sequence 15, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark

; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-15

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 211
US-10-367-654-16
; Sequence 16, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan

; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-16

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 212
US-10-367-654-17
; Sequence 17, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-17

```
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 213
US-10-367-654-18
; Sequence 18, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-18

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 214
US-10-367-654-19
; Sequence 19, Application US/10367654
; Publication No. US20040071723A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461032
; CURRENT APPLICATION NUMBER: US/10/367,654
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/171,734
; PRIOR FILING DATE: 2002-06-13
```

```
; PRIOR APPLICATION NUMBER: US 09/636,295
; PRIOR FILING DATE: 2000-08-10
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-654-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 215
US-10-367-658-10
; Sequence 10, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-10

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
```

```
RESULT 216
US-10-367-658-11
; Sequence 11, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION: synthetic peptide
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-11

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 217
US-10-367-658-12
; Sequence 12, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-12

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8
```

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-12

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 20

RESULT 218
US-10-367-658-13
; Sequence 13, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-13

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 219
US-10-367-658-14
; Sequence 14, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
```

```
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-14
```

```
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||
```

```
RESULT 220
US-10-367-658-15
; Sequence 15, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-15
```

```
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||
```

```
RESULT 221
US-10-367-658-16
; Sequence 16, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-16
```

```
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||
```

```
RESULT 222
US-10-367-658-17
; Sequence 17, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
```



```
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-17

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8
        |||||
RESULT 223
US-10-367-658-18
; Sequence 18, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-18

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      13 HWDFAPWP 20
        |||||
RESULT 224
US-10-367-658-19
; Sequence 19, Application US/10367658
; Publication No. US20040071724A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461051
```

```
; CURRENT APPLICATION NUMBER: US/10/367,658
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,529
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-658-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8
        |||||
RESULT 225
US-10-367-668-10
; Sequence 10, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-10

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
Db      13 HWDFAPWP 20
        |||||
```

```
RESULT 226
US-10-367-668-11
; Sequence 11, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; PRIOR FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR FILING DATE: 1998-02-13
; PRIOR FILING DATE: 1996-08-16
; PRIOR FILING DATE: 1995-08-18
; PRIOR FILING DATE: 1995-08-18
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-11

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 227
US-10-367-668-12
; Sequence 12, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; PRIOR FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2001-02-27
; PRIOR FILING DATE: 1998-02-13
; PRIOR FILING DATE: 1996-08-16
; PRIOR FILING DATE: 1995-08-18
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-12

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
```

```
; SEQ ID NO 12
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-12

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

RESULT 228
US-10-367-668-13
; Sequence 13, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-13

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 229
US-10-367-668-14
; Sequence 14, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
```

FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-14

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 13 HWDFAWPW 20

RESULT 230
US-10-367-668-15
; Sequence 15, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-15

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |

Db 1 HWDFAWPW 8
RESULT 231
US-10-367-668-16
; Sequence 16, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-16

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 13 HWDFAWPW 20

RESULT 232
US-10-367-668-17
; Sequence 17, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |

```
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-17

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 233
US-10-367-668-18
; Sequence 18, Application US/10367668
; Publication No. US20040071725A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/461072
; CURRENT APPLICATION NUMBER: US/10/367,668
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 09/794,517
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-668-19

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 235
US-10-258-144-212
; Sequence 212, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 212
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-212

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 236
US-10-258-144-214
; Sequence 214, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
```

; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 214
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-214

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 237
US-10-258-144-215
; Sequence 215, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 215
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-215

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 238
US-10-258-144-224
; Sequence 224, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil

; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 224
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-224

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 239
US-10-258-144-225
; Sequence 225, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 225
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-225

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20

RESULT 240
US-10-258-144-234
; Sequence 234, Application US/10258144
; Publication No. US20040101532A1

US-10-258-144-235
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 234
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue

US-10-258-144-234
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 241

US-10-258-144-235
; Sequence 235, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 235
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue

US-10-258-144-235
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||

RESULT 242

US-10-258-144-244
; Sequence 244, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 244
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue

US-10-258-144-244
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 243

US-10-258-144-245
; Sequence 245, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 245
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative

US-10-258-144-245
Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||

RESULT 244

US-10-258-144-254

; Sequence 254, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 254
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-254

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 245
US-10-258-144-255
; Sequence 255, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 255
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-255

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
|||||

RESULT 246
US-10-258-144-284
; Sequence 284, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 284
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-284

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||

RESULT 247
US-10-258-144-285
; Sequence 285, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 285
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-285

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8

```
Db          13 HWDFAWPW 20
|||||
Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
|||||
Db          13 HWDFAWPW 20
|||||

RESULT 248
US-10-258-144-294
; Sequence 294, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 294
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-294

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
|||||
Db          1 HWDFAWPW 8
|||||

RESULT 249
US-10-258-144-295
; Sequence 295, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 295
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-295

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
```

```
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
|||||
Db          13 HWDFAWPW 20
|||||

RESULT 250
US-10-258-144-314
; Sequence 314, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 314
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-314

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
|||||
Db          1 HWDFAWPW 8
|||||

RESULT 251
US-10-258-144-315
; Sequence 315, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 315
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-315
```


Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 252

US-10-258-144-324
; Sequence 324, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 324
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-324

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 253

US-10-258-144-325
; Sequence 325, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 325
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT

; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-325

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 254

US-10-258-144-384
; Sequence 384, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 384
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-384

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 255

US-10-258-144-385
; Sequence 385, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 385
; LENGTH: 20
; TYPE: PRT

```
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-385

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 20

RESULT 256
US-10-258-144-414
; Sequence 414, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 414
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-414

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 8

RESULT 257
US-10-258-144-415
; Sequence 415, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
```

```
; SEQ ID NO 415
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-415

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 20

RESULT 258
US-10-258-144-424
; Sequence 424, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 424
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-424

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

QY      1 HWDFAPWP 8
DB      13 HWDFAPWP 8

RESULT 259
US-10-258-144-425
; Sequence 425, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
```

```
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 425
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-425
```

Query Match 100.0%; Score 64; DB 4; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
```

RESULT 260

```
US-10-258-144-434
; Sequence 434, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 434
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-434
```

Query Match 100.0%; Score 64; DB 4; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
```

RESULT 261

```
US-10-258-144-435
; Sequence 435, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
```

```
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 435
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-435
```

Query Match 100.0%; Score 64; DB 4; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
```

RESULT 262

```
US-10-258-144-464
; Sequence 464, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 464
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-464
```

Query Match 100.0%; Score 64; DB 4; Length 20;

Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 1 HWDFAWPW 8
Db 13 HWDFAWPW 20
```

RESULT 263

```
US-10-258-144-465
; Sequence 465, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
```

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 465
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-465

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 264

US-10-258-144-494
; Sequence 494, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 494
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-494

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 265

US-10-258-144-495
; Sequence 495, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil

; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 495
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (10)...(12)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-495

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 13 HWDFAWPW 20

RESULT 266

US-10-367-674-10
; Sequence 10, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 10
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-10

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8

```
Db          13 HWDFAWPW 20
|||||
RESULT 267
US-10-367-674-11
; Sequence 11, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 11
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-11

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
|||||
Db          13 HWDFAWPW 20
|||||

RESULT 269
US-10-367-674-13
; Sequence 13, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 13
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-13

Query Match          100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy          1 HWDFAWPW 8
|||||
Db          13 HWDFAWPW 8
|||||

RESULT 270
US-10-367-674-14
; Sequence 14, Application US/10367674
; Publication No. US20040127684A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 14
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-14

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||||
DB      13 HWDFAWPW 20

RESULT 271
US-10-367-674-15
; Sequence 15, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 15
; LENGTH: 20
```

```
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-15

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||||
DB      1 HWDFAWPW 8

RESULT 272
US-10-367-674-16
; Sequence 16, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 16
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
; US-10-367-674-16

Query Match      100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||||
DB      13 HWDFAWPW 20

RESULT 273
US-10-367-674-17
; Sequence 17, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
```

FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 17
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-17

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 274
US-10-367-674-18
; Sequence 18, Application US/10367674
; Publication No. US20040127684A1

; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 18
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-18

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
| | | | |
Db 13 HWDFAWPW 20
RESULT 275
US-10-367-674-19
; Sequence 19, Application US/10367674
; Publication No. US20040127684A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James E.
; APPLICANT: Hartl, F. Ulrich
; APPLICANT: Hoe, Mee H.
; APPLICANT: Houghton, Alan
; APPLICANT: Takechi, Yoshizumi
; APPLICANT: Mayhew, Mark
; TITLE OF INVENTION: Heat Shock Protein-Based Vaccines and Immunotherapies
; FILE REFERENCE: 11746/4610211
; CURRENT APPLICATION NUMBER: US/10/367,674
; CURRENT FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: US 10/170,738
; PRIOR FILING DATE: 2002-06-13
; PRIOR APPLICATION NUMBER: US 09/552,868
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 09/011,645
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: PCT/US96/13363
; PRIOR FILING DATE: 1996-08-16
; PRIOR APPLICATION NUMBER: US 60/002,490
; PRIOR FILING DATE: 1995-08-18
; PRIOR APPLICATION NUMBER: US 60/002,479
; PRIOR FILING DATE: 1995-08-18
; NUMBER OF SEQ ID NOS: 349
; SOFTWARE: WordPerfect 8.0 for Windows
; SEQ ID NO 19
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-367-674-19

Query Match 100.0%; Score 64; DB 4; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 276
US-10-776-521B-369
; Sequence 369, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletchner, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18

```

; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 369
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-369

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 277
US-10-776-521B-371
; Sequence 371, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; PRIOR FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 371
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heat shock protein binding domain
US-10-776-521B-371

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 278
US-10-776-521B-373
; Sequence 373, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya

```

```

; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 373
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-373

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      13 HWDFAWPW 20

```

```

RESULT 279
US-10-776-521B-374
; Sequence 374, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; FILE REFERENCE: 8449-405-999
; CURRENT APPLICATION NUMBER: US/10/776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 374
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-374

```

```

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. NO. 0.071;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```



```
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-264

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 280
US-10-820-067A-878
; Sequence 878, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; PRIOR FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 878
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heat shock-protein binding motif to form hybrid antigen
US-10-820-067A-878

Query Match      100.0%; Score 64; DB 5; Length 20;
Best Local Similarity 100.0%; Pred. No. 0.071;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      13 HWDFAWPW 20

RESULT 281
US-10-258-144-264
; Sequence 264, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 264
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
```

```
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-264

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 282
US-10-258-144-265
; Sequence 265, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 265
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-265

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      14 HWDFAWPW 21

RESULT 283
US-10-258-144-304
; Sequence 304, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 304
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
```

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-304
Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 284
US-10-258-144-305
; Sequence 305 Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 305
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-305
Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

RESULT 285
US-10-258-144-334
; Sequence 334 Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 334
```

```
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-334
Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 286
US-10-258-144-335
; Sequence 335 Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 335
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-335
Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

RESULT 287
US-10-258-144-344
; Sequence 344 Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
```

; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 344
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-344

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 288

US-10-258-144-345
; Sequence 345, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 345
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-345

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 289

US-10-258-144-354
; Sequence 354, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144

; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 354
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-354

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 290

US-10-258-144-355
; Sequence 355, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 355
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-355

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 291

US-10-258-144-364
; Sequence 364, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

```
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 364
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-364

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 292
US-10-258-144-365
; Sequence 365, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 365
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-365

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      14 HWDFAWPW 21

RESULT 293
US-10-258-144-374
; Sequence 374, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
```

```
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 374
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-374

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      1 HWDFAWPW 8

RESULT 294
US-10-258-144-375
; Sequence 375, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 375
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-375

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
DB      14 HWDFAWPW 21

RESULT 295
US-10-258-144-394
; Sequence 394, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
```

; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 394
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-394

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 296

US-10-258-144-395
; Sequence 395, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 395
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-395

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

RESULT 297

US-10-258-144-404

; Sequence 404, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 404
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-404

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 298

US-10-258-144-405
; Sequence 405, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 405
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-405

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 14 HWDFAWPW 21

```

RESULT 299
US-10-258-144-444
; Sequence 444, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 444
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-444

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 300
US-10-258-144-445
; Sequence 445, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 445
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-445

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

Db      14 HWDFAWPW 21

RESULT 301
US-10-258-144-454
; Sequence 454, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 454
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-454

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 302
US-10-258-144-455
; Sequence 455, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 455
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-455

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 303
US-10-258-144-474
; Sequence 474, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 474
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-474

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 304
US-10-258-144-475
; Sequence 475, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 475
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (11)...(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-475

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 14 HWDFAWPW 21

RESULT 305
US-10-258-144-484
; Sequence 484, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 484
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-484

Query Match 100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 306
US-10-258-144-485
; Sequence 485, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 485
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
US-10-258-144-485

```
; LOCATION: (11)....(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-485

Query Match      100.0%; Score 64; DB 4; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      14 HWDFAWPW 21

RESULT 307
US-10-776-521B-378
; Sequence 378, Application US/10776521B
; Publication No. US20050202033A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jessica
; APPLICANT: Prince-Cohane, Kenya
; APPLICANT: Mehta, Sunil
; APPLICANT: Slusarewicz, Paul
; APPLICANT: Andjelic, Sofija
; APPLICANT: Barber, Brian
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED VACCINES AND
; TITLE OF INVENTION: IMMUNOTHERAPIES
; FILE REFERENCE: 8449-403-999
; CURRENT APPLICATION NUMBER: US/10776,521B
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/447,142
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 419
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 378
; LENGTH: 21
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-776-521B-378

Query Match      100.0%; Score 64; DB 5; Length 21;
Best Local Similarity 100.0%; Pred. No. 0.074;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      14 HWDFAWPW 21

RESULT 308
US-10-258-144-279
; Sequence 279, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 210
; LENGTH: 25
; TYPE: PRT

; LOCATION: (11)....(13)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-279

Query Match      100.0%; Score 64; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.082;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 309
US-10-258-144-283
; Sequence 283, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 283
; LENGTH: 24
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-283

Query Match      100.0%; Score 64; DB 4; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.082;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 310
US-10-258-144-210
; Sequence 210, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 210
; LENGTH: 25
; TYPE: PRT
```



```
; ORGANISM: Homo sapiens derivative
US-10-258-144-210

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 311
US-10-258-144-211
; Sequence 211, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 211
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-211

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 312
US-10-258-144-219
; Sequence 219, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 219
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-219

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
```

```
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 313
US-10-258-144-223
; Sequence 223, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 223
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-223

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8

RESULT 314
US-10-258-144-229
; Sequence 229, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 229
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-229

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
   |||||
Db 1 HWDFAWPW 8
```

```

RESULT 315
US-10-258-144-233
; Sequence 233, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 233
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-233

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 316
US-10-258-144-239
; Sequence 239, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 239
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-239

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 317
US-10-258-144-243
; Sequence 243, Application US/10258144

```

```

; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-243

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 318
US-10-258-144-249
; Sequence 249, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 249
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-249

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 319
US-10-258-144-253
; Sequence 253, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais

```

; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 253
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-253

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 320
US-10-258-144-259
; Sequence 259, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 259
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-259

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 321
US-10-258-144-263
; Sequence 263, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401

; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 263
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-263

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 322
US-10-258-144-289
; Sequence 289, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 289
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-289

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 323
US-10-258-144-293
; Sequence 293, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 293
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-293

Query Match          100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 324
US-10-258-144-299
; Sequence 299, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 299
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-299

Query Match          100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 325
US-10-258-144-303
; Sequence 303, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 303
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-303

Query Match          100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 326
US-10-258-144-319
; Sequence 319, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 319
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-319

Query Match          100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 327
US-10-258-144-323
; Sequence 323, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 323
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-323

Query Match          100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 328

US-10-258-144-329
 ; Sequence 329, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 329
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-329

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 329

US-10-258-144-333
 ; Sequence 333, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 333
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-333

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 330

US-10-258-144-389
 ; Sequence 389, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 389
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-389

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 331

US-10-258-144-393
 ; Sequence 393, Application US/10258144
 ; Publication No. US20040101532A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Houghton, Alan
 ; APPLICANT: Livingston, Phil
 ; APPLICANT: Al-Awgati, Qais
 ; APPLICANT: Mayhew, Mark
 ; APPLICANT: Hoe, Mee
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
 ; FILE REFERENCE: 11746/46401
 ; CURRENT APPLICATION NUMBER: US/10/258,144
 ; CURRENT FILING DATE: 2002-10-17
 ; PRIOR APPLICATION NUMBER: 60/197,642
 ; PRIOR FILING DATE: 2000-04-17
 ; NUMBER OF SEQ ID NOS: 502
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 393
 ; LENGTH: 25
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens derivative
 US-10-258-144-393

Query Match 100.0%; Score 64; DB 4; Length 25;
 Best Local Similarity 100.0%; Pred. No. 0.085;
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
 |||||
 Db 1 HWDFAWPW 8

RESULT 332

US-10-258-144-419
 ; Sequence 419, Application US/10258144
 ; Publication No. US20040101532A1

```

; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 419
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-419

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 333
US-10-258-144-423
; Sequence 423, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 423
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-423

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 334
US-10-258-144-429
; Sequence 429, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark

```

```

; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 429
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-429

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 335
US-10-258-144-433
; Sequence 433, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 433
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; US-10-258-144-433

```

```

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

```

RESULT 336
US-10-258-144-439
; Sequence 439, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144

```

```
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 439
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-439

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 337
US-10-258-144-443
; Sequence 443, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 443
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-443

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 338
US-10-258-144-469
; Sequence 469, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 469
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-469
```

```
; SEQ ID NO 469
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-469

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 339
US-10-258-144-473
; Sequence 473, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 473
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-473

Query Match      100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 340
US-10-258-144-499
; Sequence 499, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 499
; LENGTH: 25
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-499
```

Query Match 100.0%; Score 64; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.085;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 341
US-10-258-144-269
; Sequence 269, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 269
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-269

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 342
US-10-258-144-273
; Sequence 273, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 273
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-273

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 343
US-10-258-144-309
; Sequence 309, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 309
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-309

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 344
US-10-258-144-313
; Sequence 313, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 313
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-313

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8


```

RESULT 345
US-10-258-144-339
; Sequence 339, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 339
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-339

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 346
US-10-258-144-343
; Sequence 343, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 343
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-343

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 347
US-10-258-144-349
; Sequence 349, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 349
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-349

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 348
US-10-258-144-353
; Sequence 353, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 353
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-353

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 349
US-10-258-144-359
; Sequence 359, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 359
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-359

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 359
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-359

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 350
US-10-258-144-363
; Sequence 363, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 363
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-363

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 351
US-10-258-144-369
; Sequence 369, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17

; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 369
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-369

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 352
US-10-258-144-373
; Sequence 373, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 373
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-373

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 353
US-10-258-144-379
; Sequence 379, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 379

```

; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-379

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 354
US-10-258-144-383
; Sequence 383, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 383
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-383

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 355
US-10-258-144-399
; Sequence 399, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 399
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-399
```

```

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 356
US-10-258-144-403
; Sequence 403, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 403
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-403

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 357
US-10-258-144-409
; Sequence 409, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 409
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-409

Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
```

```
Db      1 HWDFAPWP 8
|||||
RESULT 358
US-10-258-144-413
; Sequence 413, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 413
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-413
Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
|||||
Db      1 HWDFAPWP 8
|||||
RESULT 359
US-10-258-144-449
; Sequence 449, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 449
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-449
Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
|||||
Db      1 HWDFAPWP 8
|||||
RESULT 360
US-10-258-144-479
; Sequence 479, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
```

```
US-10-258-144-453
; Sequence 453, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 453
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-453
Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
|||||
Db      1 HWDFAPWP 8
|||||
RESULT 361
US-10-258-144-459
; Sequence 459, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 459
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-459
Query Match      100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAPWP 8
|||||
Db      1 HWDFAPWP 8
|||||
RESULT 362
US-10-258-144-479
; Sequence 479, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
```

; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 479
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-479

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 363
US-10-258-144-483
; Sequence 483, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 483
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-483

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 364
US-10-258-144-489
; Sequence 489, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK

; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 489
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-489

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 365
US-10-258-144-493
; Sequence 493, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 493
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-493

Query Match 100.0%; Score 64; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.088;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 366
US-10-258-147-19
; Sequence 19, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0

```
; SEQ ID NO 19
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-19

Query Match      100.0%; Score 64; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 367
US-10-258-147-20
; Sequence 20, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 20
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-20

Query Match      100.0%; Score 64; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      20 HWDFAWPW 27

RESULT 368
US-10-258-144-463
; Sequence 463, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 463
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
```

```
US-10-258-144-463

Query Match      100.0%; Score 64; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.09;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 369
US-10-258-147-18
; Sequence 18, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 18
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-18

Query Match      100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 370
US-10-258-147-24
; Sequence 24, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 24
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Javelinized peptide of Herpes Simplex virus
US-10-258-147-24

Query Match      100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
```

```
Db 1 HWDFAWPW 8
|||||
RESULT 371
US-10-258-144-276
; Sequence 276, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 276
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (20)...(22)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-276
Query Match 100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
RESULT 372
US-10-258-144-281
; Sequence 281, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 281
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
```

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (20)...(22)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-281
Query Match 100.0%; Score 64; DB 4; Length 30;
Best Local Similarity 100.0%; Pred. No. 0.098;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
RESULT 373
US-10-258-147-27
; Sequence 27, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 27
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of gp100 melanoma antigen
US-10-258-147-27
Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
RESULT 374
US-10-258-144-213
; Sequence 213, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 213
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
US-10-258-144-213
```

```
Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
      |||||
      |||||

RESULT 375
US-10-258-144-216
; Sequence 216, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 216
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-216

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
      |||||
      |||||

RESULT 376
US-10-258-144-221
; Sequence 221, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 221
; LENGTH: 31
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-221

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
      |||||
      |||||

RESULT 377
US-10-258-144-226
; Sequence 226, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-226

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8
      |||||
      |||||

RESULT 378
US-10-258-144-231
; Sequence 231, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
```


RESULT 379
US-10-258-144-236
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 231
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-231

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 379
US-10-258-144-236
; Sequence 236, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Oais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 236
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-236

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 380
US-10-258-144-241
; Sequence 241, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Oais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 241
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-241

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 381
US-10-258-144-246
; Sequence 246, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Oais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 246
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-246

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-258-144-246

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 382

US-10-258-144-251
; Sequence 251, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 251
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-251

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 383

US-10-258-144-256
; Sequence 256, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 256

; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-256

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 384

US-10-258-144-261
; Sequence 261, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 261
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-261

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAPWP 8
Db 1 HWDFAPWP 8

RESULT 385

US-10-258-144-286
; Sequence 286, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark

; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 286
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-286

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 386
US-10-258-144-291
; Sequence 291, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 291
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-291

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 387
US-10-258-144-296
; Sequence 296, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 296
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-296

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

RESULT 388
US-10-258-144-301
; Sequence 301, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 301
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT

```
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-301

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 389
US-10-258-144-316
; Sequence 316, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 316
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-316

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 390
US-10-258-144-321
; Sequence 321, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 321
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-321

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 391
US-10-258-144-326
; Sequence 326, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 326
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-326

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 392
US-10-258-144-331
; Sequence 331, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
```

APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
SEQUENCE 391, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 331
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
FEATURE:
NAME/KEY: VARIANT
LOCATION: (21)...(23)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-331

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 393
US-10-258-144-386
Sequence 386, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 386
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
FEATURE:
NAME/KEY: VARIANT
LOCATION: (21)...(23)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-386

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8

Db 1 HWDFAWPW 8
RESULT 394
US-10-258-144-391
Sequence 391, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 391
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
FEATURE:
NAME/KEY: VARIANT
LOCATION: (21)...(23)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-391

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 395
US-10-258-144-416
Sequence 416, Application US/10258144
Publication No. US20040101532A1
GENERAL INFORMATION:
APPLICANT: Houghton, Alan
APPLICANT: Livingston, Phil
APPLICANT: Al-Awgati, Qais
APPLICANT: Mayhew, Mark
APPLICANT: Hoe, Mee
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
FILE REFERENCE: 11746/46401
CURRENT APPLICATION NUMBER: US/10258,144
CURRENT FILING DATE: 2002-10-17
PRIOR APPLICATION NUMBER: 60/197,642
PRIOR FILING DATE: 2000-04-17
NUMBER OF SEQ ID NOS: 502
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 416
LENGTH: 31
TYPE: PRT
ORGANISM: Homo sapiens derivative
FEATURE:
NAME/KEY: VARIANT
LOCATION: (9)...(11)
OTHER INFORMATION: Any amino acid residue
US-10-258-144-416

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-416

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 1 HWDFAWPW 8

RESULT 396
US-10-258-144-421
; Sequence 421, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 421
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-421

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 1 HWDFAWPW 8

RESULT 397
US-10-258-144-426
; Sequence 426, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
```

```
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 426
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-426

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 1 HWDFAWPW 8

RESULT 398
US-10-258-144-431
; Sequence 431, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 431
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-431

Query Match      100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
    |||||
Db 1 HWDFAWPW 8

RESULT 399
US-10-258-144-436
; Sequence 436, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
```

; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 436
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-436

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 400
US-10-258-144-441
; Sequence 441, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 441
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-441

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 401
US-10-258-144-466
; Sequence 466, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 466
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-466

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 402
US-10-258-144-471
; Sequence 471, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 471
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT

; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-471

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
DB 1 HWDFAWPW 8

RESULT 403
US-10-258-144-496
; Sequence 496, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 496
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-496

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
DB 1 HWDFAWPW 8

RESULT 404
US-10-258-144-501
; Sequence 501, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144

; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 501
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (21)...(23)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-501

Query Match 100.0%; Score 64; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
DB 1 HWDFAWPW 8

RESULT 405
US-10-820-067A-919
; Sequence 919, Application US/10820067A
; Publication No. US20050214312A1
; GENERAL INFORMATION:
; APPLICANT: Fletcher, J.
; APPLICANT: Prince-Cohane, K.
; APPLICANT: Mehta, S.
; APPLICANT: Slusarewicz, P.
; APPLICANT: Andjelic, S.
; APPLICANT: Barber, B.
; TITLE OF INVENTION: IMPROVED HEAT SHOCK PROTEIN-BASED
; TITLE OF INVENTION: VACCINES AND IMMUNOTHERAPIES
; FILE REFERENCE: 8449-406-999
; CURRENT APPLICATION NUMBER: US/10/820,067A
; CURRENT FILING DATE: 2004-04-08
; PRIOR APPLICATION NUMBER: 60/462,469
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/463,746
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: 60/503,417
; PRIOR FILING DATE: 2003-09-16
; NUMBER OF SEQ ID NOS: 926
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 919
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Hybrid antigen
US-10-820-067A-919

Query Match 100.0%; Score 64; DB 5; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 HWDFAWPW 8
| | | | | | | |
DB 1 HWDFAWPW 8

RESULT 406
US-10-258-144-266
; Sequence 266, Application US/10258144
; Publication No. US20040101532A1


```

; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 266
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-266

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

RESULT 407

```

US-10-258-144-271
; Sequence 271, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 271
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-271

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;

```

```

Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

RESULT 408
US-10-258-144-306
; Sequence 306, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 306
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-306

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1 HWDFAWPW 8
Db      1 HWDFAWPW 8

```

RESULT 409

```

US-10-258-144-311
; Sequence 311, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 311
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:

```

```
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-311
```

```
Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8
```

RESULT 410

```
US-10-258-144-336
; Sequence 336, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 336
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-336
```

```
Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8
```

RESULT 411

```
US-10-258-144-341
; Sequence 341, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
```

```
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 341
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-341
```

```
Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8
```

RESULT 412

```
US-10-258-144-346
; Sequence 346, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 346
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-346
```

```
Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1 HWDFAPWP 8
Db      1 HWDFAPWP 8
```

RESULT 413

```
US-10-258-144-351
```

```

; Sequence 351, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 351
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-351

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

```

```

RESULT 414
US-10-258-144-356
; Sequence 356, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 356
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-356

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 415
US-10-258-144-361
; Sequence 361, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 361
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-361

```

```

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

```

```

RESULT 416
US-10-258-144-366
; Sequence 366, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 366
; LENGTH: 32
; TYPE: PRT

```

```
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-366
```

```
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
| | | | |
DB 1 HWDFAWPW 8
```

RESULT 417

```
US-10-258-144-371
; Sequence 371, Application US/10258144
; Publication No. US20040101532A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
```

```
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
```

```
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
```

```
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 371
```

```
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
```

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-371
```

```
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
| | | | |
DB 1 HWDFAWPW 8
```

RESULT 418

```
US-10-258-144-376
; Sequence 376, Application US/10258144
; Publication No. US20040101532A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
```

```
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
```

```
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 376
```

```
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
```

```
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-376
```

```
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
| | | | |
DB 1 HWDFAWPW 8
```

RESULT 419

```
US-10-258-144-381
```

```
; Sequence 381, Application US/10258144
; Publication No. US20040101532A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Houghton, Alan
```

```
; APPLICANT: Livingston, Phil
```

```
; APPLICANT: Al-Awqati, Qais
```

```
; APPLICANT: Mayhew, Mark
```

```
; APPLICANT: Hoe, Mee
```

```
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
```

```
; FILE REFERENCE: 11746/46401
```

```
; CURRENT APPLICATION NUMBER: US/10/258,144
```

```
; CURRENT FILING DATE: 2002-10-17
```

```
; PRIOR APPLICATION NUMBER: 60/197,642
```

```
; PRIOR FILING DATE: 2000-04-17
```

```
; NUMBER OF SEQ ID NOS: 502
```

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 381
```

```
; LENGTH: 32
```

```
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens derivative
```

```
; FEATURE:
```

```
; NAME/KEY: VARIANT
```

```
; LOCATION: (9)...(11)
```

```
; OTHER INFORMATION: Any amino acid residue
```

```
; FEATURE:
```

```
; NAME/KEY: VARIANT
```

```
; LOCATION: (22)...(24)
```

```
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-381
```

```
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
| | | | |
DB 1 HWDFAWPW 8
```

RESULT 420
US-10-258-144-396
; Sequence 396, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 396
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-396

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 421
US-10-258-144-401
; Sequence 401, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 401
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue

US-10-258-144-401
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8
RESULT 422
US-10-258-144-406
; Sequence 406, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 406
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-406

Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
| | | | | | | |
Db 1 HWDFAWPW 8

RESULT 423
US-10-258-144-411
; Sequence 411, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; TITLE OF INVENTION: PROTEIN MEDIATED IMMUNOTHERAPY OF MELANOMA
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 411

```
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-411

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 424
US-10-258-144-446
; Sequence 446, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 446
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-446

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 425
US-10-258-144-451
; Sequence 451, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
```

```
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 451
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-451

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8

RESULT 426
US-10-258-144-456
; Sequence 456, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 456
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-456

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
```

```
RESULT 427
US-10-258-144-461
; Sequence 461, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 461
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-461

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
DB      1 HWDFAWPW 8

RESULT 428
US-10-258-144-476
; Sequence 476, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 476
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-476

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
DB      1 HWDFAWPW 8

RESULT 429
US-10-258-144-481
; Sequence 481, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 481
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-481

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
DB      1 HWDFAWPW 8

RESULT 430
US-10-258-144-486
; Sequence 486, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 486
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-486
```

```
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-476

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
DB      1 HWDFAWPW 8

RESULT 429
US-10-258-144-481
; Sequence 481, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 481
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-481

Query Match      100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches      8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 HWDFAWPW 8
      |||||
DB      1 HWDFAWPW 8

RESULT 430
US-10-258-144-486
; Sequence 486, Application US/10258144
; Publication No. US20040101532A1
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awgati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; PRIOR FILING DATE: 2002-10-17
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 486
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
US-10-258-144-486
```

```
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 486
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-486
```

```
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
```

RESULT 431

```
US-10-258-144-491
; Sequence 491, Application US/10258144
; Publication No. US20040101532A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Houghton, Alan
; APPLICANT: Livingston, Phil
; APPLICANT: Al-Awqati, Qais
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR HEAT SHOCK
; FILE REFERENCE: 11746/46401
; CURRENT APPLICATION NUMBER: US/10/258,144
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,642
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 502
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 491
; LENGTH: 32
; TYPE: PRT
; ORGANISM: Homo sapiens derivative
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (9)...(11)
; OTHER INFORMATION: Any amino acid residue
; FEATURE:
; NAME/KEY: VARIANT
; LOCATION: (22)...(24)
; OTHER INFORMATION: Any amino acid residue
; US-10-258-144-491
```

```
Query Match 100.0%; Score 64; DB 4; Length 32;
Best Local Similarity 100.0%; Pred. No. 0.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
```

RESULT 432

```
US-10-258-147-21
; Sequence 21, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
```

```
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 21
; LENGTH: 38
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
; US-10-258-147-21
```

```
Query Match 100.0%; Score 64; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 0.12;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
```

RESULT 433

```
US-10-258-147-28
; Sequence 28, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
; US-10-258-147-28
```

```
Query Match 100.0%; Score 64; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 HWDFAWPW 8
Db 1 HWDFAWPW 8
|||||
```

RESULT 434

```
US-10-258-147-30
; Sequence 30, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
```



```
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 30
; LENGTH: 100
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-30

Query Match      100.0%; Score 64; DB 4; Length 100;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      93 HWDFAWPW 100

RESULT 435
US-10-258-147-29
; Sequence 29, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 29
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-29

Query Match      100.0%; Score 64; DB 4; Length 103;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 436
US-10-258-147-31
; Sequence 31, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 31
; LENGTH: 103
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-31

Query Match      100.0%; Score 64; DB 4; Length 103;
Best Local Similarity 100.0%; Pred. No. 0.26;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      96 HWDFAWPW 103

RESULT 437
US-10-258-147-32
; Sequence 32, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 32
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-32

Query Match      100.0%; Score 64; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 0.27;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 HWDFAWPW 8
      |||||
Db      1 HWDFAWPW 8

RESULT 438
US-10-258-147-33
; Sequence 33, Application US/10258147
; Publication No. US20040043419A1
; GENERAL INFORMATION:
; APPLICANT: Rothman, James
; APPLICANT: Mayhew, Mark
; APPLICANT: Hoe, Mee
; TITLE OF INVENTION: JAVELINIZATION OF PROTEINS
; FILE REFERENCE: 11746/46276
; CURRENT APPLICATION NUMBER: US/10/258,147
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/197,462
; PRIOR FILING DATE: 2000-04-17
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 33
; LENGTH: 111
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: javelinized peptide of Gallus gallus ovalbumin
US-10-258-147-33

Query Match      100.0%; Score 64; DB 4; Length 111;
Best Local Similarity 100.0%; Pred. No. 0.28;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1 HWDFAWPW 8
| | | | |
Db 1 HWDFAWPW 8

Search completed: March 24, 2006, 12:48:25
Job time : 168 secs

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: March 24, 2006, 08:04:28 ; Search time 75 Seconds
(without alignments)
3.145 Million cell updates/sec

Title: US-10-053-520-143
Perfect score: 64
Sequence: 1 HWDFAWFW 8

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 174681 seqs, 29487097 residues

Total number of hits satisfying chosen parameters: 174681

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:
1: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB pep.*
2: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB pep.*
3: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB pep.*
4: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB pep.*
5: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB pep.*
6: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB pep.*
7: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB pep.*
8: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	39	60.9	126	6	US-10-492-570-1920
2	39	60.9	460	7	US-11-096-568A-21848
3	38	59.4	62	7	US-11-000-463-933
4	38	59.4	208	5	US-09-995-493-80
5	38	59.4	330	6	US-10-788-579A-10
6	38	59.4	330	6	US-10-887-475B-10
7	38	59.4	966	7	US-11-054-281-72
8	38	59.4	967	7	US-11-054-281-14
9	38	59.4	967	7	US-11-054-281-74
10	38	59.4	967	7	US-11-054-281-75
11	37.5	58.6	327	7	US-11-181-234-3
12	37	57.8	370	7	US-11-087-099-9967
13	37	57.8	371	7	US-11-087-099-3297
14	37	57.8	371	7	US-11-087-099-5697
15	37	57.8	383	7	US-11-087-099-6495
16	37	57.8	425	7	US-11-096-568A-25808
17	37	57.8	426	7	US-11-096-568A-25807
18	37	57.8	430	7	US-11-096-568A-25806
19	36	56.2	173	7	US-11-072-512-3025
20	36	56.2	345	7	US-11-210-316-14
21	36	56.2	353	7	US-11-087-099-10589
22	36	56.2	435	7	US-11-087-099-10693
23	36	56.2	486	7	US-11-210-316-10
24	36	56.2	518	7	US-11-024-959-364
25	36	56.2	522	7	US-11-096-568A-31887

26	36	56.2	529	7	US-11-024-959-496	Sequence 496, Appl
27	36	56.2	585	7	US-11-096-568A-31886	Sequence 31886, A
28	36	56.2	611	7	US-11-096-568A-31885	Sequence 31885, A
29	36	56.2	732	7	US-11-210-316-8	Sequence 8, Appl
30	36	56.2	747	7	US-11-096-568A-17900	Sequence 17900, A
31	36	56.2	747	7	US-11-210-316-2	Sequence 2, Appl
32	36	56.2	747	7	US-11-096-568A-17899	Sequence 17899, A
33	36	56.2	828	7	US-11-096-568A-17898	Sequence 17898, A
34	36	56.2	2050	6	US-10-453-372-192	Sequence 192, Appl
35	35	54.7	98	5	US-09-978-360A-480	Sequence 480, Appl
36	35	54.7	98	5	US-09-978-360A-681	Sequence 681, Appl
37	35	54.7	127	7	US-11-052-554A-312	Sequence 312, Appl
38	35	54.7	155	7	US-11-087-099-5352	Sequence 5352, Appl
39	35	54.7	183	5	US-09-978-360A-680	Sequence 680, Appl
40	35	54.7	286	6	US-10-467-657-4140	Sequence 4140, Appl
41	35	54.7	286	6	US-10-467-657-7784	Sequence 7784, Appl
42	35	54.7	350	7	US-11-218-281-23	Sequence 23, Appl
43	35	54.7	367	7	US-11-098-686-10716	Sequence 10716, A
44	35	54.7	729	7	US-11-210-316-29	Sequence 29, Appl
45	34.5	53.9	268	7	US-11-096-568A-22646	Sequence 22646, A

ALIGNMENTS

RESULT 1
US-10-492-570-1920
; Sequence 1920, Application US/10492570
; Publication No. US20060057666A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: A HUMAN G PROTEIN COUPLED RECEPTOR
; FILE REFERENCE: P0180
; CURRENT APPLICATION NUMBER: US/10/492,570
; PRIOR FILING DATE: 2004-04-12
; PRIOR APPLICATION NUMBER: US 60/329,000
; PRIOR FILING DATE: 2001-10-12
; NUMBER OF SEQ ID NOS: 1926
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1920
; LENGTH: 126
; TYPE: PRT
; ORGANISM: Rhodobacter capsulatus
US-10-492-570-1920

Query Match 60.9%; Score 39; DB 6; Length 126;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 FAWPW 8
Db 37 FAWPW 41

RESULT 2
US-11-096-568A-21848
; Sequence 21848, Application US/11096568A
; Publication No. US20060048240A1
; GENERAL INFORMATION:
; APPLICANT: Alexandrov, Nickolai et al.
; TITLE OF INVENTION: Sequence-Determined DNA Fragments and Corresponding Polypeptides
; FILE REFERENCE: 2750-1592PUS2
; CURRENT APPLICATION NUMBER: US/11/096,568A
; CURRENT FILING DATE: 2005-04-01
; NUMBER OF SEQ ID NOS: 34471
; SEQ ID NO 21848
; LENGTH: 460
; TYPE: PRT
; ORGANISM: Zea mays subsp. mays
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(460)

```
; OTHER INFORMATION: Ceres Seq. ID no. 12406509
US-11-096-568A-21848

Query Match          60.9%; Score 39; DB 7; Length 460;
Best Local Similarity 57.1%; Pred. No. 63;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
Db 6 WPFAPWP 12

RESULT 3
US-11-000-463-933
; Sequence 933, Application US/11000463
; Publication No. US20050266423A1
; GENERAL INFORMATION:
; APPLICANT: Tang, Y Tom
; APPLICANT: Liu, Chenghua
; APPLICANT: Asundi, Vinod
; APPLICANT: Chen, Rui-hong
; APPLICANT: Qian, Xiachong B.
; APPLICANT: Wang, Zhiwei
; APPLICANT: Wehman, Tom
; APPLICANT: Zhang, Jie
; APPLICANT: Zhou, Ping
; APPLICANT: Cao, Yi-Cheng
; APPLICANT: Dmanac, Radoje T.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 785C1P4CN
; CURRENT APPLICATION NUMBER: US/11/000,463
; CURRENT FILING DATE: 2004-11-29
; PRIOR APPLICATION NUMBER: 10/291,265
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: PCT/US01/02623
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 09/922,279
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: 09/491,404
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 09/617,746
; PRIOR FILING DATE: 2000-07-17
; PRIOR APPLICATION NUMBER: 09/631,451
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 09/633,870
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 944
; SOFTWARE: Fast-Seq for Windows Version 3.0
; SEQ ID NO 933
; LENGTH: 62
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-000-463-933

Query Match          59.4%; Score 38; DB 7; Length 62;
Best Local Similarity 57.1%; Pred. No. 18;
Matches 4; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2 WDFAPWP 8
Db 33 WPFAPWP 39

RESULT 4
US-09-995-493-80
; Sequence 80, Application US/09995493
; Publication No. US20060035293A1
; GENERAL INFORMATION:
; APPLICANT: Handfield, Martin
; APPLICANT: Hillman, Jeffrey
; APPLICANT: Progulski-Fox, Ann
; TITLE OF INVENTION: Identification of Actinobacillus actinomycetemcomitans Antigens for
; TITLE OF INVENTION: in the Diagnosis, Treatment, and Monitoring of Periodontal Disease
```

```
; FILE REFERENCE: MBHR01-662
; CURRENT APPLICATION NUMBER: US/09/995,493
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 234
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 80
; LENGTH: 208
; TYPE: PRT
; ORGANISM: Actinobacillus actinomycetemcomitans
US-09-995-493-80

Query Match          59.4%; Score 38; DB 5; Length 208;
Best Local Similarity 83.3%; Pred. No. 47;
Matches 5; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 WDFAPWP 7
Db 28 WGFAPWP 33

RESULT 5
US-10-798-579A-10
; Sequence 10, Application US/10798579A
; Publication No. US20060005281A1
; GENERAL INFORMATION:
; APPLICANT: Kirin Beer Kabushiki Kaisha; Japan International Research Center for
; APPLICANT: Agricultural Sciences
; TITLE OF INVENTION: A production of plants having improved rooting efficiency and vase
; TITLE OF INVENTION: using environmental stress-resistant gene
; FILE REFERENCE: PH-2034
; CURRENT APPLICATION NUMBER: US/10/798,579A
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: JP 2003-071082
; PRIOR FILING DATE: 2003-03-14
; NUMBER OF SEQ ID NOS: 30
; SEQ ID NO 10
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
US-10-798-579A-10

Query Match          59.4%; Score 38; DB 6; Length 330;
Best Local Similarity 66.7%; Pred. No. 68;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 3 DFAFPWP 8
Db 257 DYGFAPWP 262

RESULT 6
US-10-887-475B-10
; Sequence 10, Application US/10887475B
; Publication No. US20060015973A1
; GENERAL INFORMATION:
; APPLICANT: SHINOZAKI, Kazuko;
; APPLICANT: KASUGA, Mie;
; APPLICANT: SAKUMA, Yoh
; TITLE OF INVENTION: Environmental stress-tolerant plants
; FILE REFERENCE: 382.1029CIP
; CURRENT APPLICATION NUMBER: US/10/887,475B
; CURRENT FILING DATE: 2004-07-08
; PRIOR APPLICATION NUMBER: US 10/664,771
; PRIOR FILING DATE: 2003-09-19
; PRIOR APPLICATION NUMBER: US 09/301,217
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: JP 10-292348
; PRIOR FILING DATE: 1998-10-14
; NUMBER OF SEQ ID NOS: 75
; SEQ ID NO 10
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Arabidopsis thaliana
```

US-10-887-475B-10

Query Match 59.4%; Score 38; DB 6; Length 330;
Best Local Similarity 66.7%; Pred. No. 68;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3 DPAWPM 8
Db 257 DYGPWM 262

RESULT 7

US-11-054-281-72
; Sequence 72, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; PRIOR FILING DATE: 2002-01-11
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 72
; LENGTH: 966
; TYPE: PRT
; ORGANISM: Oryctolagus cuniculus
US-11-054-281-72

Query Match 59.4%; Score 38; DB 7; Length 966;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAW 6
Db 808 WDFAW 812

RESULT 8

US-11-054-281-14
; Sequence 14, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026

; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; PRIOR FILING DATE: 2002-01-11
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-281-14

Query Match 59.4%; Score 38; DB 7; Length 967;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAW 6
Db 809 WDFAW 813

RESULT 9

US-11-054-281-74
; Sequence 74, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 74
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-281-74

Query Match 59.4%; Score 38; DB 7; Length 967;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAW 6
Db 809 WDFAW 813

RESULT 10

US-11-054-281-75
; Sequence 75, Application US/11054281
; Publication No. US20060013813A1
; GENERAL INFORMATION:
; APPLICANT: Mezes et al.

; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same
; FILE REFERENCE: 21402-240CIP
; CURRENT APPLICATION NUMBER: US/11/054,281
; CURRENT FILING DATE: 2005-02-08
; PRIOR APPLICATION NUMBER: 60/261,014
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,018
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/318,410
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: 60/261,013
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,026
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/261,029
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 60/313,170
; PRIOR FILING DATE: 2001-08-17
; PRIOR APPLICATION NUMBER: 10/044,564
; PRIOR FILING DATE: 2002-01-11
; NUMBER OF SEQ ID NOS: 324
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 75
; LENGTH: 967
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-281-75

Query Match 59.4%; Score 38; DB 7; Length 967;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 WDFAW 6
|||
Db 809 WDFAW 813

RESULT 11
US-11-181-234-3
; Sequence 3, Application US/11181234
; Publication No. US20060021075A1
; GENERAL INFORMATION:
; APPLICANT: WANG, CHYUNG-RU
; TITLE OF INVENTION: GROUP 1 CD1 TRANSGENIC MICE AND THEIR
; FILE REFERENCE: 21117.000102
; CURRENT APPLICATION NUMBER: US/11/181,234
; CURRENT FILING DATE: 2005-07-14
; PRIOR APPLICATION NUMBER: 60/588,192
; PRIOR FILING DATE: 2004-07-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 327
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:/note =
; OTHER INFORMATION: Synthetic Construct
US-11-181-234-3

Query Match 58.6%; Score 37.5; DB 7; Length 327;
Best Local Similarity 42.9%; Pred. No. 79;
Matches 6; Conservative 0; Mismatches 1; Indels 7; Gaps 1;

Qy 2 WD-----FAWPK 8
|||
Db 57 WDSNSSTVFLWPK 70

RESULT 12
US-11-087-099-9967
; Sequence 9967, Application US/11087099

; Publication No. US20060041961A1
; GENERAL INFORMATION:
; APPLICANT: Abad, Mark S. et al.
; TITLE OF INVENTION: Genes and Uses for Plant Improvement
; FILE REFERENCE: 38-21(53450)B EP
; CURRENT APPLICATION NUMBER: US/11/087,099
; CURRENT FILING DATE: 2005-03-22
; NUMBER OF SEQ ID NOS: 12464
; SEQ ID NO 9967
; LENGTH: 370
; TYPE: PRT
; ORGANISM: Glycine max
US-11-087-099-9967

Query Match 57.8%; Score 37; DB 7; Length 370;
Best Local Similarity 66.7%; Pred. No. 1e+02;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 HWDFAW 6
|||
Db 216 HWDFAW 221

RESULT 13
US-11-087-099-3297
; Sequence 3297, Application US/11087099
; Publication No. US20060041961A1
; GENERAL INFORMATION:
; APPLICANT: Abad, Mark S. et al.
; TITLE OF INVENTION: Genes and Uses for Plant Improvement
; FILE REFERENCE: 38-21(53450)B EP
; CURRENT APPLICATION NUMBER: US/11/087,099
; CURRENT FILING DATE: 2005-03-22
; NUMBER OF SEQ ID NOS: 12464
; SEQ ID NO 3297
; LENGTH: 371
; TYPE: PRT
; ORGANISM: Glycine max
US-11-087-099-3297

Query Match 57.8%; Score 37; DB 7; Length 371;
Best Local Similarity 66.7%; Pred. No. 1e+02;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 HWDFAW 6
|||
Db 217 HWDFAW 222

RESULT 14
US-11-087-099-5697
; Sequence 5697, Application US/11087099
; Publication No. US20060041961A1
; GENERAL INFORMATION:
; APPLICANT: Abad, Mark S. et al.
; TITLE OF INVENTION: Genes and Uses for Plant Improvement
; FILE REFERENCE: 38-21(53450)B EP
; CURRENT APPLICATION NUMBER: US/11/087,099
; CURRENT FILING DATE: 2005-03-22
; NUMBER OF SEQ ID NOS: 12464
; SEQ ID NO 5697
; LENGTH: 371
; TYPE: PRT
; ORGANISM: Populus alba
US-11-087-099-5697

Query Match 57.8%; Score 37; DB 7; Length 371;
Best Local Similarity 66.7%; Pred. No. 1e+02;
Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 HWDFAW 6
|||
Db 220 HWDFAW 225

RESULT 15

US-11-087-099-6495
 ; Sequence 6495, Application US/11087099
 ; Publication No. US20060041961A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Abad, Mark S. et al.
 ; TITLE OF INVENTION: Genes and Uses for Plant Improvement
 ; FILE REFERENCE: 38-21(53450)B EP
 ; CURRENT APPLICATION NUMBER: US/11/087,099
 ; CURRENT FILING DATE: 2005-03-22
 ; NUMBER OF SEQ ID NOS: 12464
 ; SEQ ID NO 6495
 ; LENGTH: 383
 ; TYPE: PRT
 ; ORGANISM: Glycine max
 US-11-087-099-6495

Query Match 57.8%; Score 37; DB 7; Length 383;
 Best Local Similarity 66.7%; Pred. No. 1.1e+02;
 Matches 4; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 HWDFAW 6
 ||:|
 Db 229 HWEFLW 234

Search completed: March 24, 2006, 08:08:28
 Job time : 76 secs

THIS PAGE BLANK (USPTO)